FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU de Brito, CAA
   Marques, CDL
   Franca, RFO
   Monteiro, JR
   de Brito, MCM
   Lopes, F
   Lima, A
   Marques, GL
   Valadares, ML
   Duarte, ALBP
AF de Brito, Carlos A. A.
   Marques, Claudia D. L.
   Franca, Rafael F. O.
   Monteiro, Janaina R.
   de Brito, Marina C. M.
   Lopes, Fabiana
   Lima, Anton
   Marques, Gabriel L.
   Valadares, Maria Luisa
   Duarte, Angela L. B. P.
TI Reduced Duration of Postchikungunya Musculoskeletal Pain in
   Rheumatological Patients Treated with Biologicals
SO JOURNAL OF TROPICAL MEDICINE
LA English
DT Article
ID CHIKUNGUNYA VIRUS-INFECTION; ETANERCEPT; INHIBITION; ARTHRITIS;
   MORTALITY; DISEASE; ALPHA
AB Chikungunya fever (CHIK) has caused important epidemic outbreaks in the Americas, with musculoskeletal involvement being the main manifestation, causing chronic symptoms in half of the affected patients. This study was performed to evaluate the clinical course of the infection in 168 patients with autoimmune inflammatory disease using biological disease-modifying antirheumatic drugs (bDMARDs), comparing this group with 56 household controls. Anti-CHIKV IgG serology was positive in 42 (25%) of the patients in the bDMARD group and in 15 (27%) of the controls (p=0.79). Of those with positive serology, 32 (76%) and 14 (93%) were symptomatic among subjects in the bDMARD and control groups, respectively (p=0.87). Persistence of musculoskeletal symptoms for more than three months occurred in 64% of the patients in the control group and only in 28% in the bDMARD group (p=0.021), maintaining a statistically significant difference only for users of anti-TNF. This study found that patients affected by chikungunya fever using bDMARDs did not present severe forms or complications in the acute phase of the disease, and patients using anti-TNF biologicals had a lower frequency of chronic joint symptoms than the household controls. This favorable outcome may be related to the cytokine blockade, with a reduction in the inflammatory response and joint damage.
C1 [de Brito, Carlos A. A.] Univ Fed Pernambuco, Clin Hosp, Internal Med, Recife, PE, Brazil.
   [de Brito, Carlos A. A.] Autoimmune Inst, Recife, PE, Brazil.
   [Marques, Claudia D. L.; Duarte, Angela L. B. P.] Univ Fed Pernambuco, Clin Hosp, Rheumatol Serv, Recife, PE, Brazil.
   [Franca, Rafael F. O.] Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Inst, Dept Virol & Expt Therapy, Recife, PE, Brazil.
   [Monteiro, Janaina R.; de Brito, Marina C. M.; Lopes, Fabiana; Lima, Anton] Univ Fed Pernambuco, Recife, PE, Brazil.
   [Marques, Gabriel L.] Univ Catolica Pernambuco UNICAP, Recife, PE, Brazil.
   [Valadares, Maria Luisa] Fac Med Olinda FMO, Olinda, PE, Brazil.
RP de Brito, CAA (corresponding author), Univ Fed Pernambuco, Clin Hosp, Internal Med, Recife, PE, Brazil.; de Brito, CAA (corresponding author), Autoimmune Inst, Recife, PE, Brazil.
EM cbritoc@gmail.com; claudia.reumatologia@gmail.com;
   rafael.franca@cpqam.fiocruz.br; janainagrm@gmail.com;
   marina.cmbrito@gmail.com; nana.frcl@gmail.com; antonslima@gmail.com;
   gabrielm8708@gmail.com; maluvaladares@hotmail.com;
   angelalbpduarte@gmail.com
OI Reis, AlessanRSS/0000-0001-8486-7469; Coelho Moraes de Brito,
   Marina/0000-0002-9298-3184
CR de Brito CAA, 2017, REV SOC BRAS MED TRO, V50, P585, DOI 10.1590/0037-8682-0479-2016
   Assuncao-Miranda I, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/973516
   Atrasheuskaya A, 2003, FEMS IMMUNOL MED MIC, V35, P33, DOI 10.1111/j.1574-695X.2003.tb00646.x
   Bonifay T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207406
   Borman ZA, 2018, EXPERT REV GASTROENT, V12, P1101, DOI 10.1080/17474124.2018.1530983
   Brazil Ministry of Health, 2017, MINISTRY HEALTHSECRE
   Brunier L, 2016, JOINT BONE SPINE, V83, P245, DOI 10.1016/j.jbspin.2015.08.004
   Cunha RV, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005319
   Deligny C, 2014, J CLIN VIROL, V61, P442, DOI 10.1016/j.jcv.2014.08.011
   Economopoulou A, 2009, EPIDEMIOL INFECT, V137, P534, DOI 10.1017/S0950268808001167
   Figueiredo CP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11866-7
   Marques CDL, 2017, REV BRAS REUMATOL, V57, pS421, DOI 10.1016/j.rbre.2017.05.006
   Lopez-Medrano F, 2018, CLIN MICROBIOL INFEC, V24, P192, DOI 10.1016/j.cmi.2017.06.016
   Pan American Health Organization, 2020, NEW CAS CHIK AM 2013
   Prat CM, 2014, EMERG INFECT DIS, V20, P2129, DOI 10.3201/eid2012.141269
   Renault P, 2007, AM J TROP MED HYG, V77, P727
   Rodriguez-Morales Alfonso J, 2016, F1000Res, V5, P360, DOI 10.12688/f1000research.8235.1
   Rosario V, 2015, CLIN RHEUMATOL, V34, P1285, DOI 10.1007/s10067-015-2979-x
   Rutherford AI, 2018, ANN RHEUM DIS, V77, P905, DOI 10.1136/annrheumdis-2017-212825
   Shi XL, 2013, CRIT CARE, V17, DOI 10.1186/cc13171
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Tanabe ISB, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00345
   Tobinick E, 2004, CURR MED RES OPIN, V20, P39, DOI 10.1185/030079903125002757
   Venugopalan A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111305
   Zaid A, 2011, ARTHRITIS RHEUM-US, V63, P488, DOI 10.1002/art.30112
NR 25
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-9686
EI 1687-9694
J9 J TROP MED-US
JI J. Trop. Med.
PD JUL 10
PY 2020
VL 2020
AR 2071325
DI 10.1155/2020/2071325
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA MR2NK
UT WOS:000553426300001
PM 32695184
OA DOAJ Gold, Green Published
DA 2020-11-11
ER

PT J
AU Hiroki, CH
   Toller-Kawahisa, JE
   Fumagalli, MJ
   Colon, DF
   Figueiredo, LTM
   Fonseca, BALD
   Franca, RFO
   Cunha, FQ
AF Hiroki, Carlos H.
   Toller-Kawahisa, Juliana E.
   Fumagalli, Marcilio J.
   Colon, David F.
   Figueiredo, Luiz T. M.
   Fonseca, Bendito A. L. D.
   Franca, Rafael F. O.
   Cunha, Fernando Q.
TI Neutrophil Extracellular Traps Effectively Control Acute Chikungunya
   Virus Infection
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE NETs; Chikungunya; neutrophils; viral infection; innate response
ID REPLICATION; MODEL; HOST
AB The Chikungunya virus (CHIKV) is a re-emerging arbovirus, in which its infection causes a febrile illness also commonly associated with severe joint pain and myalgia. Although the immune response to CHIKV has been studied, a better understanding of the virus-host interaction mechanisms may lead to more effective therapeutic interventions. In this context, neutrophil extracellular traps (NETs) have been described as a key mediator involved in the control of many pathogens, including several bacteria and viruses, but no reports of this important protective mechanism were documented during CHIKV infection. Here we demonstrate that the experimental infection of mouse-isolated neutrophils with CHIKV resulted in NETosis (NETs release) through a mechanism dependent on TLR7 activation and reactive oxygen species generation. In vitro, mouse-isolated neutrophils stimulated with phorbol 12-myristate 13-acetate release NETs that once incubated with CHIKV, resulting in further virus capture and neutralization. In vivo, NETs inhibition by the treatment of the mice with DNase resulted in the enhanced susceptibility of IFNAR(-/-) mice to CHIKV experimental acute infection. Lastly, by accessing the levels of MPO-DNA complex on the acutely CHIKV-infected patients, we found a correlation between the levels of NETs and the viral load in the blood, suggesting that NETs are also released in natural human infection cases. Altogether our findings characterize NETosis as a contributing natural process to control CHIKV acute infection, presenting an antiviral effect that helps to control systemic virus levels.
C1 [Hiroki, Carlos H.; Toller-Kawahisa, Juliana E.; Cunha, Fernando Q.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Pharmacol, Ribeirao Preto, Brazil.
   [Fumagalli, Marcilio J.; Colon, David F.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Biochem & Immunol, Ribeirao Preto, Brazil.
   [Figueiredo, Luiz T. M.; Fonseca, Bendito A. L. D.] Univ Sao Paulo, Sch Med Ribeirao Preto, Virol Res Ctr, Ribeirao Preto, Brazil.
   [Franca, Rafael F. O.] Fundacao Oswaldo Cruz, Inst Aggeu Magalhaes, Dept Virol & Expt Therapy, Recife, PE, Brazil.
RP Hiroki, CH; Cunha, FQ (corresponding author), Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Pharmacol, Ribeirao Preto, Brazil.
EM chhiroki@gmail.com; fdqcunha@fmrp.usp.br
RI ; Colon, David/M-2509-2018
OI Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007; Colon,
   David/0000-0002-6911-4765
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2013/08216-2]; Center for Research in
   Inflammatory Disease (CRID) [2011/19670-0]; University of Sao Paulo
   NAP-DIN [11.1.21625.01.0]; CNPqNational Council for Scientific and
   Technological Development (CNPq); Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES; Fundacao de Amparo a Ciencia e
   Tecnologia de Pernambuco/FACEPE [APQ-0055.2.11/16, APQ-0044.2.11/16];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/CNPq under
   RF coordination and responsibilityNational Council for Scientific and
   Technological Development (CNPq) [439975/2016-6]
FX The research leading to these results received funding from Sao Paulo
   Research Foundation (FAPESP) under grant agreement no. 2013/08216-2, the
   Center for Research in Inflammatory Disease (CRID) under grant agreement
   2011/19670-0, the University of Sao Paulo NAP-DIN (11.1.21625.01.0), the
   CNPq, the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES), under FQC coordination and responsibility, and the Fundacao de
   Amparo a Ciencia e Tecnologia de Pernambuco/FACEPE grant agreement nos.
   APQ-0055.2.11/16 and APQ-0044.2.11/16, and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico/CNPq grant agreement
   439975/2016-6 under RF coordination and responsibility. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Akk A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00325
   Alves JC, 2009, P NATL ACAD SCI USA, V106, P4018, DOI 10.1073/pnas.0900196106
   Amdekar S, 2017, VIRAL IMMUNOL, V30, P691, DOI 10.1089/vim.2017.0052
   Apel F, 2018, NAT REV RHEUMATOL, V14, P467, DOI 10.1038/s41584-018-0039-z
   Barr FD, 2018, MUCOSAL IMMUNOL, V11, P1420, DOI 10.1038/s41385-018-0045-0
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Burt FJ, 2017, LANCET INFECT DIS, V17, pE107, DOI 10.1016/S1473-3099(16)30385-1
   Cortjens B, 2016, J PATHOL, V238, P401, DOI 10.1002/path.4660
   Couderc T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040029
   Czaikoski PG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148142
   Donald CL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005048
   Funchal GA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124082
   Gabriel C, 2013, DNA CELL BIOL, V32, P665, DOI 10.1089/dna.2013.2211
   Gasque P, 2015, J INFECTION, V71, P413, DOI 10.1016/j.jinf.2015.06.006
   Her ZS, 2015, EMBO MOL MED, V7, P24, DOI 10.15252/emmm.201404459
   Jenne CN, 2013, CELL HOST MICROBE, V13, P169, DOI 10.1016/j.chom.2013.01.005
   Jorch SK, 2017, NAT MED, V23, P279, DOI 10.1038/nm.4294
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   LUMSDEN W. H. R., 1955, TANGANYIKA TERRITORY IN 1952 53 II TRANS ROY SOC TROP MED AND HYG, V49, P33, DOI 10.1016/0035-9203(55)90081-X
   Agraz-Cibrian JM, 2017, VIRUS RES, V228, P124, DOI 10.1016/j.virusres.2016.11.033
   Moreno-Altamirano MMB, 2015, INTERVIROLOGY, V58, P250, DOI 10.1159/000440723
   Opasawatchai A, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03007
   Palha N, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003619
   Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105
   Petersen Lyle R, 2016, F1000Res, V5, DOI 10.12688/f1000research.7171.1
   Petitdemange C, 2015, J ALLERGY CLIN IMMUN, V135, P846, DOI 10.1016/j.jaci.2015.01.039
   Raftery MJ, 2014, J EXP MED, V211, P1484, DOI 10.1084/jem.20131092
   Rios-Santos F, 2007, AM J RESP CRIT CARE, V175, P490, DOI 10.1164/rccm.200601-103OC
   Saitoh T, 2012, CELL HOST MICROBE, V12, P109, DOI 10.1016/j.chom.2012.05.015
   Schonrich G, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00366
   Smith PK, 2001, J PAEDIATR CHILD H, V37, P146, DOI 10.1046/j.1440-1754.2001.00618.x
   Strandin T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02098
   Trevelin SC, 2016, SCI REP-UK, V6, DOI 10.1038/srep34581
   Urbaczek AC, 2014, HUM IMMUNOL, V75, P785, DOI 10.1016/j.humimm.2014.05.011
   Wojtasiak M, 2010, J GEN VIROL, V91, P2158, DOI 10.1099/vir.0.021915-0
   Yost CC, 2016, J CLIN INVEST, V126, P3783, DOI 10.1172/JCI83873
   Zhu LL, 2018, J INFECT DIS, V217, P428, DOI 10.1093/infdis/jix475
NR 37
TC 5
Z9 5
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JAN 31
PY 2020
VL 10
AR 3108
DI 10.3389/fimmu.2019.03108
PG 11
WC Immunology
SC Immunology
GA KK3YW
UT WOS:000512682700001
PM 32082301
OA DOAJ Gold, Green Published
DA 2020-11-11
ER

PT J
AU de Jesus, JG
   Wallau, GD
   Maia, ML
   Xavier, J
   Lima, MAO
   Fonseca, V
   de Abreu, AS
   Tosta, SFD
   do Amaral, HR
   Lima, IAB
   Silva, PV
   dos Santos, DC
   de Oliveira, AS
   de Souza, SC
   Falcao, MB
   Cerqueira, E
   Machado, LC
   Sobral, MC
   Rezende, TMT
   Pereira, MR
   Pereira, FM
   Maia, ZPG
   Franca, RFD
   de Abreu, AL
   Melo, CFCDE
   Faria, NR
   da Cunha, RV
   Giovanetti, M
   Alcantara, LCJ
AF de Jesus, Jaqueline Goes
   Wallau, Gabriel da Luz
   Maia, Maricelia Lima
   Xavier, Joilson
   Oliveira Lima, Maria Aparecida
   Fonseca, Vagner
   de Abreu, Alvaro Salgado
   de Oliveira Tosta, Stephane Fraga
   do Amaral, Helineide Ramos
   Barbosa Lima, Italo Andrade
   Silva, Paloma Viana
   dos Santos, Daiana Carlos
   de Oliveira, Aline Sousa
   de Souza, Siane Campos
   Falcao, Melissa Barreto
   Cerqueira, Erenilde
   Machado, Lais Ceschini
   Sobral, Mariana Carolina
   Teodoro Rezende, Tatiana Maria
   Pereira, Mylena Ribeiro
   Pereira, Felicidade Mota
   Gusmao Maia, Zuinara Pereira
   de Oliveira Franca, Rafael Freitas
   de Abreu, Andre Luiz
   de Albuquerque e Melo, Carlos Frederico Campelo
   Faria, Nuno Rodrigues
   da Cunha, Rivaldo Venancio
   Giovanetti, Marta
   Junior Alcantara, Luiz Carlos
TI Persistence of chikungunya ECSA genotype and local outbreak in an upper
   medium class neighborhood in Northeast Brazil
SO PLOS ONE
LA English
DT Article
ID INDIAN-OCEAN; VIRUS; REEMERGENCE; POPULATION; GENOME; ZIKA
AB The chikungunya East/Central/South/Africa virus lineage (CHIKV-ECSA) was first detected in Brazil in the municipality of Feira de Santana (FS) by mid 2014. Following that, a large number of CHIKV cases have been notified in FS, which is the second-most populous city in Bahia state, northeastern Brazil, and plays an important role on the spread to other Brazilian states due to climate conditions and the abundance of competent vectors. To better understand CHIKV dynamics in Bahia state, we generated 5 complete genome sequences from a local outbreak raised in Serraria Brasil, a neighbourhood in FS, by next-generation sequencing using Illumina approach. Phylogenetic reconstructions revealed that the new FS genomes belongs to the ECSA genotype and falls within a single strongly supported monophyletic clade that includes other older CHIKV sequences from the same location, suggesting the persistence of the virus during distinct epidemic seasons. We also performed minor variants analysis and found a small number of SNPs per sample (b_29L and e_45SR = 16 SNPs, c_29SR = 29 and d_45PL and f_45FL = 21 SNPs). Out of the 93 SNPs found, 71 are synonymous, 21 are non-synonymous and one generated a stop codon. Although those mutations are not related to the increase of virus replication and/or infectivity, some SNPs were found in non-structural proteins which may have an effect on viral evasion from the mammal immunological system. These findings reinforce the needing of further studies on those variants and of continued genomic surveillance strategies to track viral adaptations and to monitor CHIKV epidemics for improved public health control.
C1 [de Jesus, Jaqueline Goes; Barbosa Lima, Italo Andrade; Silva, Paloma Viana; dos Santos, Daiana Carlos; de Oliveira, Aline Sousa; de Souza, Siane Campos] Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Lab Patol Expt, Salvador, BA, Brazil.
   [Wallau, Gabriel da Luz; Machado, Lais Ceschini; Sobral, Mariana Carolina; Teodoro Rezende, Tatiana Maria] Fundacao Oswaldo Cruz, Inst Aggeu Magalhaes, Dept Entomol, Recife, PE, Brazil.
   [Maia, Maricelia Lima; Oliveira Lima, Maria Aparecida; do Amaral, Helineide Ramos; Cerqueira, Erenilde] Univ Estadual Feira De Santana, Feira De Santana, BA, Brazil.
   [Maia, Maricelia Lima; Falcao, Melissa Barreto] Minist Saude, Secretaria Sande Feira De Santana, Feira De Santana, BA, Brazil.
   [Xavier, Joilson; Fonseca, Vagner; de Abreu, Alvaro Salgado; de Oliveira Tosta, Stephane Fraga; Giovanetti, Marta; Junior Alcantara, Luiz Carlos] Univ Fed Minas Gerais, Lab Genet Celular Mol, ICB, Belo Horizonte, MG, Brazil.
   [Fonseca, Vagner] Univ KwaZulu Natal, Coll Hlth Sci, KwaZulu Natal Res Innovat & Sequencing Platform K, Durban, South Africa.
   [Pereira, Mylena Ribeiro; de Oliveira Franca, Rafael Freitas] Fundacao Oswaldo Cruz, Inst Aggeu Magalhaes, Dept Virol, Recife, PE, Brazil.
   [Pereira, Felicidade Mota; Gusmao Maia, Zuinara Pereira] Lab Cent Saude Publ Bahia, Salvador, BA, Brazil.
   [de Abreu, Andre Luiz] Minist Saude, Coordenacao Geral Labs Saude Publ, Secretaria Vigilancia Saude, Brasilia, DF, Brazil.
   [de Albuquerque e Melo, Carlos Frederico Campelo] Org Mundial Sande OPAS OMS, Org Pan Amer Saude, Brasilia, DF, Brazil.
   [Faria, Nuno Rodrigues] Univ Oxford, Dept Zool, Oxford, England.
   [da Cunha, Rivaldo Venancio] Univ Fed Mato Grosso do Sul, Dept Clin Medica, Fac Med, Campo Grande, MS, Brazil.
   [da Cunha, Rivaldo Venancio] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Giovanetti, Marta; Junior Alcantara, Luiz Carlos] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Flavivirus, Rio De Janeiro, Brazil.
RP Giovanetti, M; Alcantara, LCJ (corresponding author), Univ Fed Minas Gerais, Lab Genet Celular Mol, ICB, Belo Horizonte, MG, Brazil.; Giovanetti, M; Alcantara, LCJ (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Flavivirus, Rio De Janeiro, Brazil.
EM giovanetti.marta@gmail.com; luiz.alcantara@ioc.fiocruz.br
RI Wallau, Gabriel Luz/B-5911-2008; Maia, Zuinara/M-7713-2019; Fonseca,
   Vagner/R-5813-2019; Faria, Nuno R/I-2975-2012
OI Wallau, Gabriel Luz/0000-0002-1419-5713; Fonseca,
   Vagner/0000-0001-5521-6448; Faria, Nuno R/0000-0001-8839-2798; Xavier,
   Joilson/0000-0003-3916-2018; Andrade Barbosa Lima,
   Italo/0000-0002-7113-7579
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [440685/2016-8]; CAPESCAPES [88887.130716/2016-00]; Horizon 2020
   [PRES-005-FEX-17-4-2-33]
FX This research was funded by CNPq grant number (440685/2016-8); CAPES
   grant number (88887.130716/2016-00), and by Horizon 2020
   (PRES-005-FEX-17-4-2-33) to LCJA. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Akhrymuk I, 2012, J VIROL, V86, P7180, DOI 10.1128/JVI.00541-12
   [Anonymous], 2016, B EP MON CAS DENG FE, V47, P7
   [Anonymous], 2019, B EP ARB BAH 2019
   [Anonymous], 2017, IBGE CID FEIR SANT
   Brasil. Ministerio da Saude. OPAS, 2015, OPAS DIV DAD LEV
   Brasil. Ministerio da Saude. Secretaria de Vigilacia em Saude, 2017, SECR VIG SAUD SECR A
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Cunha MD, 2017, J CLIN VIROL, V97, P44, DOI 10.1016/j.jcv.2017.10.015
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   Dias JP, 2018, EMERG INFECT DIS, V24, P617, DOI 10.3201/eid2404.171370
   European Centre for Disease Prevention and Control, 2014, GUID SURV NAT MOSQ E, DOI [10.2900/37227, DOI 10.2900/37227]
   Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401
   Faria NR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15152-8
   Fonseca V, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007231
   Fros JJ, 2013, J VIROL, V87, P10394, DOI 10.1128/JVI.00884-13
   Fu JYL, 2019, J GEN VIROL, V100, P1541, DOI 10.1099/jgv.0.001338
   Ganesan VK, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120368
   Gill MS, 2013, MOL BIOL EVOL, V30, P713, DOI 10.1093/molbev/mss265
   Huits R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196630
   Johnson BW, 2016, AM J TROP MED HYG, V95, P182, DOI 10.4269/ajtmh.16-0013
   Jones PH, 2013, VIROLOGY, V438, P37, DOI 10.1016/j.virol.2013.01.010
   Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108
   Kozlov AM, 2015, BIOINFORMATICS, V31, P2577, DOI 10.1093/bioinformatics/btv184
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   Larsson A, 2014, BIOINFORMATICS, V30, P3276, DOI 10.1093/bioinformatics/btu531
   Lima MM, 2018, ORG YVANNA CARLA SOU, V2
   Ministerio da Saude, 2017, B EP MON CAS DENG FE, V48, P4
   Morrison CR, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.EI10-0017-2016
   Morrison TE, 2014, J VIROL, V88, P11644, DOI 10.1128/JVI.01432-14
   Musso D, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0556-9
   Naveca FG, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007065
   Njenga MK, 2008, J GEN VIROL, V89, P2754, DOI 10.1099/vir.0.2008/005413-0
   Pathak H, 2019, CLIN MED, V19, P381, DOI 10.7861/clinmed.2019-0035
   Peres RC, 2013, J VECTOR ECOL, V38, P190, DOI 10.1111/j.1948-7134.2013.12027.x
   Pialoux G, 2007, LANCET INFECT DIS, V7, P319, DOI 10.1016/S1473-3099(07)70107-X
   Powers AM, 2000, J GEN VIROL, V81, P471, DOI 10.1099/0022-1317-81-2-471
   Powers AM, 2011, EXP BIOL MED, V236, P909, DOI 10.1258/ebm.2011.011078
   Quick J, 2017, NAT PROTOC, V12, P1261, DOI 10.1038/nprot.2017.066
   Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Rezza G, 2007, LANCET, V370, P1840, DOI 10.1016/S0140-6736(07)61779-6
   Rodas JD, 2016, AM J TROP MED HYG, V95, P639, DOI 10.4269/ajtmh.16-0091
   Rodrigues Faria Nuno, 2016, PLoS Curr, V8, DOI 10.1371/currents.outbreaks.c97507e3e48efb946401755d468c28b2
   Schuffenecker I, 2006, PLOS MED, V3, P1058, DOI 10.1371/journal.pmed.0030263
   Suchard MA, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey016
   Nunes MRT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0348-x
   Tsetsarkin KA, 2011, P NATL ACAD SCI USA, V108, P7872, DOI 10.1073/pnas.1018344108
   Xavier J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217871
   Yactayo S, 2016, J INFECT DIS, V214, pS441, DOI 10.1093/infdis/jiw390
NR 49
TC 2
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 8
PY 2020
VL 15
IS 1
AR e0226098
DI 10.1371/journal.pone.0226098
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LP5DK
UT WOS:000534337700012
PM 31914137
OA DOAJ Gold, Green Published
DA 2020-11-11
ER

PT J
AU Ximenes, RAD
   Miranda, DD
   Brickley, EB
   Montarroyos, UR
   Martelli, CMT
   de Araujo, TVB
   Rodrigues, LC
   de Albuquerque, MDPM
   de Souza, WV
   Castanha, PMD
   Franca, RFO
   Dhalia, R
   Marques, ETA
   Alves, SV
   Bezerra, LCA
   Braga, MC
   Brainer, ACM
   Carvalho, MDCG
   Cordeiro, MT
   Dimech, G
   Eickmann, SH
   Brandao, SP
   Gois, ADL
   Goncalves, AV
   Gouveia, MDL
   de Melo, APL
   Muniz, LF
   Oliveira, DMD
   Pastich, F
   Pinto, MH
   Ramos, RCF
   Rocha, MAW
   Silva, PFS
   de Vasconcelos, RAL
   Ventura, CVDC
   Ventura, LMVD
AF Ximenes, Ricardo Arraes de Alencar
   Miranda-Filho, Democrito de Barros
   Brickley, Elizabeth B.
   Montarroyos, Ulisses Ramos
   Martelli, Celina Maria Turchi
   de Araujo, Thalia Velho Barreto
   Rodrigues, Laura C.
   de Albuquerque, Maria de Fatima Pessoa Militao
   de Souza, Wayner Vieira
   Castanha, Priscila Mayrelle da Silva
   Franca, Rafael F. O.
   Dhalia, Rafael
   Marques, Ernesto T. A.
   Alves, Sandra Valongueiro
   Bezerra, Luciana Caroline Albuquerque
   Braga, Maria Cynthia
   Brainer, Alessandra Cintia Mertens
   Carvalho, Maria Durce Costa Gomes
   Cordeiro, Marli Tenorio
   Dimech, Geroge
   Eickmann, Sophie Helena
   Brandao Filho, Sinval Pinto
   Gois, Adriana de Oliveira Lima
   Goncalves, Andreia Veras
   Gouveia, Mariana de Carvalho Leal
   de Melo, Ana Paula Lopes
   Muniz, Lilian Ferreira
   Oliveira, Danielle Maria da Silva
   Pastich, Fabiana
   Pinto, Maria Helena
   Ramos, Regina Coeli Ferreira
   Rocha, Maria Angela Wanderley
   Silva, Paula Fabiana Sobral
   de Vasconcelos, Romulo Augusto Lucena
   Ventura, Camila Vieira de Oliveira Carvalho
   Ventura, Liana Maria Vieira de Oliveira
CA MERG
TI Zika virus infection in pregnancy: Establishing a case definition for
   clinical research on pregnant women with rash in an active transmission
   setting
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID US TERRITORIES; ANTIBODIES; EPIDEMIC; EXPOSURE; OUTCOMES; JANUARY;
   UPDATE; BRAZIL
AB Defining cases of Zika virus (ZIKV) infection is a critical challenge for epidemiological research. Due to ZIKV's overlapping clinical features and potential immunologic cross-reactivity with other flaviviruses and the current lack of an optimal ZIKV-specific diagnostic assay, varying approaches for identifying ZIKV infections have been employed to date. This paper presents the laboratory results and diagnostic criteria developed by the Microcephaly Epidemic Research Group for defining cases of maternal ZIKV infection in a cohort of pregnant women with rash (N = 694) recruited during the declining 2015-2017 epidemic in northeast Brazil. For this investigation, we tested maternal sera for ZIKV by quantitative reverse transcription polymerase chain reaction (qRT-PCR), Immunoglobulin (Ig) M and IgG3 enzyme-linked immunosorbent assays (ELISAs), and Plaque Reduction Neutralization Test (PRNT50). Overall, 23.8% of participants tested positive by qRT-PCR during pregnancy (range of detection: 0-72 days after rash onset). However, the inter-assay concordance was lower than expected. Among women with qRT-PCR-confirmed ZIKV and further testing, only 10.1% had positive IgM tests within 90 days of rash, and only 48.5% had ZIKV-specific PRNT50 titers >= 20 within 1 year of rash. Given the complexity of these data, we convened a panel of experts to propose an algorithm for identifying ZIKV infections in pregnancy based on all available lines of evidence. When the diagnostic algorithm was applied to the cohort, 26.9% of participants were classified as having robust evidence of a ZIKV infection during pregnancy, 4.0% as having moderate evidence, 13.3% as having limited evidence of a ZIKV infection but with uncertain timing, and 19.5% as having evidence of an unspecified flavivirus infection before or during pregnancy. Our findings suggest that integrating longitudinal data from nucleic acid and serologic testing may enhance diagnostic sensitivity and underscore the need for an on-going dialogue regarding the optimization of strategies for defining cases of ZIKV in research.
C1 [Ximenes, Ricardo Arraes de Alencar] Univ Fed Pernambuco, Dept Med Trop, Recife, PE, Brazil.
   [Ximenes, Ricardo Arraes de Alencar; Miranda-Filho, Democrito de Barros] Univ Pernambuco, Dept Med Interna, Recife, PE, Brazil.
   [Brickley, Elizabeth B.; Rodrigues, Laura C.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Montarroyos, Ulisses Ramos] Univ Pernambuco, Inst Ciencias Biol, Recife, PE, Brazil.
   [Martelli, Celina Maria Turchi; de Albuquerque, Maria de Fatima Pessoa Militao; de Souza, Wayner Vieira; Castanha, Priscila Mayrelle da Silva; Franca, Rafael F. O.; Dhalia, Rafael; Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, Inst Aggeu Magalhaes, Recife, PE, Brazil.
   [de Araujo, Thalia Velho Barreto] Univ Fed Pernambuco, Dept Med Social, Recife, PE, Brazil.
   [Castanha, Priscila Mayrelle da Silva; Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Castanha, Priscila Mayrelle da Silva] Univ Pernambuco, Fac Ciencias Med, Recife, PE, Brazil.
RP Ximenes, RAD (corresponding author), Univ Fed Pernambuco, Dept Med Trop, Recife, PE, Brazil.; Ximenes, RAD (corresponding author), Univ Pernambuco, Dept Med Interna, Recife, PE, Brazil.
EM raaximenes@uol.com.br
RI Marques, Ernesto T. A/L-4967-2013; Montarroyos, Ulisses/AAJ-7527-2020;
   Dhalia, Rafael/AAD-5432-2020; Da Silva Castanha, Priscila
   Mayrelle/G-1785-2012; Brickley, Elizabeth/U-3625-2017
OI Marques, Ernesto T. A/0000-0003-3826-9358; Da Silva Castanha, Priscila
   Mayrelle/0000-0002-1220-5308; Brickley, Elizabeth/0000-0003-0280-2288;
   Turchi Martelli, Celina Maria/0000-0002-2491-0688
FU Wellcome TrustWellcome Trust [205377/Z/16/Z, MC_PC_15088]; UK's
   Department for International Development [205377/Z/16/Z]; Wellcome
   Trust's Enhancing Research Activity in Epidemic Situations programme
   [107779/Z/15/Z, ER1505, ER1601]; European Union's Horizon 2020 research
   and innovation program under ZikaPLAN grant [734584]; Medical Research
   Council on behalf of the Newton Fund [MC_PC_15088]; Conselho Nacional de
   Desenvolvimento Cientifico e TecnologicoNational Council for Scientific
   and Technological Development (CNPq) [309722/2017-9, 308590/2013-9,
   306708/2014-0, 308491/2013-0, 306222/20132]; Secretaria de Vigilancia em
   Saude/Ministerio da Saude de Brasil Resposta a Emergencia em Saude
   Publica -Zika vi'rus e Microcefalia [837058/2016]; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel SuperiorCAPES; Departamento de
   Ciencia e Tecnologia [440839/2016-5]
FX This work was supported by the: Wellcome Trust & the UK's Department for
   International Development (205377/Z/16/Z to LCR;
   https://wellcome.ac.uk/), the Wellcome Trust's Enhancing Research
   Activity in Epidemic Situations programme (107779/Z/15/Z; with ER1505 &
   ER1601 to RAAX), the European Union's Horizon 2020 research and
   innovation program (https://ec.europa.eu/programmes/horizon2020/) under
   ZikaPLAN grant agreement No. 734584 (https://zikaplan.tghn.org/), the
   Medical Research Council on behalf of the Newton Fund and the Wellcome
   Trust (MC_PC_15088 to LCR; https://mrc.ukri.org/), the Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico(309722/2017-9to RAAX,
   308590/2013-9 to DBMF, and 306708/2014-0 to CMTM, 308491/2013-0 to
   MFPMA, 306222/20132 to WVS;http://www.cnpq.br/), Secretaria de
   Vigilancia em Saude/Ministerio da Saude de Brasil Resposta a Emergencia
   em Saude Publica -Zika vi ' rus e Microcefalia (837058/2016 to RAAX),
   the Conselho Nacional de Desenvolvimento Cienti ' fico e Tecnologico,
   the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (http://www.capes.gov.br/), & the Departamento de Ciencia e Tecnologia
   (http://rebrats.saude.gov.br/noticias/59DECIT)for Prevencao e Combate a
   o virus Zika I (440839/2016-5 to RAAX). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Barzon L, 2018, CLIN INFECT DIS, V66, P1173, DOI 10.1093/cid/cix967
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Castanha PMS, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007246
   Castanha PMS, 2016, J INFECT DIS, V214, P265, DOI 10.1093/infdis/jiw143
   Centers for Disease Control and Prevention, 2018, ZIK MAC ELISA INSTR
   Collins MH, 2017, EMERG INFECT DIS, V23, P773, DOI 10.3201/eid2305.161630
   Cordeiro MT, 2016, J INFECT DIS, V214, P1897, DOI 10.1093/infdis/jiw477
   Cortes F, 2018, ACTA TROP, V182, P190, DOI 10.1016/j.actatropica.2018.03.006
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Fischer C, 2018, EMERG INFECT DIS, V24, P888, DOI 10.3201/eid2405.171747
   Hoen B, 2018, NEW ENGL J MED, V378, P985, DOI 10.1056/NEJMoa1709481
   Judice CC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22159-2
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lindsey NP, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay108
   Lowe R, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15010096
   Mansuy JM, 2017, EMERG INFECT DIS, V23, P863, DOI 10.3201/eid2305.161631
   Murray KO, 2017, EMERG INFECT DIS, V23, P99, DOI 10.3201/eid2301.161394
   Nascimento EJM, 2018, J VIROL METHODS, V257, P62, DOI 10.1016/j.jviromet.2018.04.009
   Oduyebo T, 2017, MMWR-MORBID MORTAL W, V66, P781, DOI 10.15585/mmwr.mm6629e1
   Paixao ES, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy073
   Pomar L, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4431
   Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1
   Rodriguez-Barraquer I, 2018, ZIKA EMERGENCE DENGU
   Safronetz D, 2017, EMERG INFECT DIS, V23, P1577, DOI 10.3201/eid2309.162043
   Secretaria de Vigilancia em Saude-Ministerio da Saude-Brasil. Ministerio da Saude SituacAo epidemiologica de ocorrencia de microcefalias no Brasil, 2015, B EPIDEMIOLOGICO, V46
   Shapiro-Mendoza CK, 2017, MMWR-MORBID MORTAL W, V66, P615, DOI 10.15585/mmwr.mm6623e1
   Teixeira MG, 2016, AM J PUBLIC HEALTH, V106, P601, DOI 10.2105/AJPH.2016.303113
   Theel ES, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/JCM.01972-17, 10.1128/jcm.01972-17]
   WHO, 2016, WHOZIKVSUR161
NR 30
TC 6
Z9 6
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD OCT
PY 2019
VL 13
IS 10
AR e0007763
DI 10.1371/journal.pntd.0007763
PG 17
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA JK6WK
UT WOS:000494982700021
PM 31589611
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-11-11
ER

PT J
AU Lima, MC
   de Mendonca, LR
   Rezende, AM
   Carrera, RM
   Anibal-Silva, CE
   Demers, M
   D'Aiuto, L
   Wood, J
   Chowdari, KV
   Griffiths, M
   Lucena-Araujo, AR
   Barral-Netto, M
   Azevedo, EAN
   Alves, RW
   Farias, PCS
   Marques, ETA
   Castanha, PMS
   Donald, CL
   Kohl, A
   Nimgaonkar, VL
   Franca, RFO
AF Lima, Morganna C.
   de Mendonca, Leila R.
   Rezende, Antonio M.
   Carrera, Raquel M.
   Anibal-Silva, Conceicao E.
   Demers, Matthew
   D'Aiuto, Leonardo
   Wood, Joel
   Chowdari, Kodavali, V
   Griffiths, Michael
   Lucena-Araujo, Antonio R.
   Barral-Netto, Manoel
   Azevedo, Elisa A. N.
   Alves, Renan W.
   Farias, Pablo C. S.
   Marques, Ernesto T. A.
   Castanha, Priscila M. S.
   Donald, Claire L.
   Kohl, Alain
   Nimgaonkar, Vishwajit L.
   Franca, Rafael F. O.
TI The Transcriptional and Protein Profile From Human Infected
   Neuroprogenitor Cells Is Strongly Correlated to Zika Virus Microcephaly
   Cytokines Phenotype Evidencing a Persistent Inflammation in the CNS
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE Zika virus; central nervous system; inflammation; type-I interferon;
   interferonopathy; microcephaly; Zika congenital syndrome and cytokines
ID INTERFERON-ALPHA; NEURAL PROGENITORS; GENE-EXPRESSION; HUMAN BRAIN;
   STEM-CELLS; CXCL10; ASTROCYTES; DIFFERENTIATION; ACTIVATION; EXPOSURE
AB Zika virus (ZIKV) infection during pregnancy is associated with microcephaly, a congenital malformation resulting from neuroinflammation and direct effects of virus replication on the developing central nervous system (CNS). However, the exact changes in the affected CNS remain unknown. Here, we show by transcriptome analysis (at 48 h post-infection) and multiplex immune profiling that human induced-neuroprogenitor stem cells (hiNPCs) respond to ZIKV infection with a strong induction of type-I interferons (IFNs) and several type-I IFNs stimulated genes (ISGs), notably cytokines and the pro-apoptotic chemokines CXCL9 and CXCL10. By comparing the inflammatory profile induced by a ZIKV Brazilian strain with an ancestral strain isolated from Cambodia in 2010, we observed that the response magnitude differs among them. Compared to ZIKV/Cambodia, the experimental infection of hiNPCs with ZIKV/Brazil resulted in a diminished induction of ISGs and lower induction of several cytokines (IFN-alpha, IL-1 alpha/beta, IL-6, IL-8, and IL-15), consequently favoring virus replication. From ZIKV-confirmed infant microcephaly cases, we detected a similar profile characterized by the presence of IFN-alpha, CXCL10, and CXCL9 in cerebrospinal fluid (CSF) samples collected after birth, evidencing a sustained CNS inflammation. Altogether, our data suggest that the CNS may be directly affected due to an unbalanced and chronic local inflammatory response, elicited by ZIKV infection, which contributes to damage to the fetal brain.
C1 [Lima, Morganna C.; de Mendonca, Leila R.; Rezende, Antonio M.; Anibal-Silva, Conceicao E.; Azevedo, Elisa A. N.; Alves, Renan W.; Farias, Pablo C. S.; Marques, Ernesto T. A.; Franca, Rafael F. O.] Fiocruz MS, Oswaldo Cruz Fdn, Inst Aggeu Magalhaes, Recife, PE, Brazil.
   [Carrera, Raquel M.; Griffiths, Michael] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
   [Demers, Matthew; D'Aiuto, Leonardo; Wood, Joel; Chowdari, Kodavali, V; Nimgaonkar, Vishwajit L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
   [Lucena-Araujo, Antonio R.] Fed Univ Pemambuco UFPE, Recife, PE, Brazil.
   [Barral-Netto, Manoel] Fiocruz MS, Oswaldo Cruz Fdn, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Marques, Ernesto T. A.; Castanha, Priscila M. S.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Donald, Claire L.; Kohl, Alain] Univ Glasgow, Ctr Vitus Res, MRC, Glasgow, Lanark, Scotland.
   [Nimgaonkar, Vishwajit L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
RP Franca, RFO (corresponding author), Fiocruz MS, Oswaldo Cruz Fdn, Inst Aggeu Magalhaes, Recife, PE, Brazil.
EM rafael.franca@cpqam.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013; Da Silva Castanha, Priscila
   Mayrelle/G-1785-2012; Barral Netto, Manoel/B-3904-2009; Rezende, Antonio
   Mauro/S-2126-2018
OI Marques, Ernesto T. A/0000-0003-3826-9358; Da Silva Castanha, Priscila
   Mayrelle/0000-0002-1220-5308; Donald, Claire/0000-0002-4370-0707;
   Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007; Azevedo,
   Elisa/0000-0002-1774-4095; Barral Netto, Manoel/0000-0002-5823-7903;
   Rezende, Antonio Mauro/0000-0003-4775-1779
FU Fundacao de Amparo a Ciencia e Tecnologia de Pernambuco/FACEPE
   [APQ-0055.2.11/16, APQ-0044.2.11/16]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico/CNPqNational Council for
   Scientific and Technological Development (CNPq) [439975/2016-6]; UK
   Medical Research CouncilMedical Research Council UK (MRC)
   [MC_UU_12014/8, MR/N017552/1]; Stanley Medical Research Institute
   [07R-1712]; National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [MH63480, D43 TW009114]; Cura Zika-University of Pittsburgh
FX The research leading to these results received funding from the Fundacao
   de Amparo a Ciencia e Tecnologia de Pernambuco/FACEPE, grant agreement
   nos. APQ-0055.2.11/16 and APQ-0044.2.11/16, and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico/CNPq grant agreement
   439975/2016-6 under RF coordination and responsibility. UK Medical
   Research Council Grants MC_UU_12014/8 and MR/N017552/1 under AK's
   coordination. VN received grant support from the Stanley Medical
   Research Institute (07R-1712), National Institutes of Health (MH63480
   and D43 TW009114) and Cura Zika-University of Pittsburgh. The funders
   had no role in study design, data collection, and analysis, decision to
   publish, or preparation of the manuscript.
CR Akwa Y, 1998, J IMMUNOL, V161, P5016
   Asensio VC, 2001, J VIROL, V75, P7067, DOI 10.1128/JVI.75.15.7067-7077.2001
   de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Blank T, 2016, IMMUNITY, V44, P901, DOI 10.1016/j.immuni.2016.04.005
   Bowen JR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006164
   Brahma R, 2018, VIRAL IMMUNOL, V31, P321, DOI 10.1089/vim.2017.0116
   Brito CAA, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3313-4
   Brown JA, 2019, IMMUNITY, V50, P751, DOI 10.1016/j.immuni.2019.01.005
   Brownell J, 2014, J VIROL, V88, P1582, DOI 10.1128/JVI.02007-13
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Campbell IL, 1999, BRAIN RES, V835, P46, DOI 10.1016/S0006-8993(99)01328-1
   Castro MAA, 2009, BIOINFORMATICS, V25, P1468, DOI 10.1093/bioinformatics/btp246
   Chimelli L, 2018, J NEUROPATH EXP NEUR, V77, P193, DOI 10.1093/jnen/nlx116
   Cordeiro MT, 2016, LANCET, V387, P1811, DOI 10.1016/S0140-6736(16)30253-7
   Coyne CB, 2016, NAT REV MICROBIOL, V14, P707, DOI 10.1038/nrmicro.2016.125
   Crow YJ, 2011, ANN NY ACAD SCI, V1238, P91, DOI 10.1111/j.1749-6632.2011.06220.x
   Cuadrado E, 2013, BRAIN, V136, P245, DOI 10.1093/brain/aws321
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Devakumar D, 2018, LANCET INFECT DIS, V18, pE1, DOI [10.1016/S1473-3099(17)30398-5, 10.1016/s1473-3099(17)30398-5]
   Donald CL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005048
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Esser-Nobis K, 2019, J VIROL, V93, DOI 10.1128/JVI.00640-19
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Foo SS, 2017, NAT MICROBIOL, V2, P1558, DOI 10.1038/s41564-017-0016-3
   Gabriel E, 2017, CELL STEM CELL, V20, P397, DOI 10.1016/j.stem.2016.12.005
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Goutieres F, 1998, ANN NEUROL, V44, P900, DOI 10.1002/ana.410440608
   Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009
   Groom JR, 2011, IMMUNOL CELL BIOL, V89, P207, DOI 10.1038/icb.2010.158
   Hanners NW, 2016, CELL REP, V15, P2315, DOI 10.1016/j.celrep.2016.05.075
   Hazin AN, 2016, NEW ENGL J MED, V374, P2193, DOI 10.1056/NEJMc1603617
   Hu BY, 2010, P NATL ACAD SCI USA, V107, P4335, DOI 10.1073/pnas.0910012107
   Huang WC, 2016, SCI REP-UK, V6, DOI 10.1038/srep34793
   Klein RS, 2005, J VIROL, V79, P11457, DOI 10.1128/JVI.79.17.11457-11466.2005
   Klok MD, 2015, ANN CLIN TRANSL NEUR, V2, P774, DOI 10.1002/acn3.213
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Lazear HM, 2016, JAMA-J AM MED ASSOC, V315, P1945, DOI 10.1001/jama.2016.2899
   Li C, 2016, CELL STEM CELL, V19, P672, DOI 10.1016/j.stem.2016.10.017
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   Liang QM, 2016, CELL STEM CELL, V19, P663, DOI 10.1016/j.stem.2016.07.019
   Martines RB, 2016, LANCET, V388, P898, DOI 10.1016/S0140-6736(16)30883-2
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Naveca FG, 2018, MEM I OSWALDO CRUZ, V113, DOI 10.1590/0074-02760170542
   Ornelas AMM, 2017, ANN NEUROL, V81, P152, DOI 10.1002/ana.24839
   Padovan E, 2002, J LEUKOCYTE BIOL, V71, P669
   Paz-Bailey G, 2019, NEW ENGL J MED, V380, P198, DOI 10.1056/NEJMc1814416
   Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Shipley Mackenzie M, 2016, J Vis Exp, P53193, DOI 10.3791/53193
   Singh PK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29329-2
   Souza BSF, 2016, SCI REP-UK, V6, DOI 10.1038/srep39775
   Sui YJ, 2006, EUR J NEUROSCI, V23, P957, DOI 10.1111/j.1460-9568.2006.04631.x
   Sui YJ, 2004, AM J PATHOL, V164, P1557, DOI 10.1016/S0002-9440(10)63714-5
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tappe D, 2016, MED MICROBIOL IMMUN, V205, P269, DOI 10.1007/s00430-015-0445-7
   Tran PB, 2007, J COMP NEUROL, V500, P1007, DOI 10.1002/cne.21229
   Tripathi S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006258
   van Heteren JT, 2008, GLIA, V56, P568, DOI 10.1002/glia.20639
   Yockey LJ, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao1680
   Yockey LJ, 2016, CELL, V166, P1247, DOI 10.1016/j.cell.2016.08.004
   Yuan L, 2017, SCIENCE, V358, P933, DOI 10.1126/science.aam7120
   Zanini F, 2018, ELIFE, V7, DOI 10.7554/eLife.32942
   Zhang F, 2017, EBIOMEDICINE, V25, P95, DOI 10.1016/j.ebiom.2017.10.019
NR 69
TC 5
Z9 5
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD AUG 16
PY 2019
VL 10
AR 1928
DI 10.3389/fimmu.2019.01928
PG 14
WC Immunology
SC Immunology
GA IR4ZR
UT WOS:000481443300001
PM 31474994
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-11-11
ER

PT J
AU Machado, LC
   de Morais-Sobral, MC
   Campos, TD
   Pereira, MR
   de Albuquerque, MDPM
   Gilbert, C
   Franca, RFO
   Wallau, GL
AF Machado, Lais Ceschini
   de Morais-Sobral, Mariana Carolina
   Campos, Tulio de Lima
   Pereira, Mylena Ribeiro
   Pessoa Militao de Albuquerque, Maria de Fatima
   Gilbert, Clement
   Oliveira Franca, Rafael Freitas
   Wallau, Gabriel Luz
TI Genome sequencing reveals coinfection by multiple chikungunya virus
   genotypes in a recent outbreak in Brazil
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID GUILLAIN-BARRE-SYNDROME; ZIKA; DENGUE; MANIFESTATIONS; POPULATION;
   SPREAD; INDIA
AB Chikungunya virus (CHIKV) is an RNA virus from the Togaviridae family transmitted by mosquitoes in both sylvatic and urban cycles. In humans, CHIKV infection leads to a febrile illness, denominated Chikungunya fever (CHIKF), commonly associated with more intense and debilitating outcomes. CHIKV arrived in Brazil in 2014 through two independent introductions: the Asian/Caribbean genotype entered through the North region and the African ECSA genotype was imported through the Northeast region. Following their initial introduction, both genotypes established their urban cycle among large naive human populations causing several outbreaks in the Americas. Here, we sequenced CHIKV genomes from a recent outbreak in the Northeast region of Brazil, employing an in-house developed Next-Generation Sequencing (NGS) protocol capable of directly detecting multiple known CHIKV genotypes from clinical positive samples. Our results demonstrate that both Asian/Caribbean and ECSA genotypes expanded their ranges, reaching cocirculation in the Northeast region of Brazil. In addition, our NGS data supports the findings of simultaneous infection by these two genotypes, suggesting that coinfection might be more common than previously thought in highly endemic areas. Future efforts to understand CHIKV epidemiology should thus take into consideration the possibility of coinfection by different genotypes in the human population.
   Author summary Human infection by different arthropod borne viruses such as Chikungunya, Dengue and Zika causes a continuous and extensive health burden mainly in tropical regions of the world. Most of the CHIKV infections result in only mild symptoms, however more extreme manifestations can occur, occasionally leading to death. Different CHIKV genotypes have been circulating in almost all continent around the globe but so far human outbreaks were reported only for single CHIKV genotypes. In Brazil two CHIKV genotypes arrived in the North and Northeast region: the Asian/Caribbean and African ECSA respectively. Here, through viral genome sequencing, we showed that some samples were coinfected by both Asian/Caribbean and ECSA CHIKV genotypes, indicating that these two genotypes expanded their ranges and currently co-circulate in some areas of Brazil. In summary, such findings call for improved surveillance in order to detect co-circulation of different viral genotypes and further evaluate the impact of co-infection in disease epidemiology.
C1 [Machado, Lais Ceschini; de Morais-Sobral, Mariana Carolina; Wallau, Gabriel Luz] Oswaldo Cruz Fdn Fiocruz, Aggeu Magalhaes Inst, Dept Entomol, Recife, PE, Brazil.
   [Campos, Tulio de Lima] Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Inst IAM, Bioinformat Core Facil, Recife, PE, Brazil.
   [Pereira, Mylena Ribeiro] Fed Rural Univ Pernambuco UFRPE, Dept Vet Med, Recife, PE, Brazil.
   [Pessoa Militao de Albuquerque, Maria de Fatima] Oswaldo Cruz Fdn Fiocruz, Aggeu Magalhaes Inst, Dept Publ Hlth, Recife, PE, Brazil.
   [Gilbert, Clement] Univ Paris Sud, CNRS, UMR 9191, UMR 247,IRD,Lab Evolut Genomes Comportment Ecol, Ave Terrasse, Gif Sur Yvette, France.
   [Oliveira Franca, Rafael Freitas] Oswaldo Cruz Fdn Fiocruz, Dept Virol & Expt Therapy, Aggeu Magalhaes Inst, Recife, PE, Brazil.
RP Wallau, GL (corresponding author), Oswaldo Cruz Fdn Fiocruz, Aggeu Magalhaes Inst, Dept Entomol, Recife, PE, Brazil.; Franca, RFO (corresponding author), Oswaldo Cruz Fdn Fiocruz, Dept Virol & Expt Therapy, Aggeu Magalhaes Inst, Recife, PE, Brazil.
EM rafael.franca@cpqam.fiocruz.br; gabriel.wallau@cpqam.fiocruz.br
RI de Lima Campos, Tulio/N-5204-2018; Wallau, Gabriel Luz/B-5911-2008
OI de Lima Campos, Tulio/0000-0003-0446-848X; Wallau, Gabriel
   Luz/0000-0002-1419-5713; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007
FU Pernambuco Research Foundation (FACEPE) [APQ-0078-2.02/16,
   APQ-0044-2.11/16, APQ-00552.11/16]; CNPqNational Council for Scientific
   and Technological Development (CNPq) [439975/2016-6]; Agence Nationale
   de la RechercheFrench National Research Agency (ANR)
   [ANR-15-CE32-0011-01]
FX This work was supported by the Pernambuco Research Foundation (FACEPE)
   process no APQ-0078-2.02/16 under GLW coordination and APQ-0044-2.11/16;
   APQ-00552.11/16 and CNPq Grant Number 439975/2016-6 under RFOF
   coordination. CG is supported by a grant from Agence Nationale de la
   Recherche (ANR-15-CE32-0011-01 TransVir). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agarwal A, 2017, J NEUROVIROL, V23, P504, DOI 10.1007/s13365-017-0516-1
   [Anonymous], 2017, J PROSTHET DENT, V11, pe1
   [Anonymous], 2017, J PROSTHET DENT, V11, pe1
   [Anonymous], 2016, EVIDENCE, V8, pe1000
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Bouckaert R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003537
   Charlys da Costa A, 2017, EMERG INFECT DIS, P23
   Chen RB, 2016, J VIROL, V90, P10600, DOI 10.1128/JVI.01166-16
   Chevillon C, 2008, TRENDS MICROBIOL, V16, P80, DOI 10.1016/j.tim.2007.12.003
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Coffey LL, 2011, J VIROL, V85, P1025, DOI 10.1128/JVI.01918-10
   Costa-da-Silva AL, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005630
   Crosby L, 2016, INT J INFECT DIS, V48, P78, DOI 10.1016/j.ijid.2016.05.010
   Cunha MS, 2017, EMERG INFECT DIS, V23, P1737, DOI 10.3201/eid2310.161855
   Cunha MD, 2017, J CLIN VIROL, V97, P44, DOI 10.1016/j.jcv.2017.10.015
   Danecek P, 2011, BIOINFORMATICS, V27, P2156, DOI 10.1093/bioinformatics/btr330
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   Deeba F, 2016, CURRENT TOPICS CHIKU
   Dhanoa A, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1731-8
   Dias JP, 2018, EMERG INFECT DIS, V24, P617, DOI 10.3201/eid2404.171370
   Edwards T, 2017, DIAGN MICR INFEC DIS, V89, P35, DOI 10.1016/j.diagmicrobio.2017.06.001
   Furuya-Kanamori L, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1417-2
   Gardner CL, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002719
   Gardner CL, 2011, P NATL ACAD SCI USA, V108, P16026, DOI 10.1073/pnas.1110617108
   Huang WC, 2012, BIOINFORMATICS, V28, P593, DOI 10.1093/bioinformatics/btr708
   Iles JC, 2015, J CLIN MICROBIOL, V53, P3155, DOI 10.1128/JCM.00483-15
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lebrun G, 2009, EMERG INFECT DIS, V15, P495, DOI 10.3201/eid1503.071482
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Magalhaes T, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006055
   Martin DP, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev003
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Morrison TE, 2014, J VIROL, V88, P11644, DOI 10.1128/JVI.01432-14
   Pessoa R, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003201
   Pinheiro TJ, 2016, ARQ NEURO-PSIQUIAT, V74, P937, DOI [10.1590/0004-282x20160138, 10.1590/0004-282X20160138]
   Pybus OG, 2009, NAT REV GENET, V10, P540, DOI 10.1038/nrg2583
   Rodriguez-Morales AJ, 2016, TRAVEL MED INFECT DI, V14, P177, DOI 10.1016/j.tmaid.2016.05.004
   ROSS R. W., 1956, JOUR HYG, V54, P177
   Rupp JC, 2015, J GEN VIROL, V96, P2483, DOI 10.1099/jgv.0.000249
   Marinho PES, 2017, EMERG INFECT DIS, V23, P115, DOI 10.3201/eid2301.160817
   Simon F, 2015, MED MALADIES INFECT, V45, P243, DOI 10.1016/j.medmal.2015.05.007
   Nunes MRT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0348-x
   The International Conference on Water and the Environment (ICWE), 1992, ENVIRON CONSERV, V19, P181, DOI [10.1017/S0376892900030733, DOI 10.1017/S0376892900030733]
   Vega-Rua A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003780
   Villamil-Gomez WE, 2016, INT J INFECT DIS, V51, P135, DOI 10.1016/j.ijid.2016.07.017
   Weaver SC, 2015, NEW ENGL J MED, V372, P1231, DOI 10.1056/NEJMra1406035
   Weaver SC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002921
   White SK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196857
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Xiao YH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00354-5
   Carrillo-Hernandez MY, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2976-1
NR 53
TC 6
Z9 6
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAY
PY 2019
VL 13
IS 5
AR e0007332
DI 10.1371/journal.pntd.0007332
PG 15
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA IB3ST
UT WOS:000470188100029
PM 31095561
OA DOAJ Gold, Green Published
DA 2020-11-11
ER

PT J
AU Botto-Menezes, CHA
   Neto, AM
   Calvet, GA
   Kara, EO
   Lacerda, MVG
   Castilho, MD
   Stroher, U
   de Brito, CAA
   Modjarrad, K
   Broutet, N
   Brasil, P
   de Filippis, AMB
   Franca, RFO
   de Abreu, AL
   Benzaken, AS
   Bermudez, XPD
   Broutet, NJN
   Giozza, SP
   Habib, N
   Landoulsi, S
   Lima, MC
   Lima, N
   de Mello, MB
   de Menezes, AIC
   Meurant, R
   Pimenta, C
   Storme, C
   Thorson, A
   Trautman, L
AF Aguiar Botto-Menezes, Camila Helena
   Neto, Armando Menezes
   Calvet, Guilherme Amaral
   Kara, Edna Oliveira
   Guimaraes Lacerda, Marcus Vinicius
   Castilho, Marcia da Costa
   Stroher, Ute
   Antunes de Brito, Carlos Alexandre
   Modjarrad, Kayvon
   Broutet, Nathalie
   Brasil, Patricia
   Bispo de Filippis, Ana Maria
   Oliveira Franca, Rafael Freitas
   de Abreu, Andre Luiz
   Benzaken, Adele Schwartz
   Diaz Bermudez, Ximena Pamela
   Nicole Broutet, Nathalie Jeanne
   Giozza, Silvana Pereira
   Habib, Ndema
   Landoulsi, Sihem
   Lima, Morganna Costa
   Lima, Noemia
   de Mello, Maeve Brito
   Costa de Menezes, Ana Izabel
   Meurant, Robyn
   Pimenta, Cristina
   Storme, Casey
   Thorson, Anna
   Trautman, Lydie
CA ZIKABRA Study Team
TI Zika Virus in Rectal Swab Samples
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
AB We detected Zika virus RNA in rectal swab samples from 10 patients by using real-time reverse transcription PCR, and we isolated the virus from 1 patient. The longest interval from symptom onset to detection was 14 days. These findings are applicable to diagnosis and infection prevention recommendations.
C1 [Aguiar Botto-Menezes, Camila Helena] Amazonas State Univ, Manaus, Amazonas, Brazil.
   [Aguiar Botto-Menezes, Camila Helena; Guimaraes Lacerda, Marcus Vinicius; Castilho, Marcia da Costa] Trop Med Fdn Doctor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [Neto, Armando Menezes; Antunes de Brito, Carlos Alexandre; Oliveira Franca, Rafael Freitas] Inst Aggeu Magalhaes, Recife, PE, Brazil.
   [Calvet, Guilherme Amaral; Brasil, Patricia] Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Kara, Edna Oliveira; Stroher, Ute; Broutet, Nathalie] WHO, Geneva, Switzerland.
   [Guimaraes Lacerda, Marcus Vinicius] Fundacao Oswaldo Cruz, Manaus, Amazonas, Brazil.
   [Modjarrad, Kayvon] Walter Reed Army Inst Res, Silver Spring, MD USA.
   [Bispo de Filippis, Ana Maria] Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
RP Franca, RFO (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Dept Virol & Expt Therapy, Av Prof Moraes Rego S-N,Campus UFPE,Cidade Univ, BR-50740465 Recife, PE, Brazil.
EM rafael.franca@cpqam.fiocruz.br
RI Calvet, GA/G-6959-2013
OI Calvet, GA/0000-0002-3545-5238; Menezes-Neto,
   Armando/0000-0002-2003-908X; Thorson, Anna/0000-0002-8703-6561
FU Wellcome TrustWellcome Trust [206522/Z/17/Z]; World Health Organization
   (UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research,
   Development and Research Training in Human Reproduction); Brazilian
   Ministry of Health [837059/2016, 25000162039201616]; US National
   Institutes of Health National Institute of Allergy and Infectious
   DiseasesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R21AI139777]; Henry M. Jackson Foundation
   for the Advancement of Military Medicine [W81XWH-18-2-0040]; US
   Department of the Army [W81XWH-18-2-0040]; US Defense Health Agency
   [0130602D16]; World Health Emergency Programme Organization
FX The research leading to these results received funding from Wellcome
   Trust grant no. 206522/Z/17/Z, World Health Organization
   (UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research,
   Development and Research Training in Human Reproduction), World Health
   Emergency Programme Organization, Brazilian Ministry of Health (Convenio
   no. 837059/2016, Processo 25000162039201616), US National Institutes of
   Health National Institute of Allergy and Infectious Diseases (award no.
   R21AI139777). This work was supported by a cooperative agreement
   (W81XWH-18-2-0040) between the Henry M. Jackson Foundation for the
   Advancement of Military Medicine and the US Department of the Army. The
   work was funded by the US Defense Health Agency (0130602D16). The
   funders had no role in study design, data collection, analysis, decision
   to publish, or preparation of the manuscript.
CR Barzon L, 2018, CLIN INFECT DIS, V66, P1173, DOI 10.1093/cid/cix967
   Calvet GA, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2965-4
   Deckard DT, 2016, MMWR-MORBID MORTAL W, V65, P372, DOI 10.15585/mmwr.mm6514a3
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Haddow AD, 2017, EMERG INFECT DIS, V23, P1274, DOI 10.3201/eid2308.170036
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Li CF, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0170-6
   Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108
   Swaminathan S, 2016, NEW ENGL J MED, V375, P1907, DOI 10.1056/NEJMc1610613
   Uyeki TM, 2016, NEW ENGL J MED, V374, P636, DOI 10.1056/NEJMoa1504874
   Workowski KA, 2015, MMWR RECOMM REP, V64, P1
NR 13
TC 4
Z9 4
U1 0
U2 2
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD MAY
PY 2019
VL 25
IS 5
BP 951
EP 954
DI 10.3201/eid2505.180904
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA HU0TG
UT WOS:000464983500014
PM 31002058
OA DOAJ Gold, Green Published
DA 2020-11-11
ER

PT J
AU Wilder-Smith, A
   Preet, R
   Brickley, EB
   Ximenes, RAD
   Miranda, DD
   Martelli, CMT
   de Araujo, TVB
   Montarroyos, UR
   Moreira, ME
   Turchi, MD
   Solomon, T
   Jacobs, BC
   Villamizar, CP
   Osorio, L
   de Filipps, AMB
   Neyts, J
   Kaptein, S
   Huits, R
   Arien, KK
   Willison, HJ
   Edgar, JM
   Barnett, SC
   Peeling, R
   Boeras, D
   Guzman, MG
   de Silva, AM
   Falconar, AK
   Romero-Vivas, C
   Gaunt, MW
   Sette, A
   Weiskopf, D
   Lambrechts, L
   Dolk, H
   Morris, JK
   Orioli, IM
   O'Reilly, KM
   Yakob, L
   Rocklov, J
   Soares, C
   Ferreira, MLB
   Franca, RFD
   Precioso, AR
   Logan, J
   Lang, T
   Jamieson, N
   Massad, E
AF Wilder-Smith, Annelies
   Preet, Raman
   Brickley, Elizabeth B.
   de Alencar Ximenes, Ricardo Arraes
   Miranda-Filho, Democrito de Barros
   Turchi Martelli, Celina Maria
   Barreto de Araujo, Thalia Velho
   Montarroyos, Ulisses Ramos
   Moreira, Maria Elisabeth
   Turchi, Marilia Dalva
   Solomon, Tom
   Jacobs, Bart C.
   Pardo Villamizar, Carlos
   Osorio, Lyda
   de Filipps, Ana Maria Bispo
   Neyts, Johan
   Kaptein, Suzanne
   Huits, Ralph
   Arien, Kevin K.
   Willison, Hugh J.
   Edgar, Julia M.
   Barnett, Susan C.
   Peeling, Rosanna
   Boeras, Debi
   Guzman, Maria G.
   de Silva, Aravinda M.
   Falconar, Andrew K.
   Romero-Vivas, Claudia
   Gaunt, Michael W.
   Sette, Alessandro
   Weiskopf, Daniela
   Lambrechts, Louis
   Dolk, Helen
   Morris, Joan K.
   Orioli, Ieda M.
   O'Reilly, Kathleen M.
   Yakob, Laith
   Rocklov, Joacim
   Soares, Cristiane
   Ferreira, Maria Lucia Brito
   Franca, Rafael Freitas de Oliveira
   Precioso, Alexander R.
   Logan, James
   Lang, Trudie
   Jamieson, Nina
   Massad, Eduardo
TI ZikaPLAN: addressing the knowledge gaps and working towards a research
   preparedness network in the Americas
SO GLOBAL HEALTH ACTION
LA English
DT Article
DE Zika; congenital Zika syndrome; birth defect; epidemic preparedness;
   research capacity building; European Commission; microcephaly;
   Guillain-Barr? syndrome; encephalitis; sustainability
ID GUILLAIN-BARRE-SYNDROME; VIRUS-INFECTION; TRAVELERS; BRAZIL;
   EPIDEMIOLOGY; SURVEILLANCE; TRANSMISSION; DIAGNOSIS; OUTBREAK; HISTORY
AB Zika Preparedness Latin American Network (ZikaPLAN) is a research consortium funded by the European Commission to address the research gaps in combating Zika and to establish a sustainable network with research capacity building in the Americas. Here we present a report on ZikaPLAN`s mid-term achievements since its initiation in October 2016 to June 2019, illustrating the research objectives of the 15 work packages ranging from virology, diagnostics, entomology and vector control, modelling to clinical cohort studies in pregnant women and neonates, as well as studies on the neurological complications of Zika infections in adolescents and adults. For example, the Neuroviruses Emerging in the Americas Study (NEAS) has set up more than 10 clinical sites in Colombia. Through the Butantan Phase 3 dengue vaccine trial, we have access to samples of 17,000 subjects in 14 different geographic locations in Brazil. To address the lack of access to clinical samples for diagnostic evaluation, ZikaPLAN set up a network of quality sites with access to well-characterized clinical specimens and capacity for independent evaluations. The International Committee for Congenital Anomaly Surveillance Tools was formed with global representation from regional networks conducting birth defects surveillance. We have collated a comprehensive inventory of resources and tools for birth defects surveillance, and developed an App for low resource regions facilitating the coding and description of all major externally visible congenital anomalies including congenital Zika syndrome. Research Capacity Network (REDe) is a shared and open resource centre where researchers and health workers can access tools, resources and support, enabling better and more research in the region. Addressing the gap in research capacity in LMICs is pivotal in ensuring broad-based systems to be prepared for the next outbreak. Our shared and open research space through REDe will be used to maximize the transfer of research into practice by summarizing the research output and by hosting the tools, resources, guidance and recommendations generated by these studies. Leveraging on the research from this consortium, we are working towards a research preparedness network.
C1 [Wilder-Smith, Annelies; Preet, Raman; Rocklov, Joacim] Umea Univ, Dept Epidemiol & Global Hlth, S-90185 Umea, Sweden.
   [Brickley, Elizabeth B.; Peeling, Rosanna; Boeras, Debi; Falconar, Andrew K.; Gaunt, Michael W.; O'Reilly, Kathleen M.; Yakob, Laith; Logan, James] London Sch Hyg & Trop Med, London, England.
   [de Alencar Ximenes, Ricardo Arraes] Univ Fed Pernambuco, Dept Med Trop, Recife, PE, Brazil.
   [de Alencar Ximenes, Ricardo Arraes; Miranda-Filho, Democrito de Barros] Univ Pernambuco, Dept Med Interna, Recife, PE, Brazil.
   [Turchi Martelli, Celina Maria] Fundacao Oswaldo Cruz, Inst Aggeu Magalhaes, Recife, PE, Brazil.
   [Barreto de Araujo, Thalia Velho] Univ Fed Pernambuco, Dept Med Social, Recife, PE, Brazil.
   [Montarroyos, Ulisses Ramos] Univ Pernambuco, Inst Ciencias Biol, Recife, PE, Brazil.
   [Moreira, Maria Elisabeth] Fundacao Oswaldo Cruz, Inst Fernandes Figueira, Rio De Janeiro, Brazil.
   [Turchi, Marilia Dalva] Univ Fed Goias, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil.
   [Solomon, Tom] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
   [Jacobs, Bart C.] Erasmus MC, Dept Neurol, Rotterdam, Netherlands.
   [Jacobs, Bart C.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands.
   [Pardo Villamizar, Carlos] Johns Hopkins Univ, Baltimore, MD USA.
   [Pardo Villamizar, Carlos; Osorio, Lyda] Univ Valle, Cali, Colombia.
   [de Filipps, Ana Maria Bispo] Inst Oswaldo Cruz, Lab Flavivirus, Rio De Janeiro, Brazil.
   [Neyts, Johan; Kaptein, Suzanne] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol Immunol & Transplantat, Leuven, Belgium.
   [Huits, Ralph; Arien, Kevin K.] Inst Trop Med, Antwerp, Belgium.
   [Willison, Hugh J.; Edgar, Julia M.; Barnett, Susan C.] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland.
   [Guzman, Maria G.] Inst Med Trop, Pedro Kouri, Cuba.
   [de Silva, Aravinda M.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA.
   [Falconar, Andrew K.; Romero-Vivas, Claudia] Fdn Univ Norte, Dept Med, Barranquilla, Colombia.
   [Sette, Alessandro; Weiskopf, Daniela] La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA USA.
   [Sette, Alessandro] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Lambrechts, Louis] Inst Pasteur, CNRS, Insect Virus Interact Unit, UMR2000, Paris, France.
   [Dolk, Helen] Ulster Univ, Inst Nursing & Hlth Res, Maternal Fetal & Infant Res Ctr, Newtownabbey, North Ireland.
   [Morris, Joan K.] St Georges Univ London, Populat Hlth Res Inst, London, England.
   [Orioli, Ieda M.] Univ Fed Rio de Janeiro, Inst Biol, Assoc Tecn Cient Estudo Colaborat Latino Amer Mal, Dept Genet, Rio De Janeiro, Brazil.
   [Soares, Cristiane] Hosp Fed Serv Estado, Rio De Janeiro, Brazil.
   [Ferreira, Maria Lucia Brito] Hosp Restauracao, Recife, PE, Brazil.
   [Franca, Rafael Freitas de Oliveira] Fundacao Oswaldo Cruz, Recife, PE, Brazil.
   [Precioso, Alexander R.] Inst Butantan, Sao Paulo, Brazil.
   [Precioso, Alexander R.] Univ Sao Paulo, Sch Med, Pediat Dept, Sao Paulo, Brazil.
   [Lang, Trudie; Jamieson, Nina] Univ Oxford, Global Hlth Network Masters & Scholars, Oxford, England.
RP Wilder-Smith, A (corresponding author), Umea Univ, Dept Epidemiol & Global Hlth, S-90185 Umea, Sweden.
EM anneliesws@gmail.com
RI Moreira, Maria Elisabeth Lopes/AAA-3775-2020; O'Reilly,
   Kathleen/H-9170-2019; Montarroyos, Ulisses/AAJ-7527-2020; Precioso,
   Alexander Roberto/A-9712-2013; Huits, Ralph/I-8361-2019; Kaptein,
   Suzanne JF/O-4714-2019; Brickley, Elizabeth/U-3625-2017; NEYTS,
   Johan/U-8267-2017
OI Moreira, Maria Elisabeth Lopes/0000-0002-2034-0294; O'Reilly,
   Kathleen/0000-0002-4892-8022; Precioso, Alexander
   Roberto/0000-0001-8657-9292; Huits, Ralph/0000-0001-8803-9468; Kaptein,
   Suzanne JF/0000-0002-7935-0219; Brickley, Elizabeth/0000-0003-0280-2288;
   Wilder-Smith, Annelies/0000-0003-0362-5375; Solomon,
   Tom/0000-0001-7266-6547; Rocklov, Joacim/0000-0003-4030-0449; NEYTS,
   Johan/0000-0002-0033-7514; Preet, Raman Kaur/0000-0002-4371-5941
FU European UnionEuropean Union (EU) [734584]; National Institute for
   Health Research (NIHR), Health Protection Research Unit in Emerging and
   Zoonotic Infections [IS-HPU-1112-10117]; NIHR Global Health Research
   Group on Brain Infections [17/63/110]; Wellcome Trust UKWellcome Trust;
   Department for International Development UK; Medical Research Council
   UKMedical Research Council UK (MRC); CNPqNational Council for Scientific
   and Technological Development (CNPq); Secretaria de Vigilancia de Saude
   (SVS); Fundacao do Amparo a Ciencia e Tecnologia (FACEPE)
FX This project, ZikaPLAN is funded by the European Union's Horizon 2020
   research and innovation programme under Grant Agreement No. 734584. Some
   authors have received additional research funding. For example, TS is
   supported by the National Institute for Health Research (NIHR), Health
   Protection Research Unit in Emerging and Zoonotic Infections (Grant No.
   IS-HPU-1112-10117), and NIHR Global Health Research Group on Brain
   Infections (No. 17/63/110). MERG as a group has received funding from
   Wellcome Trust UK, Department for International Development UK, Medical
   Research Council UK, the Brazilian funding through CNPq, Secretaria de
   Vigilancia de Saude (SVS), and Fundacao do Amparo a Ciencia e Tecnologia
   (FACEPE).
CR Acosta-Ampudia Y, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0163-5
   Albuquerque MSV, 2019, HLTH POLICY PLAN
   Angelo KM, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay074
   Awadh A, 2017, PLOS CURR, V9
   Barbosa F, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/taw094
   de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Beran D, 2017, LANCET GLOB HEALTH, V5, pE567, DOI 10.1016/S2214-109X(17)30180-8
   Black WC, 2011, TRENDS PARASITOL, V27, P362, DOI 10.1016/j.pt.2011.04.004
   Boggild AK, 2019, J TRAVEL MED, V26, DOI 10.1093/jtm/tay117
   Boggild AK, 2015, ANN INTERN MED, V162, P757, DOI 10.7326/M15-0074
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Chen LH, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay095
   Chen LH, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tax097
   Cumberworth SL, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0450-8
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Duong V, 2017, INT J INFECT DIS, V54, P121, DOI 10.1016/j.ijid.2016.11.420
   Duttine Antony, 2019, Wellcome Open Res, V4, P80, DOI 10.12688/wellcomeopenres.15085.1
   Einspieler C, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7235
   Moreira MEL, 2018, NEW ENGL J MED, V379, P2377, DOI 10.1056/NEJMc1800098
   Falconar AKI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021024
   Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401
   Fischer C, 2019, LANCET INFECT DIS, V19, P240, DOI 10.1016/S1473-3099(19)30049-0
   Furuya-Kanamori L, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1417-2
   Glaesser D, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax007
   Goncalves A, 2018, J INFECT DIS, V217, P1060, DOI 10.1093/infdis/jix678
   Goodyer L, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay005
   Grifoni A, 2018, J IMMUNOL, V201, P3487, DOI 10.4049/jimmunol.1801090
   Grifoni A, 2017, J VIROL, V91, DOI [10.1128/JVI.01469-17, 10.1128/jvi.01469-17]
   Gubler DJ, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay097
   Hamer DH, 2019, J TRAVEL MED, V26
   Harris AF, 2012, NAT BIOTECHNOL, V30, P828, DOI 10.1038/nbt.2350
   Heymann DL, 2016, NEW ENGL J MED, V374, P1504, DOI 10.1056/NEJMp1602278
   Heymann DL, 2016, LANCET, V387, P719, DOI 10.1016/S0140-6736(16)00320-2
   Huits R, 2019, INT J INFECT DIS, V78, P39, DOI 10.1016/j.ijid.2018.10.010
   Huits R, 2019, TRAVEL MED INFECT DI, V27, P107, DOI 10.1016/j.tmaid.2018.08.007
   Huits R, 2017, B WORLD HEALTH ORGAN, V95, P802, DOI [10.2471/BLT.17.181370, 10.2471/blt.17.181370]
   Jacobs BC, 2017, J PERIPHER NERV SYST, V22, P68, DOI 10.1111/jns.12209
   Katanami Y, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax031
   Lalani T, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw043
   Leder K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185689
   Leder K, 2015, J TRAVEL MED, V22, P13, DOI 10.1111/jtm.12170
   Leonhard Sonja Emily, 2018, Pract Neurol, V18, P271, DOI 10.1136/practneurol-2017-001789
   Massad E, 2017, EPIDEMIOL INFECT, P1
   Massad E, 2019, EPIDEMIOL INFECT, V147, DOI [10.1017/S0950268819000712, 10.1017/s0950268819000712]
   Massad E, 2016, GLOBAL HEALTH ACTION, V9, P1, DOI 10.3402/gha.v9.31669
   Mead PS, 2018, NEW ENGL J MED, V378, P1377, DOI [10.1056/NEJMoa1711038, 10.1056/nejmoa1711038]
   Mehta R, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006212
   Metz SW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04767-6
   Michal Stevens A, 2017, J TRAVEL MED, V24
   Mier-y-Teran-Romero L, 2018, BMC MED, V16, DOI [10.1186/s12916-018-1052-4, 10.1186/S12916-018-1052-4]
   de Albuquerque MDPM, 2016, MEM I OSWALDO CRUZ, V111, P774, DOI 10.1590/0074-02760160291
   Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115
   Molton JS, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay023
   Montoya M, 2018, J INFECT DIS, V218, P536, DOI 10.1093/infdis/jiy164
   dos Santos SFM, 2019, NUTR J, V18, DOI 10.1186/s12937-019-0429-3
   Msall ME, 2010, ARCH PEDIAT ADOL MED, V164, P391, DOI 10.1001/archpediatrics.2010.25
   Neumayr A, 2017, EURO SURVEILL, V22
   O'Reilly KM, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1158-8
   Orioli IM, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j5018
   Paixao ES, 2016, AM J PUBLIC HEALTH, V106, P606, DOI 10.2105/AJPH.2016.303112
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Pettersson JHO, 2016, MBIO, V7, DOI [10.1128/mBio.01239-16, 10.1128/mbio.01239-16]
   Pettersson JHO, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0082-5
   Prechtl HFR, 1997, LANCET, V349, P1361, DOI 10.1016/S0140-6736(96)10182-3
   Premkumar L, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01504-17
   Quam MB, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw059
   Rezza G, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay004
   Ricciardi MJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006000
   Ritchie SA, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay084
   Rodrigues LC, 2016, AM J PUBLIC HEALTH, V106, P582, DOI 10.2105/AJPH.2016.303114
   Salzer HJF, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay055
   SCHRECK CE, 1984, AM J TROP MED HYG, V33, P725, DOI 10.4269/ajtmh.1984.33.725
   Shanks GD, 2019, J TRAVEL MED, V26, DOI 10.1093/jtm/taz003
   Sheldrick RC, 2013, ACAD PEDIATR, V13, P577, DOI 10.1016/j.acap.2013.07.001
   Shinohara K, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/tav011
   Sinkins SP, 2013, FUTURE MICROBIOL, V8, P1249, DOI 10.2217/fmb.13.95
   Sokal A, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/taw066
   Song BH, 2017, J NEUROIMMUNOL, V308, P50, DOI 10.1016/j.jneuroim.2017.03.001
   Summers DJ, 2015, J TRAVEL MED, V22, P338, DOI 10.1111/jtm.12208
   Torresi J, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax064
   Tuite AR, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay077
   van Boheemen S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02652-w
   Wang G, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay022
   Watts AG, 2018, J TRAVEL MED, V25
   Whitehead SS, 2016, EXPERT REV VACCINES, V15, P509, DOI 10.1586/14760584.2016.1115727
   Wilder-Smith A, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1398485
   Wilder-Smith A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026092
   Wilder-Smith A, 2019, J TRAVEL MED, V26, DOI 10.1093/jtm/tay157
   Wilder-Smith A, 2018, GLOBAL HEALTH ACTION, V11, DOI 10.1080/16549716.2018.1549930
   Wilder-Smith A, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay139
   Wilder-Smith A, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay044
   Xu X, 2016, PLOS CURR, V8
   Yakob L, 2017, PLOS CURR, V9
   Yakob L, 2016, LANCET INFECT DIS, V16, P1100, DOI 10.1016/S1473-3099(16)30324-3
   Yakob L, 2016, LANCET GLOB HEALTH, V4, pE148, DOI 10.1016/S2214-109X(16)00048-6
   Zhang JW, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw047
NR 96
TC 4
Z9 4
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 1654-9880
J9 GLOBAL HEALTH ACTION
JI Glob. Health Action
PD JAN 1
PY 2019
VL 12
IS 1
AR 1666566
DI 10.1080/16549716.2019.1666566
PG 16
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA JF7EZ
UT WOS:000491550400001
PM 31640505
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-11-11
ER

PT J
AU Brito, CAA
   Henriques-Souza, A
   Soares, CRP
   Castanha, PMS
   Machado, LC
   Pereira, MR
   Sobral, MCM
   Lucena-Araujo, AR
   Wallau, GL
   Franca, RFO
AF Brito, Carlos A. A.
   Henriques-Souza, Adelia
   Soares, Cynthia R. P.
   Castanha, Priscila M. S.
   Machado, Lais C.
   Pereira, Mylena R.
   Sobral, Mariana C. M.
   Lucena-Araujo, Antonio R.
   Wallau, Gabriel L.
   Franca, Rafael F. O.
TI Persistent detection of Zika virus RNA from an infant with severe
   microcephaly - a case report
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Zika virus; Neurological disease; Microcephaly; Virus persistence
ID INFECTION; BRAZIL; BRAIN
AB Background: Zika virus (ZIKV) is a recently emerged arbovirus, which infection during pregnancy is associated with a series of congenital malformations, collectively denominated Congenital Zika Syndrome (CZS). Following infection, ZIKV RNA has a median duration period of 10 days in plasma and up to 6 months in semen in immunocompetent adult individuals. Moreover, ZIKV is able to replicate and persist in fetal brains and placentas, consequently, infection is associated with pregnancy loss, albeit the pathogenic mechanisms are still unknown.
   Case presentation: Here we report a CZS case of an infant born during the ZIKV outbreak in northeast Brazil, the child presented recurrent episodes of seizures with prolonged presence of ZIKV RNA on the central nervous system (CNS) and blood. ZIKV RNA was identified and partially sequenced from a sample of cerebrospinal fluid (CSF) obtained from the infant with 6 months of life, and later from another sample after the infant completed 17 months of life. Commonly congenital infections were discarded based on STORCH (syphilis, toxoplasmosis, rubella, cytomegalovirus and herpes simplex virus) negative laboratory results. Presence of specific ZIKV antibodies on both mother and children confirmed the association of severe microcephaly and ZIKV infection, diagnosed after birth.
   Conclusions: Altogether, our data raise the possibility that CZS cases may result in prolonged viral presence, these findings c ould be useful for therapy and diagnostic recommendations.
C1 [Brito, Carlos A. A.] Fed Univ Pernambuco UFPE, Dept Clin Med, BR-50670901 Recife, PE, Brazil.
   [Henriques-Souza, Adelia] Hosp Restauracao, Dept Pediat, BR-50110900 Recife, PE, Brazil.
   [Soares, Cynthia R. P.; Castanha, Priscila M. S.; Franca, Rafael F. O.] Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Inst, Dept Virol & Expt Therapy, Ave Prof Moraes Rego S-N, BR-50740465 Recife, PE, Brazil.
   [Machado, Lais C.; Sobral, Mariana C. M.; Wallau, Gabriel L.] Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Inst, Dept Entomol, BR-50740465 Recife, PE, Brazil.
   [Pereira, Mylena R.] Fed Rural Univ Pernambuco UFRPE, Dept Vet Med, BR-52171900 Recife, PE, Brazil.
   [Lucena-Araujo, Antonio R.] Fed Univ Pernambuco UFPE, Dept Biophys, BR-50670901 Recife, PE, Brazil.
RP Franca, RFO (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Inst, Dept Virol & Expt Therapy, Ave Prof Moraes Rego S-N, BR-50740465 Recife, PE, Brazil.
EM rafael.franca@cpqam.fiocruz.br
RI Wallau, Gabriel Luz/B-5911-2008; Da Silva Castanha, Priscila
   Mayrelle/G-1785-2012
OI Wallau, Gabriel Luz/0000-0002-1419-5713; Da Silva Castanha, Priscila
   Mayrelle/0000-0002-1220-5308
FU FACEPE - Fundacao de Amparo a Ciencia e Tecnologia de Pernambuco
   [APQ-0055.2.11/16, APQ-0044.2.11/16]; CNPq - Conselho Nacional de
   Desenvolvimento Cientifico e TecnologicoNational Council for Scientific
   and Technological Development (CNPq) [439975/2016-6]; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - CAPES under RFOFCAPES
   [88887.116624/2016-01]; Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior - CAPES under GLWCAPES [APQ-0078-2.02/16]
FX The research leading to these results received funding from the FACEPE -
   Fundacao de Amparo a Ciencia e Tecnologia de Pernambuco, grant agreement
   nos. APQ-0055.2.11/16 and APQ-0044.2.11/16 and CNPq - Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico, grant agreement
   439975/2016-6, Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior - CAPES 88887.116624/2016-01 under RFOF coordination and
   responsibility and APQ-0078-2.02/16 under GLW coordination. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Aid M, 2017, CELL, V169, P610, DOI 10.1016/j.cell.2017.04.008
   Atkinson B, 2016, EMERG INFECT DIS, V22, P940, DOI 10.3201/eid2205.160107
   de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Bhatnagar J, 2017, EMERG INFECT DIS, V23, P405, DOI 10.3201/eid2303.161499
   Bogoch II, 2016, LANCET, V387, P335, DOI 10.1016/S0140-6736(16)00080-5
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Cordeiro MT, 2016, LANCET, V387, P1811, DOI 10.1016/S0140-6736(16)30253-7
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   de Souza AS, 2016, CLIN INFECT DIS, V63, P1622, DOI 10.1093/cid/ciw613
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Gaskell KM, 2017, EMERG INFECT DIS, V23, P137, DOI 10.3201/eid2301.161300
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Gregory CJ, 2017, J INFECT DIS, V216, pS875, DOI 10.1093/infdis/jix396
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lazear HM, 2016, J VIROL, V90, P4864, DOI 10.1128/JVI.00252-16
   Leal MC, 2017, EMERG INFECT DIS, V23, P1253, DOI 10.3201/eid2308.170354
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   Li HD, 2016, CELL STEM CELL, V19, P593, DOI 10.1016/j.stem.2016.08.005
   Lozier MJ, 2018, CLIN INFECT DIS
   Manangeeswaran M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006004
   Meaney-Delman D, 2016, OBSTET GYNECOL, V128, P724, DOI 10.1097/AOG.0000000000001625
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Paz-Bailey G., 2017, N ENGL J MED
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Singh RK, 2017, FRONT MICROBIOL, V8, P2677
   Swaminathan S, 2016, NEW ENGL J MED, V375, P1907, DOI 10.1056/NEJMc1610613
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Zhang XM, 2017, NAT REV IMMUNOL, V17, P495, DOI 10.1038/nri.2017.54
NR 28
TC 5
Z9 5
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD AUG 10
PY 2018
VL 18
AR 388
DI 10.1186/s12879-018-3313-4
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA GP9YG
UT WOS:000441271700003
PM 30097025
OA DOAJ Gold, Green Published
DA 2020-11-11
ER

PT J
AU Calvet, GA
   Kara, EO
   Giozza, SP
   Botto-Menezes, CHA
   Gaillard, P
   Franca, RFD
   de Lacerda, MVG
   Castilho, MD
   Brasil, P
   de Sequeira, PC
   de Mello, MB
   Bermudez, XPD
   Modjarrad, K
   Meurant, R
   Landoulsi, S
   Benzaken, AS
   de Filippis, AMB
   Broutet, NJN
AF Calvet, Guilherme Amaral
   Kara, Edna Oliveira
   Giozza, Silvana Pereira
   Aguiar Botto-Menezes, Camila Helena
   Gaillard, Philippe
   de Oliveira Franca, Rafael Freitas
   Guimaraes de lacerda, Marcus Vinicius
   Castilho, Marcia da Costa
   Brasil, Patricia
   de Sequeira, Patricia Carvalho
   de Mello, Maeve Brito
   Diaz Bermudez, Ximena Pamela
   Modjarrad, Kayvon
   Meurant, Robyn
   Landoulsi, Sihem
   Benzaken, Adele Schwartz
   Bispo de Filippis, Ana Maria
   Nicole Broutet, Nathalie Jeanne
CA ZIKABRA Study Team
TI Study on the persistence of Zika virus (ZIKV) in body fluids of patients
   with ZIKV infection in Brazil
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Arbovirus; Flavivirus; Zika virus; Body fluids; Persistence; Rt-Pcr;
   Emerging infectious diseases
ID SEXUAL TRANSMISSION; EPIDEMIC; STATES; RNA
AB Background: Zika virus (ZIKV) has been identified in several body fluids of infected individuals. In most cases, it remained detected in blood from few days to 1 week after the onset of symptoms, and can persist longer in urine and in semen. ZIKV infection can have dramatic consequences such as microcephaly and Guillain-Barre syndrome. ZIKV sexual transmission has been documented. A better understanding of ZIKV presence and persistence across biologic compartments is needed to devise rational measures to prevent its transmission.
   Methods: This observational cohort study will recruit non-pregnant participants aged 18 years and above with confirmed ZIKV infection [positive reverse transcriptase-polymerase chain reaction (RT-PCR) test in blood and/or urine]: symptomatic men and women in ZIKV infection acute phase, and their symptomatic or asymptomatic household/sexual infected contacts. Specimens of blood, urine, semen, vaginal secretion/menstrual blood, rectal swab, oral fluids, tears, sweat, urine and breast milk (if applicable) will be collected at pre-established intervals and tested for ZIKV RNA presence by RT-PCR, other co-infection (dengue, Chikungunya, HIV, hepatitis B and C, syphilis), antibody response (including immunoglobulins M and G), plaque reduction neutralization test (if simultaneously positive for ZIKV and dengue), and ZIKV culture and RNA sequencing. Data on socio-demographic characteristics and comorbidities will be collected in parallel. Participants will be followed up for 12 months.
   Discussion: This prolonged longitudinal follow-up of ZIKV infected persons with regular biologic testing and data collection will offer a unique opportunity to investigate the presence and persistence of ZIKV in various biologic compartments, their clinical and immunological correlates as well as the possibility of ZIKV reactivation/reinfection over time. This valuable information will substantially contribute to the body of knowledge on ZIKV infection and serve as a base for the development of more effective recommendation on the prevention of ZIKV transmission.
C1 [Calvet, Guilherme Amaral; Brasil, Patricia] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Acute Febrile Illnesses Lab, Rio De Janeiro, RJ, Brazil.
   [Kara, Edna Oliveira; Gaillard, Philippe; Meurant, Robyn; Landoulsi, Sihem; Nicole Broutet, Nathalie Jeanne] WHO, Geneva, Switzerland.
   [Giozza, Silvana Pereira; Benzaken, Adele Schwartz] Minist Hlth Brazil, Secretary Hlth Surveillance, Dept STI AIDS & Viral Hepatitis, Brasilia, DF, Brazil.
   [Aguiar Botto-Menezes, Camila Helena; Guimaraes de lacerda, Marcus Vinicius; Castilho, Marcia da Costa; Benzaken, Adele Schwartz] Trop Med Fdn Doctor Heitor Vieira Dourado FMT HVD, Manaus, Amazonas, Brazil.
   [de Oliveira Franca, Rafael Freitas] Fundacao Oswaldo Cruz, Aggeu Magalhaes Res Ctr, Recife, PE, Brazil.
   [de Sequeira, Patricia Carvalho; Bispo de Filippis, Ana Maria] Fundacao Oswaldo Cruz, Flavivirus Lab, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
   [de Mello, Maeve Brito] Pan Amer Hlth Org, WHO, Dept Communicable Dis & Hlth Anal, Washington, DC USA.
   [Diaz Bermudez, Ximena Pamela] Univ Brasilia, Publ Hlth Dept, Pan Amer Hlth Org, WHO, Brasilia, DF, Brazil.
   [Modjarrad, Kayvon] Walter Reed Army Inst Res, Silver Spring, MD USA.
RP Calvet, GA (corresponding author), Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Acute Febrile Illnesses Lab, Rio De Janeiro, RJ, Brazil.
EM guilherme.calvet@ini.fiocruz.br
RI Gaillard, Philippe/E-7256-2019; Calvet, GA/G-6959-2013; amsalu,
   ribka/G-8780-2019
OI Calvet, GA/0000-0002-3545-5238; Thorson, Anna/0000-0002-8703-6561;
   /0000-0002-8529-4022; Diaz Bermudez, Ximena Pamela
   Claudia/0000-0002-3771-7684; Trautmann, Lydie/0000-0002-3012-0009
FU Brazilian Ministry of Health; World Health OrganizationWorld Health
   Organization; UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of
   Research, Development and Research Training in Human Reproduction (HRP)
   from the WHO; Wellcome TrustWellcome Trust; Walter Reed Army Institute
   of Research
FX Funding was provided by the Brazilian Ministry of Health, the World
   Health Organization, the UNDP-UNFPA-UNICEF-WHO-World Bank Special
   Programme of Research, Development and Research Training in Human
   Reproduction (HRP) from the WHO, the Wellcome Trust and Walter Reed Army
   Institute of Research.
CR [Anonymous], 2015, RAP RISK ASS ZIK VIR
   Atkinson B, 2016, EMERG INFECT DIS, V22, P940, DOI 10.3201/eid2205.160107
   Barthel A, 2013, CLIN INFECT DIS, V57, P415, DOI 10.1093/cid/cit227
   Barzon L, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.10.30159
   Bonaldo MC, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004816
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37
   Calvez E, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004374
   Campos RD, 2016, J CLIN VIROL, V77, P69, DOI 10.1016/j.jcv.2016.02.009
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Dupont-Rouzeyrol M, 2016, LANCET, V387, P1051, DOI 10.1016/S0140-6736(16)00624-3
   Fonseca K, 2014, AM J TROP MED HYG, V91, P1035, DOI 10.4269/ajtmh.14-0151
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Freour T, 2016, EUROSURVEILLANCE, V21, P10, DOI 10.2807/1560-7917.ES.2016.21.23.30254
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P405, DOI 10.1016/S1473-3099(16)00138-9
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Ognjan A, 2002, JAMA-J AM MED ASSOC, V288, P1976
   Pan American Health Organization World Health Organization, 2015, NEUR SYNDR CONG MALF
   Poloni TR, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-22
   Prefeitura do Rio de Janeiro, CLIN FAM NOV RED AT
   Roze B, 2016, EUROSURVEILLANCE, V21, P8, DOI 10.2807/1560-7917.ES.2016.21.9.30154
   Sips GJ, 2012, REV MED VIROL, V22, P69, DOI 10.1002/rmv.712
   Turmel JM, 2016, LANCET, V387, P2501, DOI 10.1016/S0140-6736(16)30775-9
   WHO Emergencies, 2016, ZIK SIT REP
   WHO Interim Guidance, 2016, BREASTF CONT ZIK VIR
   WHO Media Center, 2016, WHO DIR GEN SUMM OUT
   World Health Organization, FACT SHEET
NR 35
TC 13
Z9 13
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JAN 22
PY 2018
VL 18
AR 49
DI 10.1186/s12879-018-2965-4
PG 17
WC Infectious Diseases
SC Infectious Diseases
GA FT4GR
UT WOS:000423112300001
PM 29357841
OA DOAJ Gold, Green Published
DA 2020-11-11
ER

PT J
AU de Carvalho, OV
   Felix, DM
   de Mendonca, LR
   de Araujo, CMCS
   Franca, RFD
   Cordeiro, MT
   Silva, A
   Pena, LJ
AF de Carvalho, Otavio Valerio
   Felix, Daniele Mendes
   de Mendonca, Leila Rodrigues
   Cataldi Sabino de Araujo, Catarina Maria
   de Oliveira Franca, Rafael Freitas
   Cordeiro, Marli Tenorio
   Silva Junior, Abelardo
   Pena, Lindomar Jose
TI The thiopurine nucleoside analogue 6-methylmercaptopurine riboside
   (6MMPr) effectively blocks Zika virus replication
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE Antiviral; Zika virus; Cytotoxicity; 6MMPr; Vero cells; Neuronal cells
ID INFECTION; AZATHIOPRINE; INHIBITORS; SCREEN; PREGNANCY; DISEASE;
   PROTEIN; DRUGS; WOMEN
AB Since the emergence of Zika virus (ZIKV) in Brazil in 2015, 48 countries and territories in the Americas have confirmed autochthonous cases of disease caused by the virus. ZIKV-associated neurological manifestations and congenital defects make the development of safe and effective antivirals against ZIKV of utmost importance. Here we evaluated the antiviral activity of 6-methylmercaptopurine riboside (6MMPr), a thiopurine nucleoside analogue derived fromthe prodrug azathioprine, against the epidemic ZIKV strain circulating in Brazil. In all of the assays, an epithelial (Vero) and a human neuronal (SH-SY5Y) cell line were used to evaluate the cytotoxicity and effective concentrations of 6MMPr against ZIKV. Levels of ZIKV-RNA, viral infectious titre and the percentage of infected cells in the presence or absence of 6MMPr were used to determine antiviral efficacy. 6MMPr decreased ZIKV production by >99% in both cell lines in a dose-and time-dependent manner. Interestingly, 6MMPr was 1.6 times less toxic to SH-SY5Y cells compared with Vero cells, presenting a 50% cytotoxic concentrations (CC50) of 460.3 mu M and 291 mu M, respectively. The selectivity index of 6MMPr for Vero and SH-SY5Y cells was 11.9 and 22.7, respectively, highlighting the safety profile of the drug to neuronal cells. Taken together, these results identify, for the first time, the thiopurine nucleoside analogue 6MMPr as a promising antiviral candidate against ZIKV that warrants further in vivo evaluation. (C) 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [de Carvalho, Otavio Valerio; Felix, Daniele Mendes; de Mendonca, Leila Rodrigues; Cataldi Sabino de Araujo, Catarina Maria; de Oliveira Franca, Rafael Freitas; Cordeiro, Marli Tenorio; Pena, Lindomar Jose] Oswaldo Cruz Fdn Fiocruz, Dept Virol, Ave Prof Moraes Rego, Recife, PE, Brazil.
   [Silva Junior, Abelardo] Fed Univ Vicosa UFV, Dept Vet Med, Av PH Rolfs S-N, BR-36570900 Vicosa, MG, Brazil.
RP Pena, LJ (corresponding author), Oswaldo Cruz Fdn Fiocruz, Dept Virol, Ave Prof Moraes Rego, Recife, PE, Brazil.; Silva, A (corresponding author), Fed Univ Vicosa UFV, Dept Vet Med, Av PH Rolfs S-N, BR-36570900 Vicosa, MG, Brazil.
EM asjvet@gmail.com; lindomar.pena@cpqam.fiocruz.br
FU CNPq (National Council for Scientific and Technological Development,
   Brazil)National Council for Scientific and Technological Development
   (CNPq); FACEPE (Pernambuco State Foundation for Science and Technology,
   Brazil); FACEPE; CAPESCAPES; Scientific Initiation fellowship (PIBIC)
   from FACEPE
FX This work was supported in part by grants from CNPq (National Council
   for Scientific and Technological Development, Brazil) and FACEPE
   (Pernambuco State Foundation for Science and Technology, Brazil). OVC is
   the recipient of a postdoctoral fellowship from FACEPE. DMF is the
   recipient of a doctoral fellowship from CAPES. LRM is the recipient of a
   doctoral fellowship from FACEPE. CMCSA is the recipient of a Scientific
   Initiation fellowship (PIBIC) from FACEPE.
CR Adcock RS, 2017, ANTIVIR RES, V138, P47, DOI 10.1016/j.antiviral.2016.11.018
   Atif M, 2016, INFECTION, V44, P695, DOI 10.1007/s15010-016-0935-6
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Brasil P, 2016, LANCET, V387, P1482, DOI 10.1016/S0140-6736(16)30058-7
   Byler KG, 2016, J MOL GRAPH MODEL, V69, P78, DOI 10.1016/j.jmgm.2016.08.011
   Cleary BJ, 2009, BIRTH DEFECTS RES A, V85, P647, DOI 10.1002/bdra.20583
   Contreras D, 2016, JOVE-J VIS EXP, DOI 10.3791/54767
   Crotty S, 2000, NAT MED, V6, P1375
   D'Abramo CM, 2004, J MOL BIOL, V337, P1, DOI 10.1016/j.jmb.2004.01.030
   Donald CL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005048
   Eyer L, 2016, J INFECT DIS, V214, P707, DOI 10.1093/infdis/jiw226
   Hoffmann HH, 2008, ANTIVIR RES, V80, P124, DOI 10.1016/j.antiviral.2008.05.008
   Hoover S, 2008, J GEN VIROL, V89, P1000, DOI 10.1099/vir.0.83381-0
   Julander JG, 2017, ANTIVIR RES, V137, P14, DOI 10.1016/j.antiviral.2016.11.003
   Kok WM, 2016, EXPERT OPIN DRUG DIS, V11, P433, DOI 10.1517/17460441.2016.1160887
   Konidari Anastasia, 2014, World J Gastrointest Pharmacol Ther, V5, P63, DOI 10.4292/wjgpt.v5.i2.63
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Langagergaard V, 2007, ALIMENT PHARM THER, V25, P73, DOI 10.1111/j.1365-2036.2006.03162.x
   Lim PY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026697
   Lim SP, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005737
   Matalon ST, 2004, REPROD TOXICOL, V18, P219, DOI 10.1016/j.reprotox.2003.10.014
   Mecharles S, 2016, LANCET, V387, P1481, DOI 10.1016/S0140-6736(16)00644-9
   Mumtaz Noreen, 2016, Curr Treat Options Infect Dis, V8, P208
   Petersen EE, 2016, MMWR-MORBID MORTAL W, V65, P315, DOI 10.15585/mmwr.mm6512e2
   Plourde AR, 2016, EMERG INFECT DIS, V22, P1185, DOI 10.3201/eid2207.151990
   Ramalho Rocha Yuri Raoni, 2016, PLoS Curr, V8, DOI 10.1371/currents.outbreaks.e854dbf51b8075431a05b39042c00244
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Sahoo Maheswata, 2016, Genomics & Informatics, V14, P104, DOI 10.5808/GI.2016.14.3.104
   Saxena Shailendra K., 2016, VirusDisease, V27, P111, DOI 10.1007/s13337-016-0307-y
   Sironi M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004978
   Soares CN, 2016, J CLIN VIROL, V83, P63, DOI 10.1016/j.jcv.2016.08.297
   Stangl JR, 2004, TRANSPLANTATION, V77, P562, DOI 10.1097/01.TP.0000114610.40412.C6
   Vignuzzi M, 2008, NAT MED, V14, P154, DOI 10.1038/nm1726
   Wright S, 2004, GUT, V53, P1123, DOI 10.1136/gut.2003.032896
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Zhang FB, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003326
   Zmurko J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004695
NR 37
TC 14
Z9 14
U1 1
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD DEC
PY 2017
VL 50
IS 6
BP 718
EP 725
DI 10.1016/j.ijantimicag.2017.08.016
PG 8
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA FN2LA
UT WOS:000415822600005
PM 28803932
DA 2020-11-11
ER

PT J
AU Ayres, C
   Guedes, D
   Paiva, M
   Donato, M
   Barbosa, P
   Krokovsky, L
   Rocha, S
   Saraiva, K
   Crespo, M
   Rezende, T
   Wallau, G
   Barbosa, R
   Oliveira, C
   Melo-Santos, MA
   Pena, L
   Cordeiro, M
   Franca, R
   Oliveira, A
   Peixoto, C
   Leal, WS
AF Ayres, Constancia
   Guedes, Duschinka
   Paiva, Marcelo
   Donato, Mariana
   Barbosa, Priscilla
   Krokovsky, Larissa
   Rocha, Sura
   Saraiva, Karina
   Crespo, Monica
   Rezende, Tatiana
   Wallau, Gabriel
   Barbosa, Rosangela
   Oliveira, Claudia
   Melo-Santos, Maria Alice
   Pena, Lindomar
   Cordeiro, Marli
   Franca, Rafael
   Oliveira, Andre
   Peixoto, Christina
   Leal, Walter S.
TI Response to: 'Lack of evidence for Zika virus transmission by Culex
   mosquitoes'
SO EMERGING MICROBES & INFECTIONS
LA English
DT Letter
ID AEDES-AEGYPTI MOSQUITOS; YELLOW-FEVER; BRAZIL; ISOLATIONS
C1 [Ayres, Constancia; Guedes, Duschinka; Paiva, Marcelo; Donato, Mariana; Barbosa, Priscilla; Krokovsky, Larissa; Rocha, Sura; Saraiva, Karina; Crespo, Monica; Rezende, Tatiana; Wallau, Gabriel; Barbosa, Rosangela; Oliveira, Claudia; Melo-Santos, Maria Alice; Pena, Lindomar; Cordeiro, Marli; Franca, Rafael; Oliveira, Andre; Peixoto, Christina] Fundacao Oswaldo Cruz, FIOCRUZ, IAM, Av Moraes Rego,S-N Campus UFPE,Cidade Univ, BR-50670420 Recife, PE, Brazil.
   [Paiva, Marcelo] Univ Fed Pernambuco, Ctr Acad Agreste, BR-55002970 Caruaru, PE, Brazil.
   [Leal, Walter S.] Univ Calif Davis, Davis, CA 95616 USA.
RP Ayres, C (corresponding author), Fundacao Oswaldo Cruz, FIOCRUZ, IAM, Av Moraes Rego,S-N Campus UFPE,Cidade Univ, BR-50670420 Recife, PE, Brazil.
EM tans@cpqam.fiocruz.br
RI PEIXOTO, CHRISTINA/AAD-9608-2019; Ayres, Constancia/AAQ-3448-2020;
   Wallau, Gabriel Luz/B-5911-2008; Barbosa, Rosangela/AAC-3339-2020
OI Wallau, Gabriel Luz/0000-0002-1419-5713; Barbosa,
   Rosangela/0000-0002-1171-598X; Donato, Mariana/0000-0002-3361-2789;
   Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007
CR Akoua-Koffi C, 2001, B SOC PATHOL EXOT, V94, P227
   Ayllon T, 2017, EMERG INFECT DIS, V23, P1411, DOI 10.3201/eid2308.162007
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Elizondo-Quiroga D, 2017, BIORXIV
   Fernandes RS, 2017, MEM I OSWALDO CRUZ, V112, P577, DOI 10.1590/0074-02760170145
   Ferreira-de-Brito A, 2016, MEM I OSWALDO CRUZ, V111, P655, DOI 10.1590/0074-02760160332
   Guedes DRD, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.59
   Guerbois M, 2016, J INFECT DIS, V214, P1349, DOI 10.1093/infdis/jiw302
   Guo XX, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.102
   HADDOW A. J., 1964, BULL WORLD HEALTH ORGAN, V31, P57
   MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411
   MCCRAE AWR, 1982, T ROY SOC TROP MED H, V76, P552, DOI 10.1016/0035-9203(82)90161-4
   Tabachnick WJ, 2016, CURR OPIN VIROL, V21, P124, DOI 10.1016/j.coviro.2016.09.008
   WEINBREN M. P., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P263, DOI 10.1016/0035-9203(58)90085-3
   World Health Organization, COMMUNICATION
NR 15
TC 4
Z9 4
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD OCT 18
PY 2017
VL 6
AR e91
DI 10.1038/emi.2017.86
PG 2
WC Immunology; Microbiology
SC Immunology; Microbiology
GA FK4EV
UT WOS:000413443300002
PM 29044194
OA DOAJ Gold, Green Published
DA 2020-11-11
ER

PT J
AU Castanha, PMS
   Nascimento, EJM
   Braga, C
   Cordeiro, MT
   de Carvalho, OV
   de Mendonca, LR
   Azevedo, EAN
   Franca, RFO
   Dhalia, R
   Marques, ETA
AF Castanha, Priscila M. S.
   Nascimento, Eduardo J. M.
   Braga, Cynthia
   Cordeiro, Marli T.
   de Carvalho, Otavio V.
   de Mendonca, Leila R.
   Azevedo, Elisa A. N.
   Franca, Rafael F. O.
   Dhalia, Rafael
   Marques, Ernesto T. A.
TI Enhancement of Zika Infection by Dengue-Specific Antibodies Does Not
   Alter the Production of Interleukin 6 in Fc gamma RII-Expressing K562
   Cells
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
ID DEPENDENT ENHANCEMENT; VIRUS
C1 [Castanha, Priscila M. S.; Braga, Cynthia; Cordeiro, Marli T.; de Carvalho, Otavio V.; de Mendonca, Leila R.; Azevedo, Elisa A. N.; Franca, Rafael F. O.; Dhalia, Rafael; Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, FIOCRUZ, Aggeu Magalhaes Res Ctr, Recife, PE, Brazil.
   [Castanha, Priscila M. S.] Univ Pernambuco, Inst Biol Sci, Fac Med Sci, Recife, PE, Brazil.
   [Braga, Cynthia] Inst Med Integral Prof Fernando Figueira, Recife, PE, Brazil.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA.
RP Marques, ETA (corresponding author), Ctr Vaccine Res, 3501 Fifth Ave,9052 Biomed Sci Tower 3, Pittsburgh, PA 15261 USA.
EM marques@pitt.edu
RI Marques, Ernesto T. A/L-4967-2013; Da Silva Castanha, Priscila
   Mayrelle/G-1785-2012; Dhalia, Rafael/AAD-5432-2020; Braga, Maria
   Cynthia/A-8204-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Da Silva Castanha, Priscila
   Mayrelle/0000-0002-1220-5308; Braga, Maria Cynthia/0000-0002-7862-6455;
   Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007
FU Brazilian Federal Agency for Support and Evaluation of Graduate
   Education; Center for Vaccine Research, University of Pittsburgh;
   Fogarty Training Program [D43TW006592 Pitt GIDRTP/323 NIH]; National
   Council for Scientific and Technological DevelopmentNational Council for
   Scientific and Technological Development (CNPq) [482915/2010-2
   MCT/CNPq-321 14/2010]; Strategic Program to Support Health
   Research/PAPES VI [322 407697/2012-8]; National Institute of Allergy and
   Infectious Diseases, National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19 AI56541]
FX This work was supported by the Brazilian Federal Agency for Support and
   Evaluation of Graduate Education; Center for Vaccine Research,
   University of Pittsburgh; Fogarty Training Program (grant number
   D43TW006592 Pitt GIDRTP/323 NIH to P. M. S. C.); National Council for
   Scientific and Technological Development (grant number 482915/2010-2
   MCT/CNPq-321 14/2010); Strategic Program to Support Health
   Research/PAPES VI (grant number 322 407697/2012-8); and National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health (grant number U19 AI56541).
CR Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   Halstead SB, 2017, EMERG INFECT DIS, V23, P569, DOI 10.3201/eid2304.161879
   Halstead SB, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0022-2014
   Hueston L, 2017, J INFECT DIS, V216, P612, DOI 10.1093/infdis/jix344
   KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411
   Mahalingam S, 2017, LANCET INFECT DIS, V17, P686, DOI 10.1016/S1473-3099(17)30340-7
   Ng JKW, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004031
NR 10
TC 4
Z9 4
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 1
PY 2017
VL 216
IS 5
BP 614
EP 615
DI 10.1093/infdis/jix346
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA FG6UY
UT WOS:000410532400015
PM 28931227
OA Green Published, Bronze
DA 2020-11-11
ER

PT J
AU Guedes, DRD
   Paiva, MHS
   Donato, MMA
   Barbosa, PP
   Krokovsky, L
   Rocha, SWD
   La Saraiva, K
   Crespo, MM
   Rezende, TM
   Wallau, GL
   Barbosa, RMR
   Oliveira, CMF
   Melo-Santos, MAV
   Pena, L
   Cordeiro, MT
   Franca, RFD
   de Oliveira, ALS
   Peixoto, CA
   Leal, WS
   Ayres, CFJ
AF Guedes, Duschinka R. D.
   Paiva, Marcelo H. S.
   Donato, Mariana M. A.
   Barbosa, Priscilla P.
   Krokovsky, Larissa
   Rocha, Sura W. dos S.
   La Saraiva, Karina
   Crespo, Monica M.
   Rezende, Tatiana M. T.
   Wallau, Gabriel L.
   Barbosa, Rosangela M. R.
   Oliveira, Claudia M. F.
   Melo-Santos, Maria A. V.
   Pena, Lindomar
   Cordeiro, Marli T.
   Franca, Rafael F. de O.
   de Oliveira, Andre L. S.
   Peixoto, Christina A.
   Leal, Walter S.
   Ayres, Constancia F. J.
TI Zika virus replication in the mosquito Culex quinquefasciatus in Brazil
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE Aedes; Culex; microcephaly; vector competence; Zika
ID AEDES-AEGYPTI MOSQUITOS; PIPIENS MOSQUITOS; FEDERATED STATES; YAP STATE;
   INFECTION; MICRONESIA; EPIDEMIC; VECTOR; SUSCEPTIBILITY; SURVEILLANCE
AB Zika virus (ZIKV) is a flavivirus that has recently been associated with an increased incidence of neonatal microcephaly and other neurological disorders. The virus is primarily transmitted by mosquito bite, although other routes of infection have been implicated in some cases. The Aedes aegypti mosquito is considered to be the main vector to humans worldwide; however, there is evidence that other mosquito species, including Culex quinquefasciatus, transmit the virus. To test the potential of Cx. quinquefasciatus to transmit ZIKV, we experimentally compared the vector competence of laboratory-reared Ae. aegypti and Cx. quinquefasciatus. Interestingly, we were able to detect the presence of ZIKV in the midgut, salivary glands and saliva of artificially fed Cx. quinquefasciatus. In addition, we collected ZIKV-infected Cx. quinquefasciatus from urban areas with high microcephaly incidence in Recife, Brazil. Corroborating our experimental data from artificially fed mosquitoes, ZIKV was isolated from field-caught Cx. quinquefasciatus, and its genome was partially sequenced. Collectively, these findings indicate that there may be a wider range of ZIKV vectors than anticipated.
C1 [Guedes, Duschinka R. D.; Paiva, Marcelo H. S.; Donato, Mariana M. A.; Barbosa, Priscilla P.; Krokovsky, Larissa; Rocha, Sura W. dos S.; La Saraiva, Karina; Crespo, Monica M.; Rezende, Tatiana M. T.; Barbosa, Rosangela M. R.; Oliveira, Claudia M. F.; Melo-Santos, Maria A. V.; Peixoto, Christina A.; Ayres, Constancia F. J.] Fundacao Oswaldo Cruz Fiocruz, Inst Aggeu Magalhaes, Dept Entomol, BR-50760420 Recife, PE, Brazil.
   [Paiva, Marcelo H. S.] Univ Fed Pernambuco, Ctr Acad Agreste, Nucleo Ciencias Vida, BR-55002970 Caruaru, Brazil.
   [Pena, Lindomar; Cordeiro, Marli T.; Franca, Rafael F. de O.] Fundacao Oswaldo Cruz Fiocruz, Inst Aggeu Magalhaes, Lab Virol & Terapia Expt, BR-50670420 Recife, PE, Brazil.
   [de Oliveira, Andre L. S.] Fundacao Oswaldo Cruz Fiocruz, Inst Aggeu Magalhaes, Nucleo Estat & Geoprocessamento, BR-50670420 Recife, PE, Brazil.
   [Leal, Walter S.] Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA.
RP Ayres, CFJ (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Inst Aggeu Magalhaes, Dept Entomol, BR-50760420 Recife, PE, Brazil.
EM tans@cpqam.fiocruz.br
RI PEIXOTO, CHRISTINA/AAD-9608-2019; Wallau, Gabriel Luz/B-5911-2008;
   Barbosa, Rosangela/AAC-3339-2020; Ayres, Constancia/AAQ-3448-2020;
   Rocha, Sura/R-8479-2018
OI Wallau, Gabriel Luz/0000-0002-1419-5713; Barbosa,
   Rosangela/0000-0002-1171-598X; Rocha, Sura/0000-0003-2312-085X
FU Fundacao de Amparo a Pesquisa do Estado de Pernambuco (FACEPE)
   [APQ-1608-2.13/15, APQ-0085-2.13/16, APQ-345-2.13/13, APQ-0078-2.02/16];
   Brazilian National Council for Research and Development (CNPq)National
   Council for Scientific and Technological Development (CNPq)
   [441100/2016-3]; National Institute of Allergy and Infectious Diseases
   at the National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R01AI095514,
   1R21AI128931-01]; CNPqNational Council for Scientific and Technological
   Development (CNPq)
FX This work was partially supported by the Fundacao de Amparo a Pesquisa
   do Estado de Pernambuco (FACEPE; APQ-1608-2.13/15 and APQ-0085-2.13/16
   to CFJA; APQ-345-2.13/13 to MAVMS and APQ-0078-2.02/16 to GLW), the
   Brazilian National Council for Research and Development (CNPq; grant
   441100/2016-3) and the National Institute of Allergy and Infectious
   Diseases at the National Institutes of Health (R01AI095514 and
   1R21AI128931-01 to WSL). CFJA and CAP were supported by productivity
   fellowships from CNPq. We thank the insectary staff at the IAM for
   technical assistance, the Program for Technological Development in Tools
   for Health (PDTIS-FIOCRUZ) for allowing us to use their facilities, the
   staff of the Pernambuco State Health Department for sharing recent data
   on microcephaly and for assisting with surveillance and the Platform of
   Statistic and Geographical Information Systems (Nucleo de Estatistica e
   Geoprocessamento, NEG) for helping us with the GIS technologies and
   statistical analyses (George Tadeu Nunes Diniz).
CR Aliota MT, 2016, EMERG INFECT DIS, V22, P1857, DOI 10.3201/eid2210.161082
   Amorim LB, 2013, PEST MANAG SCI, V69, P1307, DOI 10.1002/ps.3502
   Amraoui F, 2016, EURO SURVEILL, V21
   Araujo AP, 2017, BIOL CONTROL, V41, P339
   Ayres CFJ, 2016, LANCET INFECT DIS, V16, P278, DOI 10.1016/S1473-3099(16)00073-6
   BEARCROFT W. G. C., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P442, DOI 10.1016/0035-9203(56)90090-6
   BELL TM, 1971, ARCH GES VIRUSFORSCH, V35, P183, DOI 10.1007/BF01249709
   Boccolini D, 2016, EUROSURVEILLANCE, V21
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   BOORMAN J. P. T., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P238, DOI 10.1016/0035-9203(56)90029-3
   Dutra HLC, 2016, CELL HOST MICROBE, V19, P771, DOI 10.1016/j.chom.2016.04.021
   Chang C, 2016, J AUTOIMMUN, V68, P1, DOI 10.1016/j.jaut.2016.02.006
   Chouin-Carneiro T, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004543
   Chow VTK, 1998, AM J TROP MED HYG, V58, P578, DOI 10.4269/ajtmh.1998.58.578
   Cordeiro MT, 2016, LANCET, V387, P1811, DOI 10.1016/S0140-6736(16)30253-7
   Cornet M, 1979, CAH ORSTOM, V17, P7
   Diagne CT, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1231-2
   Diallo D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109442
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Chalegre KDD, 2009, APPL ENVIRON MICROB, V75, P1044, DOI 10.1128/AEM.02032-08
   Donald CL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005048
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Faria NR, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0356-2
   Fernandes RS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004993
   Ferreira-de-Brito A, 2016, MEM I OSWALDO CRUZ, V111, P655, DOI 10.1590/0074-02760160332
   Flies EJ, 2015, VECTOR-BORNE ZOONOT, V15, P397, DOI 10.1089/vbz.2014.1759
   Fontaine A, 2016, SCI REP-UK, V6, DOI 10.1038/srep24885
   Girard YA, 2005, J MED ENTOMOL, V42, P429, DOI 10.1603/0022-2585(2005)042[0429:USOWNV]2.0.CO;2
   Girard YA, 2007, AM J TROP MED HYG, V76, P118, DOI 10.4269/ajtmh.2007.76.118
   Goertz GP, 2016, J VIROL, V90, P10145, DOI 10.1128/JVI.00930-16
   Guo XX, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.102
   Hall-Mendelin S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004959
   Hall-Mendelin S, 2010, P NATL ACAD SCI USA, V107, P11255, DOI 10.1073/pnas.1002040107
   Huang YJS, 2016, VECTOR-BORNE ZOONOT, V16, P673, DOI 10.1089/vbz.2016.2058
   Lambrechts L, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-160
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Leal Walter S, 2016, F1000Res, V5, P2546
   Li MI, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001792
   MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411
   Donato MAM, 2015, TISSUE CELL, V47, P515, DOI 10.1016/j.tice.2015.07.001
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Moron AF, 2016, BJOG-INT J OBSTET GY, V123, P1265, DOI 10.1111/1471-0528.14072
   Nasci RS, 2001, EMERG INFECT DIS, V7, P626
   Nunes AT, 2016, PROTEOMICS, V16, P2582, DOI 10.1002/pmic.201600126
   Pilotte N, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004641
   REGIS L, 1995, MEM I OSWALDO CRUZ, V90, P115, DOI 10.1590/S0074-02761995000100022
   Richard V, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005024
   ROSEN L, 1987, AM J TROP MED HYG, V37, pS69, DOI 10.4269/ajtmh.1987.37.69S
   Salazar MI, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-9
   Savage HM, 1998, AM J TROP MED HYG, V58, P519, DOI 10.4269/ajtmh.1998.58.519
   Scheuermann RH, 2016, NATURE, V531, P173, DOI 10.1038/531173a
   SUCHARIT S, 1989, Southeast Asian Journal of Tropical Medicine and Public Health, V20, P611
   Wang ZM, 2012, VECTOR-BORNE ZOONOT, V12, P605, DOI 10.1089/vbz.2011.0660
   Weger-Lucarelli J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005101
   Zhu Z, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.48
NR 56
TC 84
Z9 88
U1 1
U2 22
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD AUG 9
PY 2017
VL 6
AR e69
DI 10.1038/emi.2017.59
PG 11
WC Immunology; Microbiology
SC Immunology; Microbiology
GA FD4BU
UT WOS:000407477100004
PM 28790458
OA DOAJ Gold, Green Published
DA 2020-11-11
ER

PT J
AU Freire, MCLC
   Pol-Fachin, L
   Coelho, DF
   Viana, IFT
   Magalhaes, T
   Cordeiro, MT
   Fischer, N
   Loeffler, FF
   Jaenisch, T
   Franca, RF
   Marques, ETA
   Lins, RD
AF Freire, Marjorie C. L. C.
   Pol-Fachin, Laercio
   Coelho, Danilo F.
   Viana, Isabelle F. T.
   Magalhaes, Tereza
   Cordeiro, Marli T.
   Fischer, Nico
   Loeffler, Felix F.
   Jaenisch, Thomas
   Franca, Rafael F.
   Marques, Ernesto T. A.
   Lins, Roberto D.
TI Mapping Putative B-Cell Zika Virus NS1 Epitopes Provides Molecular Basis
   for Anti-NS1 Antibody Discrimination between Zika and Dengue Viruses
SO ACS OMEGA
LA English
DT Article
ID GROMOS FORCE-FIELD; PRINTED ELECTRODE; PROTEIN NS1; DYNAMICS;
   ASSOCIATION; LOOPS; ASSAY
AB B-cell epitope sequences from Zika virus (ZIKV) NS1 protein have been identified using epitope prediction tools. Mapping these sequences onto the NS1 surface reveals two major conformational epitopes and a single linear one. Despite an overall average sequence identity of ca. 55% between the NS1 from ZIKV and the four dengue virus (DENV) serotypes, epitope sequences were found to be highly conserved. Nevertheless, nonconserved epitope-flanking residues are responsible for a dramatically divergent electrostatic surface potential on the epitope regions of ZIKV and DENV2 serotypes. These findings suggest that strategies for differential diagnostics on the basis of short linear NS1 sequences are likely to fail due to immunological cross-reactions. Overall, results provide the molecular basis of differential discrimination between Zika and DENVs by NS1 monoclonal antibodies.
C1 [Freire, Marjorie C. L. C.; Pol-Fachin, Laercio; Coelho, Danilo F.; Viana, Isabelle F. T.; Magalhaes, Tereza; Cordeiro, Marli T.; Franca, Rafael F.; Marques, Ernesto T. A.; Lins, Roberto D.] Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, BR-50740465 Recife, PE, Brazil.
   [Pol-Fachin, Laercio; Coelho, Danilo F.; Lins, Roberto D.] Univ Fed Pernambuco, Dept Fundamental Chem, BR-50740670 Recife, PE, Brazil.
   [Fischer, Nico; Jaenisch, Thomas] Heidelberg Univ Hosp, Dept Infect Dis, Sect Clin Trop Med, INF 324, D-69120 Heidelberg, Germany.
   [Loeffler, Felix F.] Max Planck Inst Colloids & Interfaces, Dept Biomol Syst, Muhlenberg 1, D-14476 Potsdam, Germany.
   [Fischer, Nico; Loeffler, Felix F.; Jaenisch, Thomas] Heidelberg Univ, Karlsruhe Inst Technol KIT, HEiKA Heidelberg Karlsruhe Res Partnership, D-76131 Karlsruhe, Germany.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
RP Marques, ETA; Lins, RD (corresponding author), Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, BR-50740465 Recife, PE, Brazil.; Lins, RD (corresponding author), Univ Fed Pernambuco, Dept Fundamental Chem, BR-50740670 Recife, PE, Brazil.; Marques, ETA (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
EM marques@pitt.edu; roberto.lins@cpqam.fiocruz.br
RI Coelho, Danilo Fernandes/AAC-9206-2020; Loeffler, Felix F/C-7920-2017;
   Magalhaes, Tereza/V-6632-2019; Lins, Roberto D/J-7511-2012; Marques,
   Ernesto T. A/L-4967-2013; Loeffler, Felix F/K-6192-2016; Viana,
   Isabelle/M-4435-2017
OI Coelho, Danilo Fernandes/0000-0002-1111-0825; Loeffler, Felix
   F/0000-0002-8227-2522; Lins, Roberto D/0000-0002-3983-8025; Marques,
   Ernesto T. A/0000-0003-3826-9358; Loeffler, Felix F/0000-0002-8227-2522;
   Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007; Viana,
   Isabelle/0000-0003-4648-6635
FU FACEPE; CAPESCAPES; CNPqNational Council for Scientific and
   Technological Development (CNPq); CuraZika Foundation
FX This work was supported by grants from FACEPE, CAPES, CNPq and CuraZika
   Foundation. Computational resources were provided by the Brazilian
   National Supercomputing Center (LNCC).
CR Abraham M. J., 2015, SOFTWAREX, V1-2, P19
   Akey DL, 2014, SCIENCE, V343, P881, DOI 10.1126/science.1247749
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Andersen PH, 2006, PROTEIN SCI, V15, P2558, DOI 10.1110/ps.062405906
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   Borley DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061122
   Brown WC, 2016, NAT STRUCT MOL BIOL, V23, P865, DOI 10.1038/nsmb.3268
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Cavalcanti IT, 2012, BIOCHEM ENG J, V67, P225, DOI 10.1016/j.bej.2012.06.016
   Cecchetto J, 2017, BIOSENS BIOELECTRON, V87, P949, DOI 10.1016/j.bios.2016.08.097
   Chouin-Carneiro T, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004543
   Cordeiro MT, 2016, J INFECT DIS, V214, P1897, DOI 10.1093/infdis/jiw477
   Dawes BE, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.7
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Dias ACMS, 2013, BIOSENS BIOELECTRON, V44, P216, DOI 10.1016/j.bios.2012.12.033
   Edeling MA, 2014, P NATL ACAD SCI USA, V111, P4285, DOI 10.1073/pnas.1322036111
   Figueiredo A, 2015, SCI REP-UK, V5, DOI 10.1038/srep07865
   Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753
   Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362
   Flower DR, 2013, NAT CHEM BIOL, V9, P748, DOI 10.1038/nchembio.1383
   Gutsche I, 2011, P NATL ACAD SCI USA, V108, P8003, DOI 10.1073/pnas.1017338108
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Jaenisch T, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1440-3
   Johnson AJ, 2000, J CLIN MICROBIOL, V38, P1827, DOI 10.1128/JCM.38.5.1827-1831.2000
   Johnson BW, 2009, CLIN VACCINE IMMUNOL, V16, P1052, DOI 10.1128/CVI.00095-09
   Kuno G, 2007, ARCH VIROL, V152, P687, DOI 10.1007/s00705-006-0903-z
   Kuno Goro, 2003, Adv Virus Res, V61, P3, DOI 10.1016/S0065-3527(03)61001-8
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   Lazear HM, 2016, J VIROL, V90, P4864, DOI 10.1128/JVI.00252-16
   Lessler J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf8160
   Lover AA, 2016, LANCET INFECT DIS, V16, P1331, DOI 10.1016/S1473-3099(16)30462-5
   Lutteke T, 2006, GLYCOBIOLOGY, V16, p71R, DOI 10.1093/glycob/cwj049
   Maeda A, 2013, VET J, V195, P33, DOI 10.1016/j.tvjl.2012.08.019
   Martin DA, 2000, J CLIN MICROBIOL, V38, P1823, DOI 10.1128/JCM.38.5.1823-1826.2000
   Muller DA, 2013, ANTIVIR RES, V98, P192, DOI 10.1016/j.antiviral.2013.03.008
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   NOSE S, 1983, MOL PHYS, V50, P1055, DOI 10.1080/00268978300102851
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Pol-Fachin L, 2012, J CHEM THEORY COMPUT, V8, P4681, DOI 10.1021/ct300479h
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   PRYOR MJ, 1994, J GEN VIROL, V75, P1183, DOI 10.1099/0022-1317-75-5-1183
   Rubinstein ND, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-287
   Schmid N, 2011, EUR BIOPHYS J BIOPHY, V40, P843, DOI 10.1007/s00249-011-0700-9
   Silva MMS, 2014, TALANTA, V128, P505, DOI 10.1016/j.talanta.2014.06.009
   Song H, 2016, NAT STRUCT MOL BIOL, V23, P456, DOI 10.1038/nsmb.3213
   Stadler V, 2008, ANGEW CHEM INT EDIT, V47, P7132, DOI 10.1002/anie.200801616
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Sumita LM, 2016, REV INST MED TROP SP, V58, DOI [10.1590/S1678-9946201658089, 10.1590/s1678-9946201658089]
   TIRONI IG, 1995, J CHEM PHYS, V102, P5451, DOI 10.1063/1.469273
   Viana IFT, 2013, RSC ADV, V3, P11790, DOI 10.1039/c3ra41562g
   Waggoner JJ, 2016, J CLIN MICROBIOL, V54, P860, DOI 10.1128/JCM.00279-16
   Watterson D, 2016, ANTIVIR RES, V130, P7, DOI 10.1016/j.antiviral.2016.02.014
   Wong SJ, 2017, EBIOMEDICINE, V16, P136, DOI 10.1016/j.ebiom.2017.01.008
   Young PR, 2000, J CLIN MICROBIOL, V38, P1053, DOI 10.1128/JCM.38.3.1053-1057.2000
NR 55
TC 15
Z9 15
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2470-1343
J9 ACS OMEGA
JI ACS Omega
PD JUL
PY 2017
VL 2
IS 7
BP 3913
EP 3920
DI 10.1021/acsomega.7b00608
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA FG2GV
UT WOS:000409909900090
PM 30023708
OA DOAJ Gold, Green Published
DA 2020-11-11
ER

PT J
AU Brito, CAA
   Azevedo, F
   Cordeiro, MT
   Marques, ETA
   Franca, RFO
AF Brito, Carlos A. A.
   Azevedo, Fernanda
   Cordeiro, Marli T.
   Marques, Ernesto T. A., Jr.
   Franca, Rafael F. O.
TI Central and peripheral nervous system involvement caused by Zika and
   chikungunya coinfection
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID VIRUS; INFECTION; HISTORY
C1 [Brito, Carlos A. A.] Fed Univ Pernambuco UFPE, Dept Clin Med, Recife, PE, Brazil.
   [Azevedo, Fernanda] Santa Joana Hosp, Dept Neurol, Recife, PE, Brazil.
   [Cordeiro, Marli T.; Marques, Ernesto T. A., Jr.; Franca, Rafael F. O.] Fiocruz MS, Aggeu Magalhaes Inst, Oswaldo Cruz Fdn, Dept Virol & Expt Therapy, Recife, PE, Brazil.
   [Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Ctr Vaccine Res Pittsburgh, Pittsburgh, PA USA.
RP Franca, RFO (corresponding author), Fiocruz MS, Aggeu Magalhaes Inst, Oswaldo Cruz Fdn, Dept Virol & Expt Therapy, Recife, PE, Brazil.
EM rafael.franca@cpqam.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007
FU FACEPE - Fundacao de Amparo a Ciencia e Tecnologia de Pernambuco under
   RFOF [APQ-0055.2.11/16, APQ-0044.2.11/16]
FX The research leading to these results received funding from the FACEPE -
   Fundacao de Amparo a Ciencia e Tecnologia de Pernambuco, grant agreement
   nos. APQ-0055.2.11/16 and APQ-0044.2.11/16 under RFOF coordination and
   responsibility. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR [Anonymous], 2015, Wkly Epidemiol Rec, V90, P609
   Brito C, 2015, ACTA MEDICA PORT, V28, P679
   Brooks JB, 2016, J INFECT PUBLIC HLTH
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Chandak NH, 2009, NEUROL INDIA, V57, P177, DOI 10.4103/0028-3886.51289
   Chusri S, 2011, AM J TROP MED HYG, V85, P386, DOI 10.4269/ajtmh.2011.10-0725
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Franca RFO, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004760
   MATHIAS CJ, 1989, J NEUROL SCI, V94, P255, DOI 10.1016/0022-510X(89)90235-9
   Mercado M, 2016, EURO SURVEILL, P21
   Morrison TE, 2014, J VIROL, V88, P11644, DOI 10.1128/JVI.01432-14
   Omarjee R., 2014, EURO SURVEILL, V19
   Pessoa R, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003201
   Roth A, 2014, EURO SURVEILL, V19
   Solet J. L., 2007, PLOS BIOL, V77, P727
   Tandale BV, 2009, J CLIN VIROL, V46, P145, DOI 10.1016/j.jcv.2009.06.027
   Taraphdar D, 2012, AM J TROP MED HYG, V86, P720, DOI 10.4269/ajtmh.2012.11-0704
   Villamil-Gomez WE, 2016, INT J INFECT DIS
   Waggoner JJ, 2016, CLIN INFECT DIS
   Weaver SC, 2016, ANTIVIR RES, V130, P69, DOI 10.1016/j.antiviral.2016.03.010
   Zambrano H, 2016, AM J TROP MED HYG
   Zinszer K, 2017, EMERG INFECT DIS, V23, P92, DOI 10.3201/eid2301.161274
NR 24
TC 9
Z9 9
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUL
PY 2017
VL 11
IS 7
AR e0005583
DI 10.1371/journal.pntd.0005583
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA FE2PD
UT WOS:000408057300004
PM 28704365
OA DOAJ Gold, Green Published
DA 2020-11-11
ER

PT J
AU Cumberworth, SL
   Barrie, JA
   Cunningham, ME
   de Figueiredo, DPG
   Schultz, V
   Wilder-Smith, AJ
   Brennan, B
   Pena, LJ
   Franca, RFD
   Linington, C
   Barnett, SC
   Willison, HJ
   Kohl, A
   Edgar, JM
AF Cumberworth, Stephanie L.
   Barrie, Jennifer A.
   Cunningham, Madeleine E.
   de Figueiredo, Daniely Paulino Gomes
   Schultz, Verena
   Wilder-Smith, Adrian J.
   Brennan, Benjamin
   Pena, Lindomar J.
   Franca, Rafael Freitas de Oliveira
   Linington, Christopher
   Barnett, Susan C.
   Willison, Hugh J.
   Kohl, Alain
   Edgar, Julia M.
TI Zika virus tropism and interactions in myelinating neural cell cultures:
   CNS cells and myelin are preferentially affected
SO ACTA NEUROPATHOLOGICA COMMUNICATIONS
LA English
DT Article
DE Zika virus; Tropism; Murine; Central nervous system; Peripheral nervous
   system; Myelin; Axon
ID JAPANESE ENCEPHALITIS-VIRUS; MURINE SPINAL-CORD; AXONAL-TRANSPORT;
   NEURONAL DEATH; HUMAN BRAIN; INFECTION; MODEL; ACTIVATION; MICROGLIA;
   GROWTH
AB The recent global outbreak of Zika virus (ZIKV) infection has been linked to severe neurological disorders affecting the peripheral and central nervous systems (PNS and CNS, respectively). The pathobiology underlying these diverse clinical phenotypes are the subject of intense research; however, even the principal neural cell types vulnerable to productive Zika infection remain poorly characterised. Here we used CNS and PNS myelinating cultures from wild type and Ifnar1 knockout mice to examine neuronal and glial tropism and short-term consequences of direct infection with a Brazilian variant of ZIKV. Cell cultures were infected pre- or post-myelination for various intervals, then stained with cell-type and ZIKV-specific antibodies. In bypassing systemic immunity using ex vivo culture, and the type I interferon response in Ifnar1 deficient cells, we were able to evaluate the intrinsic infectivity of neural cells. Through systematic quantification of ZIKV infected cells in myelinating cultures, we found that ZIKV infection is enhanced in the absence of the type I interferon responses and that CNS cells are considerably more susceptible to infection than PNS cells. In particular, we demonstrate that CNS axons and myelinating oligodendrocytes are especially vulnerable to injury. These results have implications for understanding the pathobiology of neurological symptoms associated with ZIKV infection. Furthermore, we provide a quantifiable ex vivo infection model that can be used for fundamental and therapeutic studies on viral neuroinvasion and its consequences.
C1 [Cumberworth, Stephanie L.; Brennan, Benjamin; Kohl, Alain] Univ Glasgow, Ctr Virus Res, MRC, Glasgow G61 1QH, Lanark, Scotland.
   [Barrie, Jennifer A.; Cunningham, Madeleine E.; de Figueiredo, Daniely Paulino Gomes; Schultz, Verena; Wilder-Smith, Adrian J.; Linington, Christopher; Barnett, Susan C.; Willison, Hugh J.; Edgar, Julia M.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, Scotland.
   [Pena, Lindomar J.; Franca, Rafael Freitas de Oliveira] Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, Dept Virol, UFPE Campus,Cidade Univ, Recife, PE, Brazil.
   [Edgar, Julia M.] Max Planck Inst Expt Med, Dept Neurogenet, Hermann Rein Str 3, D-37075 Gottingen, Germany.
RP Kohl, A (corresponding author), Univ Glasgow, Ctr Virus Res, MRC, Glasgow G61 1QH, Lanark, Scotland.; Edgar, JM (corresponding author), Univ Glasgow, Coll Med Vet & Life Sci, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, Scotland.
EM alain.kohl@glasgow.ac.uk; Julia.Edgar@glasgow.ac.uk
RI Linington, Chris/M-4883-2019; Brennan, Benjamin/AAJ-9850-2020; Edgar,
   Julia M/U-8456-2019
OI Brennan, Benjamin/0000-0003-4707-726X; Edgar, Julia
   M/0000-0002-3869-0962; Schultz, Verena/0000-0002-8172-1525; Freitas de
   Oliveira Franca, Rafael/0000-0002-1846-6007; Cunningham,
   Madeleine/0000-0002-7545-6868
FU UK Medical Research CouncilMedical Research Council UK (MRC)
   [MC_UU_12014, MR/N017552/1, MC_PC_15105, MR/K501335/1]; National Centre
   for Replacement, Reduction and Refinement [NC/L000423/1]; Wellcome
   TrustWellcome Trust [203680/Z/16/Z, WT092805]; European UnionEuropean
   Union (EU) [734584]
FX This study was funded by the UK Medical Research Council [MC_UU_12014,
   MR/N017552/1 (AK); ZIKA Rapid Response MC_PC_15105 (HW, JME, AK);
   MR/K501335/1 (Doctoral Training Grant; SLC)], National Centre for
   Replacement, Reduction and Refinement (NC/L000423/1; JME, CL) and
   Wellcome Trust (203680/Z/16/Z, WT092805; HJW). This project was
   partially funded through the European Union's Horizon 2020 research and
   innovation programme under ZikaPLAN grant agreement No 734584 (HJW, JME,
   SB, CL).
CR Adibi JJ, 2016, LANCET, V387, P1587, DOI 10.1016/S0140-6736(16)00650-4
   Ashraf U, 2016, J VIROL, V90, P4780, DOI 10.1128/JVI.02586-15
   Bayless NL, 2016, CELL HOST MICROBE, V20, P423, DOI 10.1016/j.chom.2016.09.006
   Boeuf P, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0660-0
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cheeran MCJ, 2005, J NEUROVIROL, V11, P512, DOI 10.1080/13550280500384982
   Chen CJ, 2012, GLIA, V60, P487, DOI 10.1002/glia.22282
   Chen CJ, 2010, J GEN VIROL, V91, P1028, DOI 10.1099/vir.0.013565-0
   Chen CJ, 2004, J VIROL, V78, P12107, DOI 10.1128/JVI.78.22.12107-12119.2004
   Chen ST, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002655
   Chimelli L, 2017, ACTA NEUROPATHOL, V133, P983, DOI 10.1007/s00401-017-1699-5
   Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   Dang J, 2016, CELL STEM CELL, V19, P258, DOI 10.1016/j.stem.2016.04.014
   Melo ASD, 2016, JAMA NEUROL, V73, P1407, DOI 10.1001/jamaneurol.2016.3720
   Diniz JAP, 2006, AM J TROP MED HYG, V75, P691, DOI 10.4269/ajtmh.2006.75.691
   Donald CL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005048
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Edgar JM, 2004, J CELL BIOL, V166, P121, DOI 10.1083/jcb.200312012
   Edgar JM, 2009, CURR OPIN NEUROBIOL, V19, P498, DOI 10.1016/j.conb.2009.08.003
   El Costa H, 2016, SCI REP-UK, V6, DOI 10.1038/srep35296
   Esposito S, 2017, AUTOIMMUN REV, V16, P96, DOI 10.1016/j.autrev.2016.09.022
   Faizan MI, 2016, INTERVIROLOGY, V59, P152, DOI 10.1159/000452950
   Fernandes NCCA, 2017, EXP TOXICOL PATHOL, V69, P63, DOI 10.1016/j.etp.2016.11.004
   Ferreira-de-Brito A, 2016, MEM I OSWALDO CRUZ, V111, P655, DOI 10.1590/0074-02760160332
   Gabriel E, 2017, CELL STEM CELL, V20, P397, DOI 10.1016/j.stem.2016.12.005
   Garcez PP, 2017, SCI REP-UK, V7, DOI 10.1038/srep40780
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Gatherer D, 2016, J GEN VIROL, V97, P269, DOI 10.1099/jgv.0.000381
   Ghoshal A, 2007, GLIA, V55, P483, DOI 10.1002/glia.20474
   Goodfellow JA, 2016, NAT REV NEUROL, V12, P723, DOI 10.1038/nrneurol.2016.172
   Govero J, 2016, NATURE, V540, P438, DOI 10.1038/nature20556
   Hastings AK, 2017, CELL REP, V19, P558, DOI 10.1016/j.celrep.2017.03.058
   He XL, 2010, INT J CLIN EXP PATHO, V3, P156
   Jiang R, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/787023
   Kalia M, 2013, J VIROL, V87, P148, DOI 10.1128/JVI.01399-12
   Kaushik DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032270
   KIMURAKURODA J, 1993, ARCH VIROL, V130, P477, DOI 10.1007/BF01309676
   Kiryu-Seo S, 2010, J NEUROSCI, V30, P6658, DOI 10.1523/JNEUROSCI.5265-09.2010
   Klase ZA, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004877
   Li C, 2016, CELL STEM CELL, V19, P672, DOI 10.1016/j.stem.2016.10.017
   Li F, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.10
   Li XF, 2016, EBIOMEDICINE, V12, P170, DOI 10.1016/j.ebiom.2016.09.022
   Lindqvist R, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0748-7
   Liu SF, 2016, CIRC RES, V119, P1183, DOI [10.1161/CIRCRESAHA.116.309866, 10.1161/circresaha.116.309866]
   Lum FM, 2017, CLIN INFECT DIS, V64, P914, DOI 10.1093/cid/ciw878
   Manangeeswaran M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006004
   Maximova OA, 2009, J HISTOCHEM CYTOCHEM, V57, P973, DOI 10.1369/jhc.2009.954180
   McGrath EL, 2017, STEM CELL REPORTS
   Meertens L, 2017, CELL REP, V18, P324, DOI 10.1016/j.celrep.2016.12.045
   Miner JJ, 2016, CELL REP, V16, P3208, DOI 10.1016/j.celrep.2016.08.079
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Misra UK, 2010, PROG NEUROBIOL, V91, P108, DOI 10.1016/j.pneurobio.2010.01.008
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Montgomery RR, 2017, CLIN EXP IMMUNOL, V187, P26, DOI 10.1111/cei.12863
   Morfini GA, 2009, J NEUROSCI, V29, P12776, DOI 10.1523/JNEUROSCI.3463-09.2009
   da Silva AAM, 2016, EMERG INFECT DIS, V22, P1953, DOI 10.3201/eid2211.160956
   Mukherjee S, 2015, CELL BIOL INT, V39, P224, DOI 10.1002/cbin.10354
   Myint KSA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002980
   van den Pol AN, 2017, J NEUROSCI, V37, P2161, DOI 10.1523/JNEUROSCI.3124-16.2017
   Nazmi A, 2014, NEUROBIOL DIS, V69, P235, DOI 10.1016/j.nbd.2014.05.036
   Nazmi A, 2011, J NEUROIMMUNE PHARM, V6, P420, DOI 10.1007/s11481-011-9271-x
   Nowakowski TJ, 2016, CELL STEM CELL, V18, P591, DOI 10.1016/j.stem.2016.03.012
   Onorati M, 2016, CELL REP, V16, P2576, DOI 10.1016/j.celrep.2016.08.038
   Owens T, 2014, GLIA, V62, P339, DOI 10.1002/glia.22608
   Paivalainen S, 2008, MOL CELL NEUROSCI, V37, P568, DOI 10.1016/j.mcn.2007.12.005
   Perez S, 2016, EUROSURVEILLANCE, V21, P1, DOI 10.2807/1560-7917.ES.2016.21.24.30261
   Qian XY, 2016, CELL, V165, P1238, DOI 10.1016/j.cell.2016.04.032
   Qiao ZW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114536
   Quick ED, 2014, J VIROL, V88, P13005, DOI 10.1128/JVI.01994-14
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Rust RS, 2012, SEMIN PEDIATR NEUROL, V19, P130, DOI 10.1016/j.spen.2012.03.002
   Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   Simonin Y, 2016, EBIOMEDICINE, V12, P161, DOI 10.1016/j.ebiom.2016.09.020
   Smith DR, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005296
   Smith KJ, 2001, ANN NEUROL, V49, P470
   Solbrig MV, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0550-4
   Solomon T, 2003, J NEUROVIROL, V9, P274, DOI 10.1080/13550280390194037
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Szretter KJ, 2009, J VIROL, V83, P9329, DOI 10.1128/JVI.00836-09
   Thomson CE, 2008, EUR J NEUROSCI, V28, P1518, DOI 10.1111/j.1460-9568.2008.06415.x
   Thomson CE, 2006, J NEUROSCI RES, V84, P1703, DOI 10.1002/jnr.21084
   Thongtan T, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/890586
   Thongtan T, 2010, MICROBES INFECT, V12, P37, DOI 10.1016/j.micinf.2009.09.013
   Ticconi C, 2016, PATHOG GLOB HEALTH, V110, P262, DOI 10.1080/20477724.2016.1234804
   Tripathi S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006258
   Truett GE, 2000, BIOTECHNIQUES, V29, P52, DOI 10.2144/00291bm09
   Tseng YF, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-20
   Uncini A, 2017, J NEUROL NEUROSUR PS, V88, P266, DOI 10.1136/jnnp-2016-314310
   van Marle G, 2007, J VIROL, V81, P10933, DOI 10.1128/JVI.02422-06
   Vasek MJ, 2016, NATURE, V534, P538, DOI 10.1038/nature18283
   Waldorf KMA, 2016, NAT MED, V22, P1256, DOI 10.1038/nm.4193
   Wang JN, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13101031
   Wang J, 2011, STEM CELLS, V29, P1589, DOI 10.1002/stem.699
   White MK, 2016, ANN NEUROL, V80, P479, DOI 10.1002/ana.24748
   Winkelmann ER, 2016, NERVOUS SYSTEM, P5, DOI 10.12688/f1000research.7404.1
   Yang CM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-12
   Zhang FR, 2016, NUCLEIC ACIDS RES, V44, P8610, DOI [10.1093/nar/gkw765, 10]
NR 99
TC 21
Z9 21
U1 1
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2051-5960
J9 ACTA NEUROPATHOL COM
JI Acta Neuropathol. Commun.
PD JUN 23
PY 2017
VL 5
AR 50
DI 10.1186/s40478-017-0450-8
PG 16
WC Neurosciences
SC Neurosciences & Neurology
GA FF6RL
UT WOS:000409144200001
PM 28645311
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-11-11
ER

PT J
AU Faria, NR
   Quick, J
   Claro, IM
   Theze, J
   de Jesus, JG
   Giovanetti, M
   Kraemer, MUG
   Hill, SC
   Black, A
   da Costa, AC
   Franco, LC
   Silva, SP
   Wu, CH
   Raghwani, J
   Cauchemez, S
   du Plessis, L
   Verotti, MP
   de Oliveira, WK
   Carmo, EH
   Coelho, GE
   Santelli, ACFS
   Vinhal, LC
   Henriques, CM
   Simpson, JT
   Loose, M
   Andersen, KG
   Grubaugh, ND
   Somasekar, S
   Chiu, CY
   Munoz-Medina, JE
   Gonzalez-Bonilla, CR
   Arias, CF
   Lewis-Ximenez, LL
   Baylis, SA
   Chieppe, AO
   Aguiar, SF
   Fernandes, CA
   Lemos, PS
   Nascimento, BLS
   Monteiro, HAO
   Siqueira, IC
   de Queiroz, MG
   de Souza, TR
   Bezerra, JF
   Lemos, MR
   Pereira, GF
   Loudal, D
   Moura, LC
   Dhalia, R
   Franca, RF
   Magalhaes, T
   Marques, ET
   Jaenisch, T
   Wallau, GL
   de Lima, MC
   Nascimento, V
   de Cerqueira, EM
   de Lima, MM
   Mascarenhas, DL
   Neto, JPM
   Levin, AS
   Tozetto-Mendoza, TR
   Fonseca, SN
   Mendes-Correa, MC
   Milagres, FP
   Segurado, A
   Holmes, EC
   Rambaut, A
   Bedford, T
   Nunes, MRT
   Sabino, EC
   Alcantara, LCJ
   Loman, NJ
   Pybus, OG
AF Faria, N. R.
   Quick, J.
   Claro, I. M.
   Theze, J.
   de Jesus, J. G.
   Giovanetti, M.
   Kraemer, M. U. G.
   Hill, S. C.
   Black, A.
   da Costa, A. C.
   Franco, L. C.
   Silva, S. P.
   Wu, C. -H.
   Raghwani, J.
   Cauchemez, S.
   du Plessis, L.
   Verotti, M. P.
   de Oliveira, W. K.
   Carmo, E. H.
   Coelho, G. E.
   Santelli, A. C. F. S.
   Vinhal, L. C.
   Henriques, C. M.
   Simpson, J. T.
   Loose, M.
   Andersen, K. G.
   Grubaugh, N. D.
   Somasekar, S.
   Chiu, C. Y.
   Munoz-Medina, J. E.
   Gonzalez-Bonilla, C. R.
   Arias, C. F.
   Lewis-Ximenez, L. L.
   Baylis, S. A.
   Chieppe, A. O.
   Aguiar, S. F.
   Fernandes, C. A.
   Lemos, P. S.
   Nascimento, B. L. S.
   Monteiro, H. A. O.
   Siqueira, I. C.
   de Queiroz, M. G.
   de Souza, T. R.
   Bezerra, J. F.
   Lemos, M. R.
   Pereira, G. F.
   Loudal, D.
   Moura, L. C.
   Dhalia, R.
   Franca, R. F.
   Magalhaes, T.
   Marques, E. T., Jr.
   Jaenisch, T.
   Wallau, G. L.
   de Lima, M. C.
   Nascimento, V.
   de Cerqueira, E. M.
   de Lima, M. M.
   Mascarenhas, D. L.
   Moura Neto, J. P.
   Levin, A. S.
   Tozetto-Mendoza, T. R.
   Fonseca, S. N.
   Mendes-Correa, M. C.
   Milagres, F. P.
   Segurado, A.
   Holmes, E. C.
   Rambaut, A.
   Bedford, T.
   Nunes, M. R. T.
   Sabino, E. C.
   Alcantara, L. C. J.
   Loman, N. J.
   Pybus, O. G.
TI Establishment and cryptic transmission of Zika virus in Brazil and the
   Americas
SO NATURE
LA English
DT Article
ID PHYLOGENETIC ANALYSIS; EVOLUTION; TIME; EMERGENCE; MODELS; DENGUE;
   BAHIA; RECOMBINATION; SEQUENCES; SELECTION
AB Transmission of Zika virus (ZIKV) in the Americas was first confirmed in May 2015 in northeast Brazil(1). Brazil has had the highest number of reported ZIKV cases worldwide (more than 200,000 by 24 December 20162) and the most cases associated with microcephaly and other birth defects (2,366 confirmed by 31 December 20162). Since the initial detection of ZIKV in Brazil, more than 45 countries in the Americas have reported local ZIKV transmission, with 24 of these reporting severe ZIKV-associated disease(3). However, the origin and epidemic history of ZIKV in Brazil and the Americas remain poorly understood, despite the value of this information for interpreting observed trends in reported microcephaly. Here we address this issue by generating 54 complete or partial ZIKV genomes, mostly from Brazil, and reporting data generated by a mobile genomics laboratory that travelled across northeast Brazil in 2016. One sequence represents the earliest confirmed ZIKV infection in Brazil. Analyses of viral genomes with ecological and epidemiological data yield an estimate that ZIKV was present in northeast Brazil by February 2014 and is likely to have disseminated from there, nationally and internationally, before the first detection of ZIKV in the Americas. Estimated dates for the international spread of ZIKV from Brazil indicate the duration of pre-detection cryptic transmission in recipient regions. The role of northeast Brazil in the establishment of ZIKV in the Americas is further supported by geographic analysis of ZIKV transmission potential and by estimates of the basic reproduction number of the virus.
C1 [Faria, N. R.; Theze, J.; Kraemer, M. U. G.; Hill, S. C.; Raghwani, J.; du Plessis, L.; Pybus, O. G.] Univ Oxford, Dept Zool, Oxford OX1 3SY, England.
   [Faria, N. R.; Franco, L. C.; Silva, S. P.; Lemos, P. S.; Nascimento, B. L. S.; Monteiro, H. A. O.; Nunes, M. R. T.] Minist Hlth, Evandro Chagas Inst, Ananindeua, Brazil.
   [Quick, J.; Loman, N. J.] Univ Birmingham, Inst Microbiol & Infect, Birmingham, W Midlands, England.
   [Claro, I. M.; da Costa, A. C.; Levin, A. S.; Tozetto-Mendoza, T. R.; Mendes-Correa, M. C.; Segurado, A.; Sabino, E. C.] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Claro, I. M.; da Costa, A. C.; Levin, A. S.; Tozetto-Mendoza, T. R.; Mendes-Correa, M. C.; Segurado, A.; Sabino, E. C.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [de Jesus, J. G.; Giovanetti, M.; Siqueira, I. C.; Alcantara, L. C. J.] Fiocruz MS, Fundacao Oswaldo Cruz, Salvador, BA, Brazil.
   [Giovanetti, M.] Univ Roma Tor Vergata, Rome, Italy.
   [Kraemer, M. U. G.] Harvard Med Sch, Boston, MA USA.
   [Kraemer, M. U. G.] Boston Childrens Hosp, Boston, MA USA.
   [Black, A.; Bedford, T.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Black, A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [Wu, C. -H.] Univ Oxford, Dept Stat, Oxford OX1 3LB, England.
   [Cauchemez, S.] Inst Pasteur, Math Modelling Infect Dis, Paris, France.
   [Cauchemez, S.] Inst Pasteur, Ctr Bioinformat Biostat & Integrat Biol, Paris, France.
   [Cauchemez, S.] Ctr Natl Rech Sci, URA3012, Paris, France.
   [Verotti, M. P.] Minist Hlth, Coordena Lab Saude CGLAB DEVIT SVS, Brasilia, DF, Brazil.
   [de Oliveira, W. K.] Minist Hlth, Coordena Geral Vigilincia & Resposta Emergencias, Brasilia, DF, Brazil.
   [de Oliveira, W. K.] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Data & Knowledge Integrat Hlth CIDACS, Salvador, BA, Brazil.
   [Carmo, E. H.; Henriques, C. M.] Minist Hlth, Dept Vigilincia Doencas Transmissiveis, Brasilia, DF, Brazil.
   [Coelho, G. E.; Santelli, A. C. F. S.; Vinhal, L. C.] Minist Hlth, Coordena Geral Programas Controle & Preven Malari, Brasilia, DF, Brazil.
   [Coelho, G. E.] PAHO, Buenos Aires, DF, Argentina.
   [Santelli, A. C. F. S.] Fundacao Oswaldo Cruz FIOCRUZ, Rio De Janeiro, Brazil.
   [Simpson, J. T.] Ontario Inst Canc Res, Toronto, ON, Canada.
   [Loose, M.] Univ Nottingham, Nottingham, England.
   [Andersen, K. G.; Grubaugh, N. D.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Somasekar, S.; Chiu, C. Y.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Somasekar, S.; Chiu, C. Y.] Univ Calif San Francisco, Dept Med Infect & Dis, San Francisco, CA 94143 USA.
   [Munoz-Medina, J. E.; Gonzalez-Bonilla, C. R.] Inst Mexicano Seguro Social, Div Labs Vigilancia & Invest Epidemiol, Mexico City, DF, Mexico.
   [Arias, C. F.] Univ Nacl Autonoma Mexico, Inst Biotecnol, Cuernavaca, Morelos, Mexico.
   [Lewis-Ximenez, L. L.] Inst Oswaldo Cruz FIOCRUZ, Rio De Janeiro, Brazil.
   [Baylis, S. A.] Paul Ehrlich Inst, Langen, Germany.
   [Chieppe, A. O.; Aguiar, S. F.; Fernandes, C. A.] Lab Cent Saude Publ Noel Nutels, Rio De Janeiro, Brazil.
   [de Queiroz, M. G.; de Souza, T. R.; Bezerra, J. F.] Labo Cent Saude Publ Estado Rio Grande Norte, Natal, RN, Brazil.
   [de Souza, T. R.] Univ Potiguar Rio Grande Norte, Natal, RN, Brazil.
   [Bezerra, J. F.] Fundacao Natalense Ensino & Cultura, Natal, RN, Brazil.
   [Lemos, M. R.; Pereira, G. F.; Loudal, D.; Moura, L. C.] Lab Cent Saude Publ Estado Paraiba, Joao Pessoa, Paraiba, Brazil.
   [Dhalia, R.; Franca, R. F.; Magalhaes, T.; Marques, E. T., Jr.; Wallau, G. L.] Fundacao Oswaldo Cruz FIOCRUZ, Recife, PE, Brazil.
   [Magalhaes, T.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Jaenisch, T.] Univ Heidelberg Hosp, Dept Infect Dis, Sect Clin Trop Med, Heidelberg, Germany.
   [de Lima, M. C.; Nascimento, V.; de Cerqueira, E. M.] Lab Cent Saude Publ Estado Alagoas, Maceio, Brazil.
   [de Lima, M. M.] Univ Estadual Feira de Santana, Feira Santana, Bahia, Argentina.
   [Mascarenhas, D. L.] Secretaria Saude Feira Santana, Feira De Santana, Bahia, Brazil.
   [Moura Neto, J. P.] Univ Fed Amazonas, Manaus, Amazonas, Brazil.
   [Fonseca, S. N.] Hosp Sao Francisco, Ribeirao Preto, Brazil.
   [Milagres, F. P.] Univ Fed Tocantins, Palmas, Brazil.
   [Holmes, E. C.] Univ Sydney, Sydney, NSW, Australia.
   [Rambaut, A.] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh EH9 3FL, Midlothian, Scotland.
   [Rambaut, A.] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
   [Nunes, M. R. T.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
   [Pybus, O. G.] Metabiota, San Francisco, CA 94104 USA.
RP Pybus, OG (corresponding author), Univ Oxford, Dept Zool, Oxford OX1 3SY, England.; Loman, NJ (corresponding author), Univ Birmingham, Inst Microbiol & Infect, Birmingham, W Midlands, England.; Sabino, EC (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.; Sabino, EC (corresponding author), Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.; Alcantara, LCJ (corresponding author), Fiocruz MS, Fundacao Oswaldo Cruz, Salvador, BA, Brazil.; Pybus, OG (corresponding author), Metabiota, San Francisco, CA 94104 USA.
EM sabinoec@usp.br; lalcan@bahia.fiocruz.br; n.j.loman@bham.ac.uk;
   oliver.pybus@zoo.ox.ac.uk
RI Segurado, Aluisio C/K-2229-2012; Sabino, Ester Cerdeira/F-7750-2010;
   Rambaut, Andrew/B-2481-2009; Oliveira, Claudia DL/G-8618-2011; milagres,
   flavio/Q-2403-2019; Levin, Anna S/C-8831-2012; Bezerra, Joao
   Felipe/AAE-2500-2020; Bezerrra, Joao/C-8867-2017; Magalhaes,
   Tereza/V-6632-2019; Esteban, Munoz Medina Jose/B-6186-2015; Giovanetti,
   Marta/AAK-7408-2020; Faria, Nuno R/I-2975-2012; Wallau, Gabriel
   Luz/B-5911-2008; da-Costa, Antonio Charlys/G-1548-2010; Arias,
   Carlos/O-4036-2019; Loman, Nicholas/Z-1573-2019; Dhalia,
   Rafael/AAD-5432-2020; de Siqueira, Isadora Cristina/R-9953-2016;
   Marques, Ernesto T. A/L-4967-2013; Pybus, Oliver G/B-2640-2012
OI Segurado, Aluisio C/0000-0002-6311-8036; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Rambaut, Andrew/0000-0003-4337-3707;
   Levin, Anna S/0000-0003-2427-8368; Bezerrra, Joao/0000-0002-9978-628X;
   Esteban, Munoz Medina Jose/0000-0002-1289-4457; Faria, Nuno
   R/0000-0001-8839-2798; Wallau, Gabriel Luz/0000-0002-1419-5713;
   da-Costa, Antonio Charlys/0000-0001-5516-5177; Arias,
   Carlos/0000-0003-3130-4501; de Siqueira, Isadora
   Cristina/0000-0002-2520-4099; Marques, Ernesto T. A/0000-0003-3826-9358;
   Pybus, Oliver G/0000-0002-8797-2667; Wu, Chieh-Hsi/0000-0001-9386-725X;
   Vinhal Frutuoso, Livia Carla/0000-0001-7926-1075; Raghwani,
   Jayna/0000-0001-8538-4995; Loman, Nicholas/0000-0002-9843-8988; Hill,
   Sarah/0000-0002-2995-2596; Giovanetti, Marta/0000-0002-5849-7326; Theze,
   Julien/0000-0001-8188-9494; Holmes, Edward/0000-0001-9596-3552; Freitas
   de Oliveira Franca, Rafael/0000-0002-1846-6007; Grubaugh,
   Nathan/0000-0003-2031-1933; Loose, Matthew/0000-0002-5264-0929;
   Alcantara, Luiz/0000-0002-6769-9931; Black, Allison/0000-0002-6618-4127
FU MRC/Wellcome Trust/Newton Fund Zika Rapid Response grant
   [MC_PC_15100/ZK/16-078]; USAID Emerging Pandemic Threats Program-2
   PREDICT-2United States Agency for International Development (USAID)
   [AID-OAA-A-14-00102]; MRC Bioinformatics Fellowship; Sir Henry Dale
   Fellowship [204311/Z/16/Z]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [457480/2014-9, 302584/2015-3,
   439975/2016-6]; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2012/03417-7]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R35 GM119774,
   R01 HL105704]; NSFNational Science Foundation (NSF) [DGE-1256082];
   Abbott Laboratories, Inc.Abbott Laboratories; National Health and
   Medical Research CouncilNational Health and Medical Research Council of
   Australia [GNT1037231]; MRCMedical Research Council UK (MRC); CRUKCancer
   Research UK [ANR00310]; Wellcome TrustWellcome Trust; Royal SocietyRoyal
   Society of London [101237/Z/13/Z]; ERCEuropean Research Council (ERC)
   [614725-PATHPHYLODYN, 278433-PREDEMICS]; EUEuropean Union (EU)
   [643476-COMPARE, 734548-ZIKAlliance]; IDAMS; DENFREE; DengueTools;
   PPSUSFACEPE [APQ-0302-4.01/13]; FACEPE [APQ-0044.2.11/16,
   APQ-0055.2.11/16]; German Ministry of Health
FX We thank Fundacao Oswaldo Cruz in Bahia and Pernambuco states,
   University of Sao Paulo, Instituto Evandro Chagas, and the Brazilian
   Zika virus surveillance network for their essential contributions. We
   thank the following for giving us permission to use their unpublished
   genomes available on GenBank: R. Lanciotti, J. Lednicky, A. Enfissi, F.
   Baldanti, R. Shabman, B. Picket, R. Schinazi, M. Bonaldo, M. Gale, M.
   Capobianchi and C. Concetta, M. Leguia, J. Alberto Diaz, E.
   Sevilla-Reyes, A. Franz, M. GarciaBlanco and M. J. van Hemert. We thank
   P. Fernando da Costa Vasconcelos, S. Guerreiro Rodrigues, J. Cardoso, J.
   Vasconcelos, J. Vianez Jr, J. Gil Melgaco, J. Blumel, M. C. Brito
   Lobato, L. Nunes Fava, C. Ayres, L. Abade and F. Campos. L. C. J. A.
   thanks QIAGEN for reagents and equipment and M. R. T. N. thanks FERPEL
   for consumables. We thank Oxford Nanopore for technical support,
   particularly R. Dokos, Z. McDougall, S. Cowan, G. Sanghera, and O.
   Hartwell. This work was supported by an MRC/Wellcome Trust/Newton Fund
   Zika Rapid Response grant (MC_PC_15100/ZK/16-078) and by the USAID
   Emerging Pandemic Threats Program-2 PREDICT-2 (Cooperative Agreement
   AID-OAA-A-14-00102). N. J. L. is supported by an MRC Bioinformatics
   Fellowship. N. R. F. is funded by a Sir Henry Dale Fellowship (grant
   204311/Z/16/Z). CNPq contributed to trip expenses (grant 457480/2014-9).
   A.C.d.C. was supported by FAPESP # 2012/03417-7 and M. R. T. N. by CNPq
   grant no. 302584/2015-3. A. B. and T. B. were supported by NIH award R35
   GM119774. A. B. is supported by the NSF Graduate Research Fellowship
   Program (grant DGE-1256082). T. B. is a Pew Biomedical Scholar. C.Y.C.
   is partially supported by NIH grant R01 HL105704 and an award from
   Abbott Laboratories, Inc. E. C. H. is supported by a National Health and
   Medical Research Council Australia Fellowship (GNT1037231). C.- H. W. is
   supported by the MRC and CRUK (ANR00310) and by the Wellcome Trust and
   Royal Society (grant 101237/Z/13/Z). S. C. H. is supported by the
   Wellcome Trust. This research received funding from the ERC under grant
   agreements 614725-PATHPHYLODYN and 278433-PREDEMICS, and from EU Horizon
   2020 under agreements 643476-COMPARE and 734548-ZIKAlliance. T. J. and
   E. T. M. acknowledge funding from IDAMS, DENFREE, DengueTools, and
   PPSUSFACEPE (project APQ-0302-4.01/13). R. F. F. received funding from
   FACEPE (APQ-0044.2.11/16 and APQ-0055.2.11/16) and from CNPq
   (439975/2016-6). S. A. B. was supported by the Sicherheit von Blut und
   Geweben hinsichtlich der Abwesenheit von Zikaviren from the German
   Ministry of Health.
CR [Anonymous], 2014, R LANG ENV COMP
   Baele G, 2013, MOL BIOL EVOL, V30, P239, DOI 10.1093/molbev/mss243
   Bogoch II, 2016, LANCET INFECT DIS, V16, P1237, DOI 10.1016/S1473-3099(16)30270-5
   Bogoch II, 2016, LANCET, V387, P335, DOI 10.1016/S0140-6736(16)00080-5
   Bouckaert R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003537
   Bruen TC, 2006, GENETICS, V172, P2665, DOI 10.1534/genetics.105.048975
   Caminade C, 2017, P NATL ACAD SCI USA, V114, P119, DOI 10.1073/pnas.1614303114
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cori A, 2013, AM J EPIDEMIOL, V178, P1505, DOI 10.1093/aje/kwt133
   Corman VM, 2016, B WORLD HEALTH ORGAN, V94, P880, DOI 10.2471/BLT.16.175950
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   De Maio N, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005421
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Edwards CJ, 2011, CURR BIOL, V21, P1251, DOI 10.1016/j.cub.2011.05.058
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Ferguson NM, 2016, SCIENCE, V353, P353, DOI 10.1126/science.aag0219
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Gharbi M, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-166
   Giovanetti M, 2016, INFECT GENET EVOL, V41, P142, DOI 10.1016/j.meegid.2016.03.030
   Grubaugh N. D., 2017, NATURE
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694
   Cuong HQ, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001322
   Holmes EC, 2003, J VIROL, V77, P11296, DOI 10.1128/JVI.77.20.11296-11298.2003
   Holmes EC, 2016, NATURE, V538, P193, DOI 10.1038/nature19790
   Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030
   Kindhauser MK, 2016, B WORLD HEALTH ORGAN, V94, P675, DOI 10.2471/BLT.16.171082
   Kozlov AM, 2015, BIOINFORMATICS, V31, P2577, DOI 10.1093/bioinformatics/btv184
   Kraemer MUG, 2015, ELIFE, V4, DOI 10.7554/eLife.08347
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Lessler J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf8160
   Lessler J, 2016, B WORLD HEALTH ORGAN, V94, P841, DOI 10.2471/BLT.16.174540
   Liu H, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.109
   Liu-Helmersson J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089783
   Martin DP, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev003
   Metsky HC, 2017, NATURE
   Minin VN, 2008, PHILOS T R SOC B, V363, P3985, DOI 10.1098/rstb.2008.0176
   Ministerio da Saade, 2017, B EP SECR VIG SAUD
   Naccache SN, 2016, EMERG INFECT DIS, V22, P1788, DOI 10.3201/eid2210.160663
   O'Brien JD, 2009, MOL BIOL EVOL, V26, P801, DOI 10.1093/molbev/msp003
   Pacheco O., 2016, NEW ENGL J MED
   PAHO/WHO, 2016, PAHO WHO ZIK EP UPD
   Park DJ, 2015, CELL, V161, P1516, DOI 10.1016/j.cell.2015.06.007
   Paules CI, 2017, NEW ENGL J MED, V376, P1397, DOI 10.1056/NEJMp1702172
   Perkins TA, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.126, 10.1038/NMICROBIOL.2016.126]
   Pettersson JHO, 2016, MBIO, V7, DOI [10.1128/mBio.01239-16, 10.1128/mbio.01239-16]
   Pond SLK, 2005, MOL BIOL EVOL, V22, P1208, DOI 10.1093/molbev/msi105
   Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079
   Quick J., 2017, NAT PROTOCOLS
   Quick J, 2016, NATURE, V530, P228, DOI 10.1038/nature16996
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Rocklov J, 2016, EBIOMEDICINE, V9, P250, DOI 10.1016/j.ebiom.2016.06.009
   Schierup MH, 2000, GENETICS, V156, P879
   Shapiro B, 2006, MOL BIOL EVOL, V23, P7, DOI 10.1093/molbev/msj021
   Trosemeier J-H, 2016, GENOME ANNOUNC, V4
   Vasconcelos PFC, 2016, VECTOR-BORNE ZOONOT, V16, P295, DOI 10.1089/vbz.2016.1952
   Vogel G, 2016, SCIENCE, V354, P1088, DOI 10.1126/science.354.6316.1088
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   World Health Organization, 2017, SIT REP ZIK VIR MICR
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 62
TC 225
Z9 229
U1 6
U2 80
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUN 15
PY 2017
VL 546
IS 7658
BP 406
EP +
DI 10.1038/nature22401
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EX5BK
UT WOS:000403250900035
PM 28538727
OA Green Published, Green Accepted
DA 2020-11-11
ER

PT J
AU Castanha, PMS
   Nascimento, EJM
   Braga, C
   Cordeiro, MT
   de Carvalho, OV
   de Mendonca, LR
   Azevedo, EAN
   Franca, RFO
   Dhalia, R
   Marques, ETA
AF Castanha, Priscila M. S.
   Nascimento, Eduardo J. M.
   Braga, Cynthia
   Cordeiro, Marli T.
   de Carvalho, Otavio V.
   de Mendonca, Leila R.
   Azevedo, Elisa A. N.
   Franca, Rafael F. O.
   Dhalia, Rafael
   Marques, Ernesto T. A.
TI Dengue Virus-Specific Antibodies Enhance Brazilian Zika Virus Infection
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Zika virus; antibody dependent enhancement; dengue antibodies
AB Anti-Flavivirus antibodies are highly cross-reactive and may facilitate Zika virus (ZIKV) infection through the antibody-dependent enhancement (ADE) mechanism. We demonstrate that dengue-specific antibodies enhance the infection of a primary Brazilian ZIKV isolate in a Fc gamma RII-expressing K562 cell line. In addition, we demonstrate that serum samples from dengue-immune pregnant women enhanced ZIKV infection. These findings highlight the need for epidemiological studies and animal models to further confirm the role of ADE in the development of congenital and neurological complications associated with ZIKV infections.
C1 [Castanha, Priscila M. S.; Braga, Cynthia; Cordeiro, Marli T.; de Carvalho, Otavio V.; de Mendonca, Leila R.; Azevedo, Elisa A. N.; Franca, Rafael F. O.; Dhalia, Rafael; Marques, Ernesto T. A.] Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Res Ctr, Recife, PE, Brazil.
   [Castanha, Priscila M. S.] Univ Pernambuco, Inst Biol Sci, Fac Med Sci, Recife, PE, Brazil.
   [Braga, Cynthia] Inst Med Integral Prof Fernando Figueira, Recife, PE, Brazil.
   [de Carvalho, Otavio V.] Univ Fed Vicosa, Vicosa, MG, Brazil.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA.
RP Marques, ETA (corresponding author), Ctr Vaccine Res, 3501 5th Ave,9052 Biomed Sci Tower 3, Pittsburgh, PA 15261 USA.
EM marques@pitt.edu
RI amsalu, ribka/G-8780-2019; Dhalia, Rafael/AAD-5432-2020; Da Silva
   Castanha, Priscila Mayrelle/G-1785-2012; Marques, Ernesto T.
   A/L-4967-2013; Braga, Maria Cynthia/A-8204-2013
OI Da Silva Castanha, Priscila Mayrelle/0000-0002-1220-5308; Marques,
   Ernesto T. A/0000-0003-3826-9358; Braga, Maria
   Cynthia/0000-0002-7862-6455; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007
FU Brazilian Federal Agency for Support and Evaluation of Graduate
   Education (CAPES)CAPES; Center for Vaccine Research, University of
   Pittsburgh; Fogarty Training Program [D43TW006592 Pitt GIDRTP/ 323 NIH];
   National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [482915/2010-2 MCT/CNPq-321 14/2010]; Strategic Program to
   Support Health Research/PAPES VI [322 407697/2012-8]; National Institute
   of Allergy and Infectious DiseasesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U19 AI56541]
FX This work was supported by the Brazilian Federal Agency for Support and
   Evaluation of Graduate Education (CAPES); Center for Vaccine Research,
   University of Pittsburgh; Fogarty Training Program (D43TW006592 Pitt
   GIDRTP/ 323 NIH to P. M. S. C.); National Council for Scientific and
   Technological Development (CNPq) (482915/2010-2 MCT/CNPq-321 14/2010);
   Strategic Program to Support Health Research/PAPES VI (322
   407697/2012-8); and the National Institute of Allergy and Infectious
   Diseases (U19 AI56541).
CR Braga C, 2016, CAD SAUDE PUBLICA, V32, DOI 10.1590/0102-311X00095815
   Braga C, 2010, ACTA TROP, V113, P234, DOI 10.1016/j.actatropica.2009.10.021
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Castanha PMS, 2016, J INFECT DIS, V214, P265, DOI 10.1093/infdis/jiw143
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Donald CL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005048
   Durbin AP, 2016, TRENDS IMMUNOL, V37, P635, DOI 10.1016/j.it.2016.08.006
   FAGBAMI AH, 1987, CYTOBIOS, V49, P49
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lessler J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf8160
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Swanstrom JA, 2016, MBIO, V7, DOI 10.1128/mBio.01123-16
NR 15
TC 66
Z9 68
U1 0
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR 1
PY 2017
VL 215
IS 5
BP 781
EP 785
DI 10.1093/infdis/jiw638
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA ER2PO
UT WOS:000398636500018
PM 28039355
OA Bronze, Green Published
DA 2020-11-11
ER

PT J
AU Wu, C
   Chen, ZJ
   Dardalhon, V
   Xiao, S
   Thalhamer, T
   Liao, MY
   Madi, A
   Franca, RF
   Han, T
   Oukka, M
   Kuchroo, V
AF Wu, Chuan
   Chen, Zuojia
   Dardalhon, Valerie
   Xiao, Sheng
   Thalhamer, Theresa
   Liao, Mengyang
   Madi, Asaf
   Franca, Rafael F.
   Han, Timothy
   Oukka, Mohammed
   Kuchroo, Vijay
TI The transcription factor musculin promotes the unidirectional
   development of peripheral T-reg cells by suppressing the T(H)2
   transcriptional program
SO NATURE IMMUNOLOGY
LA English
DT Article
ID GROWTH-FACTOR-BETA; TGF-BETA; FOXP3 GENE; EXPRESSION; BINDING;
   DIFFERENTIATION; PLASTICITY; INDUCTION; INFECTION; PROTEINS
AB Although master transcription factors (TFs) are key to the development of specific T cell subsets, whether additional transcriptional regulators are induced by the same stimuli that dominantly repress the development of other, non-specific T cell lineages has not been fully elucidated. Through the use of regulatory T cells (T-reg cells) induced by transforming growth factor-beta (TGF-(3), we identified the TF musculin (MSC) as being critical for the development of induced Treg cells (iT(reg) cells) by repression of the T helper type 2 (T(H)2) transcriptional program. Loss of MSC reduced expression of the Treg cell master TF Foxp3 and induced TH2 differentiation even under iT(reg)-cell-differentiation conditions. MSC interrupted binding of the TF GATA-3 to the locus encoding T(H)2-cell-related cytokines and diminished intrachromosomal interactions within that locus. MSC-deficient (Msc(-/-)) iTreg cells were unable to suppress T(H)2 responses, and Msc(-/-) mice spontaneously developed gut and lung inflammation with age. MSC therefore enforced Foxp3 expression and promoted the unidirectional induction of iT(reg) cells by repressing the T(H)2 developmental program.
C1 [Wu, Chuan; Chen, Zuojia; Dardalhon, Valerie; Xiao, Sheng; Thalhamer, Theresa; Madi, Asaf; Franca, Rafael F.; Han, Timothy; Kuchroo, Vijay] Harvard Med Sch, Evergrande Ctr Immunol Dis, Boston, MA 02115 USA.
   [Wu, Chuan; Chen, Zuojia; Dardalhon, Valerie; Xiao, Sheng; Thalhamer, Theresa; Madi, Asaf; Franca, Rafael F.; Han, Timothy; Kuchroo, Vijay] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
   [Liao, Mengyang] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA USA.
   [Oukka, Mohammed] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA.
   [Wu, Chuan] NCI, Expt Immunol Branch, US NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Dardalhon, Valerie] CNRS, UMR5535, GMM, Montpellier, France.
   [Franca, Rafael F.] Univ Sao Paulo, Dept Pharmacol, Ribeirao Preto, SP, Brazil.
RP Wu, C; Kuchroo, V (corresponding author), Harvard Med Sch, Evergrande Ctr Immunol Dis, Boston, MA 02115 USA.; Wu, C; Kuchroo, V (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.; Wu, C (corresponding author), NCI, Expt Immunol Branch, US NIH, Bldg 10, Bethesda, MD 20892 USA.
EM cwu11@rics.bwh.harvard.edu; vkuchroo@evergrande.hms.harvard.edu
RI Chen, Zuojia/AAM-9465-2020; Wu, Chuan/H-6379-2013
OI Madi, Asaf/0000-0003-3441-3228; Wu, Chuan/0000-0003-2288-353X; Han,
   Timothy/0000-0001-5365-0259; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007
FU National Multiple Sclerosis SocietyNational Multiple Sclerosis Society
   [TA 3059-A-2]; US National Institutes of HealthUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [KAI110649A, K01DK09105, P01AI073748, P01AI056299, P01AI039671,
   R01NS045937, R01 NS030843]
FX We thank D. Kozoriz for cell sorting; T. Chatila for advice; M. Collins
   for advice and editing the manuscript; E.N. Olson (University of Texas
   Southwestern Medical Center at Dallas) for Msc<SUP>-/-</SUP> mice; L.
   Maggio-Price (University of Washington) for Smad3<SUP>-/-</SUP> mice;
   and A. Yoshimura (Keio University School of Medicine) for the plasmid
   pCMV5-Smad3. Supported by the National Multiple Sclerosis Society
   (Career Transition Award TA 3059-A-2 to C.W.) and the US National
   Institutes of Health (K99 NIH Pathway to Independence Award KAI110649A
   to C.W.; K01DK09105 to S.X.; and P01AI073748, P01AI056299, P01AI039671,
   R01NS045937 and R01 NS030843 to V.K.).
CR Beal AM, 2012, NAT IMMUNOL, V13, P77, DOI 10.1038/ni.2154
   Belkaid Y, 2007, NAT REV IMMUNOL, V7, P875, DOI 10.1038/nri2189
   Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032
   Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784
   Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152
   Ciofani M, 2012, CELL, V151, P289, DOI 10.1016/j.cell.2012.09.016
   Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590
   Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677
   Davidson TS, 2007, J IMMUNOL, V178, P4022, DOI 10.4049/jimmunol.178.7.4022
   de Almeida CR, 2009, J IMMUNOL, V182, P999
   Debuisson D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084415
   Flavell RA, 2010, NAT REV IMMUNOL, V10, P554, DOI 10.1038/nri2808
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Hall AO, 2012, IMMUNITY, V37, P511, DOI 10.1016/j.immuni.2012.06.014
   Joller N, 2014, IMMUNITY, V40, P569, DOI 10.1016/j.immuni.2014.02.012
   Jones S, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-226
   Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623
   Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772
   Kishikawa H, 2001, J IMMUNOL, V167, P4414, DOI 10.4049/jimmunol.167.8.4414
   Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552
   Lu JR, 2002, SCIENCE, V298, P2378, DOI 10.1126/science.1078273
   Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276
   Maruyama T, 2011, NAT IMMUNOL, V12, P86, DOI 10.1038/ni.1965
   Massari ME, 1998, MOL CELL BIOL, V18, P3130, DOI 10.1128/MCB.18.6.3130
   Mathas S, 2006, NAT IMMUNOL, V7, P207, DOI 10.1038/ni1285
   Murphy KM, 2010, NAT IMMUNOL, V11, P674, DOI 10.1038/ni.1899
   Oestreich KJ, 2012, NAT REV IMMUNOL, V12, P799, DOI 10.1038/nri3321
   Pillemer BBL, 2009, J IMMUNOL, V183, P155, DOI 10.4049/jimmunol.0803733
   Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9
   RUEGEMER JJ, 1990, J IMMUNOL, V144, P1767
   Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785
   Sanyal A, 2012, NATURE, V489, P109, DOI 10.1038/nature11279
   Siddiqui KRR, 2008, MUCOSAL IMMUNOL, V1, pS34, DOI 10.1038/mi.2008.43
   Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115
   Takimoto T, 2010, J IMMUNOL, V185, P842, DOI 10.4049/jimmunol.0904100
   Tanaka S, 2011, NAT IMMUNOL, V12, P77, DOI 10.1038/ni.1966
   Tao Xiaojuan, 2008, Int J Biomed Sci, V4, P52
   Tussiwand R, 2012, NATURE, V490, P502, DOI 10.1038/nature11531
   WAHL SM, 1988, J IMMUNOL, V140, P3026
   Wei G, 2011, IMMUNITY, V35, P299, DOI 10.1016/j.immuni.2011.08.007
   Weiss JM, 2012, J EXP MED, V209, P1723, DOI 10.1084/jem.20120914
   Wohlfert EA, 2011, J CLIN INVEST, V121, P4503, DOI 10.1172/JCI57456
   Xu LL, 2010, IMMUNITY, V33, P313, DOI 10.1016/j.immuni.2010.09.001
   Xu W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040314
   Yadav M, 2012, J EXP MED, V209, P1713, DOI 10.1084/jem.20120822
   Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8
   Zheng Y, 2007, NAT IMMUNOL, V8, P457, DOI 10.1038/ni1455
   Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750
NR 48
TC 28
Z9 30
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
EI 1529-2916
J9 NAT IMMUNOL
JI Nat. Immunol.
PD MAR
PY 2017
VL 18
IS 3
BP 344
EP 353
DI 10.1038/ni.3667
PG 10
WC Immunology
SC Immunology
GA EL1WZ
UT WOS:000394413400014
PM 28114290
OA Green Accepted
DA 2020-11-11
ER

PT J
AU Lucena-Araujo, AR
   Coelho-Silva, JL
   Pereira-Martins, DA
   Thome, C
   Scheucher, PS
   Lange, AP
   Paiva, HH
   Hemmelgarn, BT
   Morais-Sobral, MC
   Azevedo, EA
   Franca-Neto, PL
   Franca, RF
   Silva, CL
   Krause, A
   Rego, EM
AF Lucena-Araujo, Antonio R.
   Coelho-Silva, Juan L.
   Pereira-Martins, Diego A.
   Thome, Carolina
   Scheucher, Priscila S.
   Lange, Ana P.
   Paiva, Helder H.
   Hemmelgarn, Benjamin T.
   Morais-Sobral, Mariana C.
   Azevedo, Elisa A.
   Franca-Neto, Pedro L.
   Franca, Rafael F.
   Silva, Cleide L.
   Krause, Alexandre
   Rego, Eduardo M.
TI Delta Np73 overexpression promotes resistance to apoptosis but does not
   cooperate with PML/RARA in the induction of an APL-leukemic phenotype
SO ONCOTARGET
LA English
DT Article
DE acute promyelocytic leukemia; Delta Np73; apoptosis; bone marrow
   transplantation; lentiviral gene transfer
ID ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; TRANSGENIC MICE;
   POOR-PROGNOSIS; P73 ISOFORMS; HUMAN TUMORS; IN-VIVO; EXPRESSION;
   PROTEIN; CANCER
AB Here, we evaluated whether the overexpression of transcriptionally inactive Delta Np73 cooperates with PML/RARA fusion protein in the induction of an APL-leukemic phenotype, as well as its role in vitro in proliferation, myeloid differentiation, and drug-induced apoptosis. Using lentiviral gene transfer, we showed in vitro that Delta Np73 overexpression resulted in increased proliferation in murine bone marrow (BM) cells from hCG-PML/RARA transgenic mice and their wild-type (WT) counterpart, with no accumulation of cells at G2/M or S phases; instead, Delta Np73-expressing cells had a lower rate of induced apoptosis. Next, we evaluated the effect of Delta Np73 on stem-cell self-renewal and myeloid differentiation. Primary BM cells lentivirally infected with human Delta Np73 were not immortalized in culture and did not present significant changes in the percentage of CD11b. Finally, we assessed the impact of Delta Np73 on leukemogenesis or its possible cooperation with PML/RARA fusion protein in the induction of an APL-leukemic phenotype. After 120 days of follow-up, all transplanted mice were clinically healthy and, no evidence of leukemia/myelodysplasia was apparent. Taken together, our data suggest that Delta Np73 had no leukemic transformation capacity by itself and apparently did not cooperate with the PML/RARA fusion protein to induce a leukemic phenotype in a murine BM transplantation model. In addition, the forced expression of Delta Np73 in murine BM progenitors did not alter the ATRA-induced differentiation rate in vitro or induce aberrant cell proliferation, but exerted an important role in cell survival, providing resistance to drug-induced apoptosis.
C1 [Lucena-Araujo, Antonio R.; Scheucher, Priscila S.; Lange, Ana P.; Paiva, Helder H.; Krause, Alexandre; Rego, Eduardo M.] Med Sch Ribeirao Preto, Dept Internal Med, Ribeirao Preto, Brazil.
   [Lucena-Araujo, Antonio R.; Coelho-Silva, Juan L.; Pereira-Martins, Diego A.; Franca-Neto, Pedro L.] Univ Fed Pernambuco, Dept Genet, Recife, PE, Brazil.
   [Thome, Carolina; Silva, Cleide L.; Rego, Eduardo M.] Univ Sao Paulo, Ctr Cell Based Therapy, Ribeirao Preto, Brazil.
   [Hemmelgarn, Benjamin T.] Ohio State Univ, Columbus, OH 43210 USA.
   [Morais-Sobral, Mariana C.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Microbiol, Recife, PE, Brazil.
   [Azevedo, Elisa A.; Franca, Rafael F.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol, Recife, PE, Brazil.
RP Lucena-Araujo, AR (corresponding author), Med Sch Ribeirao Preto, Dept Internal Med, Ribeirao Preto, Brazil.; Lucena-Araujo, AR (corresponding author), Univ Fed Pernambuco, Dept Genet, Recife, PE, Brazil.
EM araujoarl@hotmail.com
RI Rego, Eduardo M./Y-5572-2019; Coelho-Silva, Juan/U-1450-2019; Krause,
   Alexandre/K-7221-2013; Rego, Eduardo M/A-1058-2012; CTC USP, CEPID 13
   18/J-8951-2014
OI Rego, Eduardo M./0000-0003-1567-4086; Coelho-Silva,
   Juan/0000-0001-8384-6551; Rego, Eduardo M/0000-0003-1567-4086; CTC USP,
   CEPID 13 18/0000-0002-7123-9524; Scheucher, Priscila
   Santos/0000-0003-3111-8506; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/08135-2,
   2007/55067-1]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNpQ)National Council for Scientific and Technological
   Development (CNPq) [573754/2008-0, 130614/20157]; Fundacao de Amparo a
   Ciencia e Tecnologia de Pernambuco (FACEPE) [IBPG-1433-2.02/13]
FX This investigation was supported by Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP, Grant #2013/08135-2) and Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNpQ, Grant
   #573754/2008-0). A.R.L-A. received a fellowship from FAPESP (Grant
   #2007/55067-1). J.L.C-S, D.A.P-M and P.L.F-N received fellowships from
   Fundacao de Amparo a Ciencia e Tecnologia de Pernambuco (FACEPE; Grants
   #IBPG-1433-2.02/13) and CNpQ (Grant #130614/20157), respectively.
CR Ablain J, 2014, NAT MED, V20, P167, DOI 10.1038/nm.3441
   Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943
   Buhlmann S, 2008, BBA-REV CANCER, V1785, P207, DOI 10.1016/j.bbcan.2008.01.002
   Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993
   Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350
   dos Santos GAS, 2012, LEUKEMIA, V26, P451, DOI 10.1038/leu.2011.216
   Gaillard C, 2015, HAEMATOLOGICA, V100, P1064, DOI 10.3324/haematol.2014.123018
   Grignani F, 1998, NATURE, V391, P815
   GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F
   Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376
   Guibal FC, 2009, BLOOD, V114, P5415, DOI 10.1182/blood-2008-10-182071
   He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302
   Ishimoto O, 2002, CANCER RES, V62, P636
   Jacomo RH, 2012, BLOOD, V120, P207, DOI 10.1182/blood-2011-04-347187
   Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238
   Leung THY, 2013, BRIT J CANCER, V109, P965, DOI 10.1038/bjc.2013.397
   Liu SS, 2006, CLIN CANCER RES, V12, P3922, DOI 10.1158/1078-0432.CCR-05-2573
   Lucena-Araujo AR, 2008, BRIT J HAEMATOL, V142, P74, DOI 10.1111/j.1365-2141.2008.07160.x
   Lucena-Araujo AR, 2015, BLOOD, V126, P2302, DOI 10.1182/blood-2015-01-623330
   Meier M, 2006, LEUKEMIA, V20, P1377, DOI 10.1038/sj.leu.2404288
   Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774
   Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382
   Peters UR, 1999, CANCER RES, V59, P4233
   Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003
   Rego EM, 2013, BLOOD, V121, P1935, DOI 10.1182/blood-2012-08-449918
   Sahu GR, 2005, AM J HEMATOL, V79, P1, DOI 10.1002/ajh.20284
   Soldevilla B, 2011, CLIN CANCER RES, V17, P6029, DOI 10.1158/1078-0432.CCR-10-2388
   Steder M, 2013, CANCER CELL, V24, P512, DOI 10.1016/j.ccr.2013.08.023
   Stiewe T, 2002, CANCER RES, V62, P3598
   Tannapfel A, 2008, CARCINOGENESIS, V29, P211, DOI 10.1093/carcin/bgm236
   Thome CH, 2012, MOL CELL PROTEOMICS, V11, P1898, DOI 10.1074/mcp.M112.019661
   Tuve S, 2006, APOPTOSIS, V11, P235, DOI 10.1007/s10495-006-3407-0
   Uramoto H, 2004, CLIN CANCER RES, V10, P6905, DOI 10.1158/1078-0432.CCR-04-0290
   Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910
   Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179
   Zhang J., 2007, CELL BIOL, V27, P3868, DOI DOI 10.1128/MCB.02112-06
NR 36
TC 1
Z9 1
U1 0
U2 1
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 31
PY 2017
VL 8
IS 5
BP 8475
EP 8483
DI 10.18632/oncotarget.14295
PG 9
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA EJ5YP
UT WOS:000393295500108
PM 28035072
OA Green Published, Other Gold
DA 2020-11-11
ER

PT J
AU Donald, CL
   Brennan, B
   Cumberworth, SL
   Rezelj, VV
   Clark, JJ
   Cordeiro, MT
   Franca, RFD
   Pena, LJ
   Wilkie, GS
   Filipe, AD
   Davis, C
   Hughes, J
   Varjak, M
   Selinger, M
   Zuvanov, L
   Owsianka, AM
   Patel, AH
   McLauchlan, J
   Lindenbach, BD
   Fall, G
   Sall, AA
   Biek, R
   Rehwinkel, J
   Schnettler, E
   Kohl, A
AF Donald, Claire L.
   Brennan, Benjamin
   Cumberworth, Stephanie L.
   Rezelj, Veronica V.
   Clark, Jordan J.
   Cordeiro, Marli T.
   de Oliveira Franca, Rafael Freitas
   Pena, Lindomar J.
   Wilkie, Gavin S.
   Filipe, Ana Da Silva
   Davis, Christopher
   Hughes, Joseph
   Varjak, Margus
   Selinger, Martin
   Zuvanov, Luiza
   Owsianka, Ania M.
   Patel, Arvind H.
   McLauchlan, John
   Lindenbach, Brett D.
   Fall, Gamou
   Sall, Amadou A.
   Biek, Roman
   Rehwinkel, Jan
   Schnettler, Esther
   Kohl, Alain
TI Full Genome Sequence and sfRNA Interferon Antagonist Activity of Zika
   Virus from Recife, Brazil
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID RNA INTERFERENCE; DENGUE; INFECTION; COINFECTION; ACTIVATION; RESPONSES;
   ALIGNMENT; HISTORY; BAHIA; STATE
AB Background
   The outbreak of Zika virus (ZIKV) in the Americas has transformed a previously obscure mosquito-transmitted arbovirus of the Flaviviridae family into a major public health concern. Little is currently known about the evolution and biology of ZIKV and the factors that contribute to the associated pathogenesis. Determining genomic sequences of clinical viral isolates and characterization of elements within these are an important prerequisite to advance our understanding of viral replicative processes and virus-host interactions.
   Methodology/Principal findings
   We obtained a ZIKV isolate from a patient who presented with classical ZIKV-associated symptoms, and used high throughput sequencing and other molecular biology approaches to determine its full genome sequence, including non-coding regions. Genome regions were characterized and compared to the sequences of other isolates where available. Furthermore, we identified a subgenomic flavivirus RNA (sfRNA) in ZIKV-infected cells that has antagonist activity against RIG-I induced type I interferon induction, with a lesser effect on MDA-5 mediated action.
   Conclusions/Significance
   The full-length genome sequence including non-coding regions of a South American ZIKV isolate from a patient with classical symptoms will support efforts to develop genetic tools for this virus. Detection of sfRNA that counteracts interferon responses is likely to be important for further understanding of pathogenesis and virus-host interactions.
C1 [Donald, Claire L.; Brennan, Benjamin; Cumberworth, Stephanie L.; Rezelj, Veronica V.; Clark, Jordan J.; Wilkie, Gavin S.; Filipe, Ana Da Silva; Davis, Christopher; Hughes, Joseph; Varjak, Margus; Zuvanov, Luiza; Owsianka, Ania M.; Patel, Arvind H.; McLauchlan, John; Schnettler, Esther; Kohl, Alain] Univ Glasgow, MRC, Glasgow Ctr Virus Res, Glasgow, Lanark, Scotland.
   [Cordeiro, Marli T.; de Oliveira Franca, Rafael Freitas; Pena, Lindomar J.] Fundacao Oswaldo Cruz PE, Ctr Pesquisas Aggeu Magalhaes, Dept Virol, Campus UFPE Cidade Univ, Recife, PE, Brazil.
   [Selinger, Martin] Univ South Bohemia, Fac Sci, Ceske Budejovice, Czech Republic.
   [Selinger, Martin] Acad Sci Czech Republ, Ctr Biol, Inst Parasitol, Ceske Budejovice, Czech Republic.
   [Lindenbach, Brett D.] Yale Univ, Dept Microbial Pathogenesis, New Haven, CT USA.
   [Fall, Gamou; Sall, Amadou A.] Inst Pasteur, Pole Virol, Unite Arbovirus & Virus Fievres Hemorrag, Dakar, Senegal.
   [Biek, Roman] Univ Glasgow, Inst Biodivers Anim Hlth & Comparat Med, Coll Med Vet & Life Sci, Boyd Orr Ctr Populat & Ecosyst Hlth, Glasgow, Lanark, Scotland.
   [Rehwinkel, Jan] Univ Oxford, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford, England.
   [Rehwinkel, Jan] Univ Oxford, Radcliffe Dept Med, Oxford, England.
   [Schnettler, Esther] Bernhard Nocht Inst Trop Med, Hamburg, Germany.
RP Kohl, A (corresponding author), Univ Glasgow, MRC, Glasgow Ctr Virus Res, Glasgow, Lanark, Scotland.
EM alain.kohl@glasgow.ac.uk
RI Biek, Roman/AAT-8109-2020; Schnettler, Esther/AAV-8774-2020; Brennan,
   Benjamin/AAJ-9850-2020; Zuvanov, Luiza/AAF-2582-2020; Donald,
   Claire/AAC-7556-2019; Hughes, Joseph/B-7711-2009; Selinger,
   Martin/U-7604-2018
OI Biek, Roman/0000-0003-3471-5357; Brennan, Benjamin/0000-0003-4707-726X;
   Donald, Claire/0000-0002-4370-0707; Hughes, Joseph/0000-0003-2556-2563;
   Selinger, Martin/0000-0002-5420-9702; Clark, Jordan/0000-0003-1790-7883;
   Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007; Varjak,
   Margus/0000-0003-2608-5148; Rehwinkel, Jan/0000-0003-3841-835X; Zuvanov,
   Luiza/0000-0003-0132-4894; da Silva Filipe, Ana
   Cristina/0000-0002-9442-2903
FU UK Medical Research CouncilMedical Research Council UK (MRC)
   [MC_UU_12014, MR/N017552/1]; FACEPE (Fundacao de Amparo a Ciencia e
   Tecnologia de Pernambuco) [APQ-0044-2.11/16]; Czech Science Foundation
   (GACR)Grant Agency of the Czech Republic [15-03044S]; Czech Research
   Infrastructure for Systems Biology (C4SYS) [LM2015055]; Biotechnology
   and Biological Sciences Research CouncilBiotechnology and Biological
   Sciences Research Council (BBSRC) [1518059] Funding Source:
   Researchfish; Medical Research CouncilMedical Research Council UK (MRC)
   [MC_UU_12010/8, MR/N017552/1, MC_UU_12014/8, G0801822] Funding Source:
   Researchfish
FX This study was funded by the UK Medical Research Council [(MC_UU_12014)
   (AK, ES, AHP, JM) and (MR/N017552/1) (AK, ES)], and FACEPE (Fundacao de
   Amparo a Ciencia e Tecnologia de Pernambuco, APQ-0044-2.11/16) (RFdOF,
   LJP). MS is supported by the Czech Science Foundation (GACR) [15-03044S]
   and the Czech Research Infrastructure for Systems Biology (C4SYS)
   [LM2015055]. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Bayer A, 2016, CELL HOST MICROBE, V19, P705, DOI 10.1016/j.chom.2016.03.008
   Bidet K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004242
   Brennan B, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003922
   Brinton MA, 2015, VIRUS RES, V206, P108, DOI 10.1016/j.virusres.2015.02.006
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cao-Lormeau VM, 2014, LANCET, V384, P1571, DOI 10.1016/S0140-6736(14)61977-2
   Carlos TS, 2009, J GEN VIROL, V90, P2147, DOI 10.1099/vir.0.012047-0
   Ramirez JAC, 2015, J INTERF CYTOK RES, V35, P421, DOI 10.1089/jir.2014.0129
   Chang RY, 2013, VET MICROBIOL, V166, P11, DOI 10.1016/j.vetmic.2013.04.026
   Chouin-Carneiro T, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004543
   Clarke BD, 2015, VIRUS RES, V206, P53, DOI 10.1016/j.virusres.2015.01.026
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   de Melo Freire C.C., 2015, BIORXIV, DOI DOI 10.1101/032839
   de Oliveira CS, 2016, J PEDIAT-BRAZIL, V92, P103, DOI 10.1016/j.jped.2016.02.003
   Diamond MS, 2012, TRENDS IMMUNOL, V33, P522, DOI 10.1016/j.it.2012.05.008
   Dupont-Rouzeyrol M, 2015, EMERG INFECT DIS, V21, P381, DOI 10.3201/eid2102.141553
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Giovanetti M, 2016, INFECT GENET EVOL, V41, P142, DOI 10.1016/j.meegid.2016.03.030
   Grant A, CELL HOST M IN PRESS
   Grard G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002681
   Green AM, 2014, J MOL BIOL, V426, P1148, DOI 10.1016/j.jmb.2013.11.023
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Haddow AD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001477
   Hancock WT, 2014, EMERG INFECT DIS, V20, P1960, DOI [10.3201/eid2011.141253, 10.3201/eid2011.141380]
   Hilton L, 2006, J VIROL, V80, P11723, DOI 10.1128/JVI.01145-06
   Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Ladner JT, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.00377-16
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanciotti RS, 2016, EMERG INFECT DIS, V22, P933, DOI 10.3201/eid2205.160065
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Lazear HM, 2015, CURR OPIN VIROL, V11, P1, DOI 10.1016/j.coviro.2014.12.001
   Lindenbach B., 2013, FIELDS VIROLOGY, V1, P712
   Manokaran G, 2015, SCIENCE, V350, P217, DOI 10.1126/science.aab3369
   Martin DP, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev003
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Moon SL, 2015, VIROLOGY, V485, P322, DOI 10.1016/j.virol.2015.08.009
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Oehler E, 2014, EURO SURVEILL, V19
   Oshiumi H, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00200
   Pichlmair A, 2009, J VIROL, V83, P10761, DOI 10.1128/JVI.00770-09
   Pijlman GP, 2008, CELL HOST MICROBE, V4, P579, DOI 10.1016/j.chom.2008.10.007
   Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Rehwinkel J, 2010, CELL, V140, P397, DOI 10.1016/j.cell.2010.01.020
   Roby JA, 2014, VIRUSES-BASEL, V6, P404, DOI 10.3390/v6020404
   Schnettler E, 2014, NUCLEIC ACIDS RES, V42, P9436, DOI 10.1093/nar/gku657
   Schnettler E, 2012, J VIROL, V86, P13486, DOI 10.1128/JVI.01104-12
   Schuessler A, 2012, J VIROL, V86, P5708, DOI 10.1128/JVI.00207-12
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Shan C, 2016, CELL HOST MICROBE, V19, P891, DOI 10.1016/j.chom.2016.05.004
   Tognarelli J, 2016, ARCH VIROL, V161, P665, DOI 10.1007/s00705-015-2695-5
   Villamil-Gomez WE, 2016, J INFECT PUBLIC HEAL, V9, P684, DOI 10.1016/j.jiph.2015.12.002
   Villordo SM, 2016, TRENDS MICROBIOL, V24, P270, DOI 10.1016/j.tim.2016.01.002
   Weaver SC, 2016, ANTIVIR RES, V130, P69, DOI 10.1016/j.antiviral.2016.03.010
   Weaver SC, 2010, ANTIVIR RES, V85, P328, DOI 10.1016/j.antiviral.2009.10.008
   Wong PSJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002348
   World Health Organization, 2016, SIT REP ZIK VIR MICR
   Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087
   Yoneyama M, 2015, CURR OPIN IMMUNOL, V32, P48, DOI 10.1016/j.coi.2014.12.012
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 65
TC 84
Z9 85
U1 1
U2 30
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD OCT
PY 2016
VL 10
IS 10
AR e0005048
DI 10.1371/journal.pntd.0005048
PG 20
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EA5QH
UT WOS:000386676200035
PM 27706161
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-11-11
ER

PT J
AU Franca, RFO
   Costa, RS
   Silva, JR
   Peres, RS
   Mendonca, LR
   Colon, DF
   Alves, JC
   Cunha, FQ
AF Franca, Rafael F. O.
   Costa, Renata S.
   Silva, Jaqueline R.
   Peres, Raphael S.
   Mendonca, Leila R.
   Colon, David F.
   Alves-Filho, Jose Carlos
   Cunha, Fernando Q.
TI IL-33 signaling is essential to attenuate viral-induced encephalitis
   development by downregulating iNOS expression in the central nervous
   system
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Interleukin 33; ST2 receptor; Experimental viral encephalitis; Nitric
   oxide; Flavivirus
ID BLOOD-BRAIN-BARRIER; INNATE LYMPHOID-CELLS; NITRIC-OXIDE; DENDRITIC
   CELLS; ROCIO VIRUS; SPINAL-CORD; MICE; DISRUPTION; CYTOKINE; TYPE-2
AB Background: Viral encephalitis is a common cause of lethal infections in humans, and several different viruses are documented to be responsible. Rocio virus is a flavivirus that causes a severe lethal encephalitis syndrome in humans and also mice, providing an interesting model to study the CNS compartmentalized immune response. Interleukin 33 (IL-33), a member of the IL-1 family, is an immunomodulatory cytokine that is highly expressed in the CNS. However, the role of IL-33 on viral encephalitis remains unclear. Therefore, we aimed to explore how the IL-33/ST2 axis regulates the local immune response during Rocio virus infection.
   Methods: Wild-type (WT), ST2 (ST2(-/-)), and nitric oxide synthase-deficient mice (iNOS(-/-)) and Stat6 (Stat6(-/-))-deficient mice were infected with different concentrations of the Rocio virus by intraperitoneal route, the cytokine mRNA level in CNS was analyzed by qPCR, and cellular immunophenotyping was performed on infected mice by the flow cytometry of isolated CNS mononuclear cells.
   Results: We have shown that the mRNA expression of IL-33 and ST2 receptors is increased in the CNS of Rocio virus-infected WT mice and that ST2(-/-) mice showed increased susceptibility to infection. ST2 deficiency was correlated with increased tissue pathology, cellular infiltration, and tumor necrosis factor alpha (TNF-alpha) and interferon-gamma (IFN-gamma) mRNA levels and higher viral load in the CNS, compared with wild-type mice. The increased Th1 cytokine levels released in the CNS acted on infiltrating macrophages, as evidenced by flow cytometry characterization of cellular infiltrates, inducing the expression of iNOS, contributing to brain injury. Moreover, iNOS(-/-) mice were more resistant to Rocio virus encephalitis, presenting a lower clinical score and reduced mortality rate, despite the increased tissue pathology.
   Conclusions: We provide evidences of a specific role for IL-33 receptor signaling in nitric oxide induction through local IFN-gamma modulation, suggesting that nitric oxide overproduction might have an important role in the progression of experimental viral encephalitis.
C1 [Franca, Rafael F. O.; Mendonca, Leila R.] Oswaldo Cruz Fdn FIOCRUZ, Dept Virol & Expt Therapy LAVITE, IAM, Av Prof Moraes Rego S-N, BR-50740465 Recife, PE, Brazil.
   [Alves-Filho, Jose Carlos; Cunha, Fernando Q.] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Pharmacol, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Costa, Renata S.; Silva, Jaqueline R.; Peres, Raphael S.; Colon, David F.] Univ Sao Paulo, Program Basic & Appl Immunol, BR-14049900 Ribeirao Preto, SP, Brazil.
RP Franca, RFO (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Dept Virol & Expt Therapy LAVITE, IAM, Av Prof Moraes Rego S-N, BR-50740465 Recife, PE, Brazil.; Cunha, FQ (corresponding author), Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Pharmacol, BR-14049900 Ribeirao Preto, SP, Brazil.
EM rafael.franca@cpqam.fiocruz.br; fdqcunha@fmrp.uspbr
RI Sesti-Costa, Renata/H-9115-2012; Alves-Filho, Jose Carlos/B-5814-2008;
   Colon, David/M-2509-2018; Cunha, Fernando Q/M-3090-2014
OI Sesti-Costa, Renata/0000-0002-7098-2850; Alves-Filho, Jose
   Carlos/0000-0002-9918-8714; Colon, David/0000-0002-6911-4765; Freitas de
   Oliveira Franca, Rafael/0000-0002-1846-6007; Cunha, Fernando
   Queiroz/0000-0003-4755-1670; Sanches Peres, Raphael/0000-0002-0417-779X
FU European UnionEuropean Union (EU) [HEALTH-F4-2011-281608]; Sao Paulo
   Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2011/19670-0, 2010/19770-2]; University of Sao Paulo
   NAP-DIN [11.1.21625.01.0, 2013/08216-2]
FX The research leading to these results received funding from the European
   Union Seventh Framework Programme (FP7-2007-2013) under grant agreement
   no. HEALTH-F4-2011-281608 (TIMER), the Sao Paulo Research Foundation
   (FAPESP) under grant agreements nos. 2011/19670-0 (Thematic Project),
   from the University of Sao Paulo NAP-DIN under grant agreement no.
   11.1.21625.01.0. and 2013/08216-2 (Center for Research in Inflammatory
   Disease) under FQC coordination and responsibility. R.F.O.F received a
   postdoctoral fellowship from the Sao Paulo Research Foundation (FAPESP)
   under grant number 2010/19770-2.
CR Baruch K, 2015, EMBO J, V34, P1816, DOI 10.15252/embj.201591468
   Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038
   Bonilla WV, 2012, SCIENCE, V335, P984, DOI 10.1126/science.1215418
   Calabrese V, 2007, NAT REV NEUROSCI, V8, P766, DOI 10.1038/nrn2214
   Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045
   Chavez JH, 2013, AM J TROP MED HYG, V89, P1013, DOI 10.4269/ajtmh.12-0591
   Chen H, 2015, NEUROSCIENCE, V308, P157, DOI 10.1016/j.neuroscience.2015.09.019
   Franca RFD, 2010, EXP MOL PATHOL, V89, P321, DOI 10.1016/j.yexmp.2010.07.007
   Barros VED, 2009, REV INST MED TROP SP, V51, P141, DOI 10.1590/S0036-46652009000300004
   de Barros VED, 2011, AM J TROP MED HYG, V85, P363, DOI 10.4269/ajtmh.2011.10-0246
   Gadani SP, 2015, NEURON, V85, P703, DOI 10.1016/j.neuron.2015.01.013
   Gao K, 2013, CANCER LETT, V335, P463, DOI 10.1016/j.canlet.2013.03.002
   Griffin DE, 2003, NAT REV IMMUNOL, V3, P493, DOI 10.1038/nri1105
   Hiroi M, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/369693
   Hung LY, 2013, P NATL ACAD SCI USA, V110, P282, DOI 10.1073/pnas.1206587110
   Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC
   Jiang HR, 2012, EUR J IMMUNOL, V42, P1804, DOI 10.1002/eji.201141947
   Jones LA, 2010, EUR J IMMUNOL, V40, P426, DOI 10.1002/eji.200939705
   Kim JH, 2015, SCI REP-UK, V5, DOI 10.1038/srep17548
   Kuang Y, 2009, VIRUS RES, V144, P18, DOI 10.1016/j.virusres.2009.03.014
   Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575
   Li F, 2015, J VIROL, V89, P5602, DOI 10.1128/JVI.00143-15
   Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692
   Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930
   Mills SY, 2007, COMPLEMENT THER MED, V15, P1, DOI 10.1002/0471142735.im1501s77
   Moss DW, 2001, EUR J NEUROSCI, V13, P529, DOI 10.1046/j.1460-9568.2001.01418.x
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Pino Paula A, 2011, J Vis Exp, DOI 10.3791/2348
   Roe K, 2012, J GEN VIROL, V93, P1193, DOI 10.1099/vir.0.040899-0
   Rostan O, 2013, MBIO, V4, DOI 10.1128/mBio.00383-13
   Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015
   Sesti-Costa R, 2013, J IMMUNOL, V191, P283, DOI 10.4049/jimmunol.1202806
   Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012
   Su Z, 2013, MUCOSAL IMMUNOL, V6, P921, DOI 10.1038/mi.2012.130
   Talabot-Ayer D, 2012, J LEUKOCYTE BIOL, V91, P119, DOI 10.1189/jlb.0811425
   TANAKA H, 1983, ARCH VIROL, V78, P309, DOI 10.1007/BF01311327
   Toborek M, 2005, CELL MOL NEUROBIOL, V25, P181, DOI 10.1007/s10571-004-1383-x
   Villarreal DO, 2014, CURR OPIN IMMUNOL, V28, P102, DOI 10.1016/j.coi.2014.03.004
   Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787
   Yasuda K, 2012, P NATL ACAD SCI USA, V109, P3451, DOI 10.1073/pnas.1201042109
NR 40
TC 15
Z9 15
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD JUN 22
PY 2016
VL 13
AR 159
DI 10.1186/s12974-016-0628-1
PG 13
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA DQ0BT
UT WOS:000378863400001
PM 27334012
OA DOAJ Gold, Green Published
DA 2020-11-11
ER

PT J
AU Franca, RFO
   Neves, MHL
   Ayres, CFJ
   Melo-Neto, OP
   Brandao, SP
AF Franca, Rafael F. O.
   Neves, Maria Helena L.
   Junqueira Ayres, Constancia F.
   Melo-Neto, Osvaldo P.
   Brandao Filho, Sinval P.
TI First International Workshop on Zika Virus Held by Oswaldo Cruz
   Foundation FIOCRUZ in Northeast Brazil March 2016-A Meeting Report
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID SEXUAL CONTACT; TRANSMISSION
C1 [Franca, Rafael F. O.; Neves, Maria Helena L.; Junqueira Ayres, Constancia F.; Melo-Neto, Osvaldo P.; Brandao Filho, Sinval P.] Fundacao Oswaldo Cruz Fiocruz, IAM, Recife, PE, Brazil.
RP Franca, RFO; Brandao, SP (corresponding author), Fundacao Oswaldo Cruz Fiocruz, IAM, Recife, PE, Brazil.
EM rafael.franca@cpqam.fiocruz.br; sinval@cpqam.fiocruz.br
RI Ayres, Constancia/AAQ-3448-2020; de Melo Neto, Osvaldo P/B-1366-2015;
   Brandao-Filho, Sinval Pinto/AAP-4792-2020
OI de Melo Neto, Osvaldo P/0000-0001-5402-7346; Brandao-Filho, Sinval
   Pinto/0000-0003-3768-2810; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007
CR Barreto ML, 2016, LANCET
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Brasil P, 2016, N ENGL J MED
   Calvet G, 2016, LANCET INFECT DIS
   Christofferson RC, 2016, AM J TROP MED HYG
   Cohen J, 2016, Q A SCOTT HALSTEAD Z, DOI [10.1126/science.aaf4154, DOI 10.1126/SCIENCE.AAF4154]
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i720
   Mlakar J, 2016, N ENGL J MED
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Rodriguez-Morales AJ, 2016, ANN CLIN MICROB ANTI, V15, DOI 10.1186/s12941-016-0128-2
NR 14
TC 23
Z9 28
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2016
VL 10
IS 6
AR e0004760
DI 10.1371/journal.pntd.0004760
PG 5
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DQ6WL
UT WOS:000379346200026
PM 27258065
OA DOAJ Gold, Green Published
DA 2020-11-11
ER

PT J
AU Miranda, DD
   Martelli, CMT
   Ximenes, RAD
   Araujo, TVB
   Rocha, MAW
   Ramos, RCF
   Dhalia, R
   Franca, RFD
   Marques, ETD
   Rodrigues, LC
AF Miranda-Filho, Democrito de Barros
   Turchi Martelli, Celina Maria
   de Alencar Ximenes, Ricardo Arraes
   Barreto Araujo, Thalia Velho
   Wanderley Rocha, Maria Angela
   Ferreira Ramos, Regina Coeli
   Dhalia, Rafael
   de Oliveira Franca, Rafael Freitas
   de Azevedo Marques Junior, Ernesto Torres
   Rodrigues, Laura Cunha
TI Initial Description of the Presumed Congenital Zika Syndrome
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID VIRUS; INFECTIONS; BRAZIL
AB Objectives. To provide an initial description of the congenital syndrome presumably associated with infection by Zika virus compared with other syndromes including congenital infections of established etiologies.
   Methods. We provide an overview of a published case series of 35 cases, a clinical series of 104 cases, and published and unpublished reports of clinical and laboratory findings describing cases diagnosed since the beginning of the epidemic of microcephaly in Brazil.
   Results. About 60% to 70% of mothers report rash during pregnancy; mainly in the first trimester. Principal features are microcephaly, facial disproportionality, cutis girata, hypertonia/spasticity, hyperreflexia, and irritability; abnormal neuroimages include calcifications, ventriculomegaly, and lissencephaly. Hearing and visual abnormalities may be present.
   Conclusions. Preliminary data suggest that severe congenital abnormalities are linked to Zika virus infection. Cases have severe abnormalities, and although sharing many characteristics with congenital abnormalities associated with other viral infections, abnormalities presumably linked to the Zika virus may have distinguishing characteristics. These severe neurologic abnormalities may result in marked mental retardation and motor disabilities for many surviving offspring.
   Policy Implications. Affected nations need to prepare to provide complex and costly multidisciplinary care that children diagnosed with this new congenital syndrome will require.
C1 [Miranda-Filho, Democrito de Barros; de Alencar Ximenes, Ricardo Arraes; Wanderley Rocha, Maria Angela; Ferreira Ramos, Regina Coeli] Univ Pernambuco, Recife, PE, Brazil.
   [Turchi Martelli, Celina Maria; Dhalia, Rafael; de Oliveira Franca, Rafael Freitas; de Azevedo Marques Junior, Ernesto Torres] Fiocruz MS, Oswaldo Cruz Fdn, Res Ctr Aggeu Magalhaes CPqAM, Recife, PE, Brazil.
   [de Alencar Ximenes, Ricardo Arraes; Barreto Araujo, Thalia Velho] Univ Fed Pernambuco, Recife, PE, Brazil.
   [Rodrigues, Laura Cunha] London Sch Hyg & Trop Med, London WC1, England.
RP Miranda, DD (corresponding author), Rua Arnobio Marques 310, BR-50100130 Recife, PE, Brazil.
EM demofilho@gmail.com
RI Dhalia, Rafael/AAD-5432-2020; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Turchi Martelli, Celina
   Maria/0000-0002-2491-0688; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007
FU Brazilian Ministry of Health, Pernambuco State Health Department
   (SES-PE); Pan American Health Organization; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - CNPqNational Council for
   Scientific and Technological Development (CNPq) [306489/2010-4,
   308311/2009-4, 308590/2013-9]
FX We thank the support of the Brazilian Ministry of Health, Pernambuco
   State Health Department (SES-PE) and Pan American Health Organization.
   The authors received partial support from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - CNPq (scholarship
   306489/2010-4 to C. M. T. M., 308311/2009-4 to R. A. A. X.,
   308590/2013-9 to D. B. M. F.).
CR Balm MND, 2012, J MED VIROL, V84, P1501, DOI 10.1002/jmv.23241
   Brazilian Ministry of Health, 10 BRAZ MIN HLTH
   Faye O, 2008, J CLIN VIROL, V43, P96, DOI 10.1016/j.jcv.2008.05.005
   John CC, 2015, NATURE, V527, pS178, DOI 10.1038/nature16033
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Neu N, 2015, CLIN PERINATOL, V42, P77, DOI 10.1016/j.clp.2014.11.001
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
NR 8
TC 144
Z9 150
U1 0
U2 24
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD APR
PY 2016
VL 106
IS 4
BP 598
EP 600
DI 10.2105/AJPH.2016.303115
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DL8SY
UT WOS:000375913000013
PM 26959258
OA Green Published
DA 2020-11-11
ER

PT J
AU Franca, RFO
   Vieira, SM
   Talbot, J
   Peres, RS
   Pinto, LG
   Zamboni, DS
   Louzada, P
   Cunha, FQ
   Cunha, TM
AF Franca, R. F. O.
   Vieira, S. M.
   Talbot, J.
   Peres, R. S.
   Pinto, L. G.
   Zamboni, D. S.
   Louzada-Junior, P.
   Cunha, F. Q.
   Cunha, T. M.
TI Expression and activity of NOD1 and NOD2/RIPK2 signalling in mononuclear
   cells from patients with rheumatoid arthritis
SO SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
LA English
DT Article
ID SYNOVIAL FIBROBLASTS; RECEPTORS
AB Objectives: The aim of this study was to analyse the expression and function of nucleotide-binding oligomerization domain (NOD)1 and NOD2 in isolated cells of patients with rheumatoid arthritis (RA).Method: mRNA expression levels of NOD1, NOD2, and receptor-interacting serine/threonine kinase 2 (RIPK2) genes were determined by quantitative polymerase chain reaction (qPCR) in peripheral blood mononuclear cells (PBMCs) and synovial fluid T cells (SFTCs) isolated from RA and osteoarthritis (OA) patients. Cytokines were measured by enzyme-linked immunosorbent assay (ELISA) in plasma and cell culture supernatants. The stimulatory effect of RA SF was assessed by an in-vitro NOD2 activation assay using nuclear factor kappa B (NF-B) luciferase-transfected cells.Results: A significantly higher level of NOD2 and RIPK2 mRNA expression, but not NOD1, was observed on PBMCs and SFTCs isolated from RA patients compared to the OA control group. In addition, the NOD2 pathway up-regulation was functional, as stimulation of PBMCs with muramyl dipeptide (MDP) induced the production of higher amounts of tumour necrosis factor (TNF)-, interleukin (IL)-8, and IL-1 compared with OA PBMCs. Incubation of PBMCs from healthy donors with recombinant TNF- or RA serum induced the expression of NOD2 mRNA. Finally, SF isolated from RA patients is able to activate the NF-B signalling pathway in HEK293T-transfected cells in a NOD2-dependent manner.Conclusions: Our findings suggest that NOD2/RIPK2 signalling is up-regulated in immune cells of RA patients. Moreover, it seems that there is a NOD2 agonist in the SF of RA patients. Therefore, NOD2/RIPK2 activation can modulate the innate immune response and may play a role in the perpetuation of the inflammatory response in RA.
C1 [Franca, R. F. O.] Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Res Ctr, Recife, PE, Brazil.
   [Vieira, S. M.; Talbot, J.; Peres, R. S.; Pinto, L. G.; Cunha, F. Q.; Cunha, T. M.] Univ Sao Paulo, Dept Pharmacol, Ribeirao Preto Med Sch, BR-14049900 Sao Paulo, Brazil.
   [Zamboni, D. S.] Univ Sao Paulo, Dept Cell & Mol Biol, Ribeirao Preto Med Sch, BR-14049900 Sao Paulo, Brazil.
   [Louzada-Junior, P.] Univ Sao Paulo, Div Clin Immunol, Ribeirao Preto Med Sch, BR-14049900 Sao Paulo, Brazil.
RP Cunha, TM (corresponding author), Univ Sao Paulo, Dept Pharmacol, Ribeirao Preto Med Sch, Ave Bandeirantes 3900, BR-14049900 Sao Paulo, Brazil.
EM thicunha@fmrp.usp.br
RI Cunha, Thiago M/B-7729-2012; Louzada-Junior, Paulo/E-4132-2012; Cunha,
   Fernando Q/M-3090-2014; Zamboni, Dario S/D-3024-2012; Vieira, Silvio
   Manfredo/T-8283-2019
OI Cunha, Thiago M/0000-0003-1084-0065; Louzada-Junior,
   Paulo/0000-0003-2585-3870; Zamboni, Dario S/0000-0002-7856-7512; Vieira,
   Silvio Manfredo/0000-0001-8036-4223; Cunha, Fernando
   Queiroz/0000-0003-4755-1670; Sanches Peres, Raphael/0000-0002-0417-779X;
   Pinto, Larissa G/0000-0002-3619-907X; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007
FU European Union Seventh Framework Programme (TIMER)
   [HEALTH-F4-2011-281608]; Sao Paulo Research Foundation (FAPESP)
   (Thematic Project) [2011/19670-0]; University of SAo Paulo NAP-DIN
   [11.1.21625.01.0]; Sao Paulo Research Foundation (FAPESP) (Centre for
   Research in Inflammatory Disease) [2013/08216-2]; Sao Paulo Research
   Foundation (FAPESP) postdoctoral fellowship [2010/19770-2]
FX This research received funding from the European Union Seventh Framework
   Programme (FP7-2007-2013) under grant agreement HEALTH-F4-2011-281608
   (TIMER), the Sao Paulo Research Foundation (FAPESP) under grant
   agreements 2011/19670-0 (Thematic Project) and 2013/08216-2 (Centre for
   Research in Inflammatory Disease) and a 2010/19770-2 postdoctoral
   fellowship, from the University of Sao Paulo NAP-DIN, under grant
   agreement no. 11.1.21625.01.0.
CR Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584
   Blandizzi C, 2014, INT J IMMUNOPATH PH, V27, P1, DOI 10.1177/03946320140270S101
   Farkas L, 2008, SCAND J IMMUNOL, V68, P315, DOI 10.1111/j.1365-3083.2008.02145.x
   Joosten LAB, 2008, P NATL ACAD SCI USA, V105, P9017, DOI 10.1073/pnas.0710445105
   Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200
   Ospelt C, 2009, ARTHRITIS RHEUM, V60, P355, DOI 10.1002/art.24226
   Ospelt C, 2008, ARTHRITIS RHEUM-US, V58, P3684, DOI 10.1002/art.24140
   Rosenstiel P, 2003, GASTROENTEROLOGY, V124, P1001, DOI 10.1053/gast.2003.50157
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shaw MH, 2008, CURR OPIN IMMUNOL, V20, P377, DOI 10.1016/j.coi.2008.06.001
   Szekanecz Z, 2007, CURR OPIN RHEUMATOL, V19, P289, DOI 10.1097/BOR.0b013e32805e87ae
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Vieira SM, 2012, J IMMUNOL, V188, P5116, DOI 10.4049/jimmunol.1004190
   Yokota K, 2012, ARTHRITIS RHEUM-US, V64, P1329, DOI 10.1002/art.34318
   Zhang X, 2005, ARTHRITIS RHEUM-US, V52, P1297, DOI 10.1002/art.20984
NR 15
TC 9
Z9 9
U1 1
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0300-9742
EI 1502-7732
J9 SCAND J RHEUMATOL
JI Scand. J. Rheumatol.
PD JAN 2
PY 2016
VL 45
IS 1
BP 8
EP 12
DI 10.3109/03009742.2015.1047403
PG 5
WC Rheumatology
SC Rheumatology
GA DA2GG
UT WOS:000367612700002
PM 26202066
DA 2020-11-11
ER

PT J
AU Tricarico, PM
   Franca, RFD
   Pacor, S
   Ceglia, V
   Crovella, S
   Celsi, F
AF Tricarico, Paola Maura
   Franca, Rafael Freitas de Oliveira
   Pacor, Sabrina
   Ceglia, Valentina
   Crovella, Sergio
   Celsi, Fulvio
TI HIV Protease Inhibitors Apoptotic Effect in SH-SY5Y Neuronal Cell Line
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Mother-to-child HIV transmission; Lopinavir; Ritonavir; Neuronal cell;
   Apoptosis; Mitochondrial damage
ID OXIDATIVE STRESS; LOPINAVIR/RITONAVIR; NEURODEGENERATION; MECHANISMS;
   RITONAVIR; LOPINAVIR; PATHWAY; HAART; BRAIN
AB Background: Prophylactic treatment regimens to prevent mother-to-child HIV transmission include protease inhibitors Lopinavir and Ritonavir. Lopinavir and Ritonavir have been reported to be able to induce intracellular oxidative stress in diverse cellular models, however scarce informations are available about protease inhibitor effects of in the central nervous system (CNS). In our study we evaluated the impact of protease inhibitors on a cell neuronal model. Methods: We treated a neuroblastoma cell line (SH-SY5Y) with increasing doses of Lopinavir and Ritonavir (0.1-1-10-25-50 mu M), used alone or in combination, evaluating the impact of these drugs in terms of mitochondrial activity, with MTT cell proliferation assay; mRNA expression of heme oxygenase (HemeOH) and reactive oxygen species (ROS) levels with 2',7'-dichlorofluorescin diacetate (H2DCFDA) in order to assess oxidative stress; apoptotic cell death with flow cytometry. Results: We observed that Lopinavir and Ritonavir treatment, at 25 and/or 50 mu M concentrations, induced mitochondrial damage, increase of heme oxygenase RNA expression levels and ROS generation, followed by apoptosis in SH-SY5Y. Conclusions: Our in vitro model demonstrates a damaging effect of HIV protease inhibitors on the neuroblastoma cell line, thus partially mimicking the impact of these drugs on the CNS of children born to HIV positive mothers undergone to antiretroviral treatment.
C1 [Pacor, Sabrina; Ceglia, Valentina; Crovella, Sergio] Univ Trieste, Trieste, Italy.
   [Franca, Rafael Freitas de Oliveira] Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Res Ctr, Recife, PE, Brazil.
   [Tricarico, Paola Maura; Crovella, Sergio; Celsi, Fulvio] Inst Maternal & Child Hlth Burlo Garofolo, Via Istria 65-1, I-34137 Trieste, Italy.
RP Celsi, F (corresponding author), Inst Maternal & Child Hlth Burlo Garofolo, Via Istria 65-1, I-34137 Trieste, Italy.
EM fulvio.celsi@gmail.com
RI tricarico, paola/AAB-8972-2019
OI tricarico, paola/0000-0002-1954-4126; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007
FU Institute for Maternal and Child Health IRCCS "Burlo Garofolo" [RC
   42/11, RC07/08]
FX This work was supported by grants from the Institute for Maternal and
   Child Health IRCCS "Burlo Garofolo" (RC 42/11; RC07/08).
CR Arend C, 2013, NEUROCHEM RES, V38, P732, DOI 10.1007/s11064-013-0971-x
   Bansal S, 2014, REDOX BIOL, V2, P273, DOI 10.1016/j.redox.2013.07.004
   Bissinger R, 2015, CELL PHYSIOL BIOCHEM, V37, P2486, DOI 10.1159/000438601
   Calcagno A, 2014, CLIN PHARMACOKINET, V53, P891, DOI 10.1007/s40262-014-0171-0
   Chandra S, 2009, EXP BIOL MED, V234, P442, DOI 10.3181/0811-RM-317
   Chougrani I, 2013, HIV AIDS-RES PALLIAT, V5, P253, DOI 10.2147/HIV.S33058
   Deng W, 2010, J MOL CELL CARDIOL, V49, P746, DOI 10.1016/j.yjmcc.2010.08.013
   Evers S, 2004, AIDS RES HUM RETROV, V20, P483, DOI 10.1089/088922204323087723
   Federico A, 2012, J NEUROL SCI, V322, P254, DOI 10.1016/j.jns.2012.05.030
   Gupta S, 2012, ANTIVIR RES, V95, P19, DOI 10.1016/j.antiviral.2012.04.010
   Lan XQ, 2012, J NEUROIMMUNE PHARM, V7, P412, DOI 10.1007/s11481-011-9304-5
   Pistell PJ, 2010, ANTIVIR RES, V88, P334, DOI 10.1016/j.antiviral.2010.10.006
   Pope S, 2008, BBA-BIOENERGETICS, V1777, P794, DOI 10.1016/j.bbabio.2008.03.011
   Rudin C, 2008, PEDIATR INFECT DIS J, V27, P431, DOI 10.1097/INF.0b013e3181646d5a
   Saunders NR, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00046
   Schipper HM, 2009, CURR ALZHEIMER RES, V6, P424, DOI 10.2174/156720509789207985
   Spaulding AB, 2016, AIDS RES HUM RETROV, V32, P349, DOI [10.1089/aid.2015.0254, 10.1089/AID.2015.0254]
   Taura M, 2013, FREE RADICAL BIO MED, V65, P778, DOI 10.1016/j.freeradbiomed.2013.08.161
   Touzet O, 2010, AIDS, V24, P1437, DOI 10.1097/QAD.0b013e32833a6114
   Tricarico PM, 2014, INT J MOL SCI, V15, P6843, DOI 10.3390/ijms15046843
   Tubiana R, 2013, CLIN INFECT DIS, V57, P891, DOI 10.1093/cid/cit390
   VISTICA DT, 1991, CANCER RES, V51, P2515
   Whitehead N, 2014, AIDS CARE, V26, P497, DOI 10.1080/09540121.2013.841828
   Zhou HP, 2006, AM J PHYSIOL-GASTR L, V291, pG1071, DOI 10.1152/ajpgi.00182.2006
NR 24
TC 10
Z9 11
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2016
VL 39
IS 4
BP 1463
EP 1470
DI 10.1159/000447849
PG 8
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA DX5IQ
UT WOS:000384415000020
PM 27607424
OA DOAJ Gold, Green Published
DA 2020-11-11
ER

PT J
AU Lauretti, F
   Chattopadhyay, A
   Franca, RFD
   Castro-Jorge, L
   Rose, J
   da Fonseca, BAL
AF Lauretti, Flavio
   Chattopadhyay, Anasuya
   de Oliveira Franca, Rafael Freitas
   Castro-Jorge, Luiza
   Rose, John
   da Fonseca, Benedito A. L.
TI Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate
   induces humoral response and protects mice against lethal infection
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE dengue 2; dengue vaccine candidate; mouse challenge; neutralizing
   antibodies; recombinant vesicular stomatitis virus
ID ANTIBODIES; IMMUNOGENICITY; NEUTRALIZATION; PROGRESS; BROAD
AB Dengue is the most important arbovirus disease throughout the world and it is responsible for more than 500,000 dengue hemorrhagic cases and 22,000 deaths every year. One vaccine was recently licensed for human use in Brazil, Mexico and Philippines and although at least seven candidates have been in clinical trials the results of the most developed CYD vaccine have demonstrated immunization problems, such as uneven protection and interference between serotypes. We constructed a vaccine candidate based on vesicular stomatitis virus (VSV) expression of pre-membrane (prM) and envelope (E) proteins of dengue-2 virus (DENV-2) and tested it in mice to evaluate immunogenicity and protection against DENV-2 infection. VSV has been successfully used as vaccine vectors for several viruses to induce strong humoral and cellular immune responses. The VSV-DENV-2 recombinant was constructed by inserting the DENV-2 structural proteins into a VSV plasmid DNA for recombinant VSV-DENV-2 recovery. Infectious recombinant VSV viruses were plaque purified and prM and E expression were confirmed by immunofluorescence and radiolabeling of proteins of infected cells. Forty Balb/C mice were inoculated through subcutaneous (s.c.) route with VSV-DENV-2 vaccine in a two doses schedule 15d apart and 29d after first inoculation, sera were collected and the mice were challenged with 50 lethal doses (LD50) of a neurovirulent DENV-2. The VSV-DENV-2 induced anti-DENV-2 antibodies and protected animals in the challenge experiment comparable to DENV-2 immunization control group. We conclude that VSV is a promising platform to test as a DENV vaccine and perhaps against others Flaviviridae.
C1 [Lauretti, Flavio; de Oliveira Franca, Rafael Freitas; Castro-Jorge, Luiza; da Fonseca, Benedito A. L.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Internal Med, Ribeirao Preto, SP, Brazil.
   [Chattopadhyay, Anasuya; Rose, John] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.
RP da Fonseca, BAL (corresponding author), Fac Med Ribeirao Preto, Ave Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM baldfons@fmrp.usp.br
RI de Castro Jorge, Luiza Antunes/D-3773-2009; Fonseca,
   Benedito/F-3252-2012
OI Fonseca, Benedito/0000-0003-3159-5687; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007
FU National Counsel of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [307703/2014-2]; U.S. National Institute of Allergy and
   Infectious Disease (NIAID/NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U54AI057158]; Coordination for
   the Improvement of Higher Education Personnel (CAPES)CAPES [PNPD
   07171532828]
FX This work was supported in part by National Counsel of Technological and
   Scientific Development (CNPq), grant 307703/2014-2 and U.S. National
   Institute of Allergy and Infectious Disease (NIAID/NIH), grant
   U54AI057158. Flavio Lauretti was supported by Posdoctoral fellowship of
   Coordination for the Improvement of Higher Education Personnel (CAPES),
   grant PNPD 07171532828. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Barban V, 2012, VIROLOGY, V429, P91, DOI 10.1016/j.virol.2012.03.007
   Blaney JE, 2005, J VIROL, V79, P5516, DOI 10.1128/JVI.79.9.5516-5528.2005
   Brien JD, 2010, J VIROL, V84, P10630, DOI 10.1128/JVI.01190-10
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Caufour PS, 2001, VIRUS RES, V79, P1, DOI 10.1016/S0168-1702(01)00273-8
   Chattopadhyay A, 2013, J VIROL, V87, P395, DOI 10.1128/JVI.01860-12
   de Alwis R, 2012, P NATL ACAD SCI USA, V109, P7439, DOI 10.1073/pnas.1200566109
   Edelman R, 2007, CLIN INFECT DIS, V45, pS56, DOI 10.1086/518148
   Geisbert TW, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000225
   Guzman E, 2015, LANCET, V385, P453
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Halstead SB, 2013, VACCINE, V31, P4501, DOI 10.1016/j.vaccine.2013.06.079
   Hernandez-Avila M, 2016, SALUD PUBLICA MEXICO, V58, P71, DOI 10.21149/spm.v58i1.7670
   Innis BL, 2003, AM J TROP MED HYG, V69, P1
   LAWSON ND, 1995, P NATL ACAD SCI USA, V92, P4477, DOI 10.1073/pnas.92.10.4477
   LEWIS JA, 1993, VIROLOGY, V197, P216, DOI 10.1006/viro.1993.1582
   Messer WB, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001486
   Norrby R, 2014, CLIN MICROBIOL INFEC, V20, P92, DOI 10.1111/1469-0691.12442
   Putnak R, 1996, J INFECT DIS, V174, P1176, DOI 10.1093/infdis/174.6.1176
   Reuter JD, 2002, J VIROL, V76, P8900, DOI 10.1128/JVI.76.17.8900-8909.2002
   RUSSELL PK, 1967, J IMMUNOL, V99, P285
   SABIN AB, 1945, SCIENCE, V101, P640, DOI 10.1126/science.101.2634.640
   Schnell MJ, 1996, P NATL ACAD SCI USA, V93, P11359, DOI 10.1073/pnas.93.21.11359
   Schwartz JA, 2011, J VIROL, V85, P4602, DOI 10.1128/JVI.02491-10
   STEINHOFF U, 1995, J VIROL, V69, P2153, DOI 10.1128/JVI.69.4.2153-2158.1995
   Van Der Most RG, 2000, J VIROL, V74, P8094, DOI 10.1128/JVI.74.17.8094-8101.2000
   Wahala WMPB, 2011, VIRUSES-BASEL, V3, P2374, DOI 10.3390/v3122374
   Wahala WMPB, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000821
   Wan SW, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-37
   WHO media centre, 2015, DENG SEV DENG, V117
   World Health Organization, 2013, WEEKLY EPIDEMIOLOGIC, V20, P205
NR 31
TC 5
Z9 5
U1 0
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PY 2016
VL 12
IS 9
BP 2327
EP 2333
DI 10.1080/21645515.2016.1183857
PG 7
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA DX2RA
UT WOS:000384217200028
PM 27185081
OA Green Published, Bronze
DA 2020-11-11
ER

PT J
AU Pinto, LG
   Talbot, J
   Peres, RS
   Franca, RF
   Ferreira, SH
   Ryffel, B
   Aves, JCF
   Figueiredo, F
   Cunha, TM
   Cunha, FQ
AF Pinto, Larissa G.
   Talbot, Jhimmy
   Peres, Raphael S.
   Franca, Rafael F.
   Ferreira, Sergio H.
   Ryffel, Bernhard
   Aves-Filho, Jose Carlos F.
   Figueiredo, Florencio
   Cunha, Thiago M.
   Cunha, Fernando Q.
TI Joint production of IL-22 participates in the initial phase of
   antigen-induced arthritis through IL-1 beta production
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID COLLAGEN-INDUCED ARTHRITIS; TUMOR-NECROSIS-FACTOR; MECHANICAL
   INFLAMMATORY HYPERNOCICEPTION; RHEUMATOID-ARTHRITIS; T-CELLS; SYNOVIAL
   FIBROBLASTS; INDUCIBLE FACTOR; INTERLEUKIN 22; POTENTIAL ROLE;
   FACTOR-ALPHA
AB Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by neutrophil articular infiltration, joint pain and the progressive destruction of cartilage and bone. IL-22 is a key effector molecule that plays a critical role in autoimmune diseases. However, the function of IL-22 in the pathogenesis of RA remains controversial. In this study, we investigated the role of IL-22 in the early phase of antigen-induced arthritis (AIA) in mice.
   Methods: AIA was induced in C57BL/6, IL-22(-/-), ASC(-/-) and IL-1R1(-/-) immunized mice challenged intra-articularly with methylated bovine serum albumin (mBSA). Expression of IL-22 in synovial membranes was determined by RT-PCR. Articular hypernociception was evaluated using an electronic von Frey. Neutrophil recruitment and histopathological analyses were assessed in inflamed knee joint. Joint levels of inflammatory mediators and mBSA-specific IgG concentration in the serum were measured by ELISA.
   Results: The IL-22 mRNA expression and protein levels in synovial tissue were increased during the onset of AIA. In addition, pharmacological inhibition (anti-IL-22 antibody) and genetic deficiency (IL-22(-/-) mice) reduced articular pain and neutrophil migration in arthritic mice. Consistent with these findings, recombinant IL-22 joint administration promoted articular inflammation per se in WT mice, restoring joint nociception and neutrophil infiltration in IL-22(-/-) mice. Moreover, IL-22-deficient mice showed reduced synovitis (inflammatory cell influx) and lower joint IL-1 alpha levels, whereas the production of IL-17, MCP-1/CCL2, and KC/CXCL1 and the humoral immune response were similar, compared with WT mice. Corroborating these results, the exogenous administration of IL-22 into the joints induced IL-1 alpha production in WT mice and reestablished IL-1 beta production in IL-22(-/-) mice challenged with mBSA. Additionally, IL-1R1(-/-) mice showed attenuated inflammatory features induced by mBSA or IL-22 challenge. Articular nociception and neutrophil migration induced by IL-22 were also reduced in ASC(-/-) mice.
   Conclusions: These results suggest that IL-22 plays a pro-inflammatory/pathogenic role in the onset of AIA through an ASC-dependent stimulation of IL-1 beta production.
C1 [Pinto, Larissa G.; Talbot, Jhimmy; Peres, Raphael S.; Franca, Rafael F.; Ferreira, Sergio H.; Aves-Filho, Jose Carlos F.; Cunha, Thiago M.; Cunha, Fernando Q.] Univ Sao Paulo, Dept Pharmacol, Ribeirao Preto Med Sch, BR-14049900 Sao Paulo, Brazil.
   [Ryffel, Bernhard] Univ Orleans, F-45071 Orleans, France.
   [Ryffel, Bernhard] CNRS, UMR Mol & Expt Immunol & Neurogenet 7355, F-45071 Orleans, France.
   [Figueiredo, Florencio] Univ Brasilia, Sch Med, Lab Pathol, BR-70910900 Brasilia, DF, Brazil.
RP Cunha, TM (corresponding author), Univ Sao Paulo, Dept Pharmacol, Ribeirao Preto Med Sch, Ave Bandeirantes 3900, BR-14049900 Sao Paulo, Brazil.
EM thicunha@usp.br; fdqcunha@fmrp.usp.br
RI Cunha, Thiago M/B-7729-2012; Cunha, Fernando Q/M-3090-2014; Alves-Filho,
   Jose Carlos/B-5814-2008
OI Cunha, Thiago M/0000-0003-1084-0065; Alves-Filho, Jose
   Carlos/0000-0002-9918-8714; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007; Sanches Peres, Raphael/0000-0002-0417-779X;
   Cunha, Fernando Queiroz/0000-0003-4755-1670; Pinto, Larissa
   G/0000-0002-3619-907X
FU European UnionEuropean Union (EU) [HEALTH-F4-2011-281608]; Sao Paulo
   Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2011/19670-0, 2013/08216-2]; University of Sao Paulo
   NAP-DIN [11.1.21625.01.0]
FX We thank Ieda Regina dos Santos Schivo, Sergio Roberto Rosa, Ana Katia
   dos Santos and Giuliana Bertozi Francisco for their excellent technical
   assistance. This work was supported by grants from the European Union
   Seventh Framework Programme [FP7-2007-2013] under grant agreement number
   HEALTH-F4-2011-281608 (TIMER), from the Sao Paulo Research Foundation
   (FAPESP) under grant agreements number 2011/19670-0 (Projeto Tematico)
   and 2013/08216-2 (Center for Research in Inflammatory Disease) and from
   the University of Sao Paulo NAP-DIN under grant agreement number
   11.1.21625.01.0.
CR Amaral FA, 2012, ARTHRITIS RHEUM-US, V64, P474, DOI 10.1002/art.33355
   ANGEL J, 1994, EUR J BIOCHEM, V226, P125, DOI 10.1111/j.1432-1033.1994.tb20033.x
   AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202
   Aujla SJ, 2009, J MOL MED, V87, P451, DOI 10.1007/s00109-009-0448-1
   Besnard AG, 2011, AM J RESP CRIT CARE, V183, P1153, DOI 10.1164/rccm.201008-1383OC
   Binshtok AM, 2008, J NEUROSCI, V28, P14062, DOI 10.1523/JNEUROSCI.3795-08.2008
   Boettger MK, 2008, ARTHRITIS RHEUM-US, V58, P2368, DOI 10.1002/art.23608
   BRACKERTZ D, 1977, ARTHRITIS RHEUM, V20, P841, DOI 10.1002/art.1780200314
   Brenn D, 2007, ARTHRITIS RHEUM, V56, P351, DOI 10.1002/art.22282
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Burmester GR, 2014, NAT REV RHEUMATOL, V10, P77, DOI 10.1038/nrrheum.2013.168
   Carrion M, 2013, RHEUMATOLOGY, V52, P2177, DOI 10.1093/rheumatology/ket315
   Rocha FAC, 2008, INFECT IMMUN, V76, P2736, DOI 10.1128/IAI.01085-07
   Copray JCVM, 2001, J NEUROIMMUNOL, V118, P203, DOI 10.1016/S0165-5728(01)00324-1
   Cornelissen F, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2893
   Cunha TM, 2008, EUR J PAIN, V12, P1059, DOI 10.1016/j.ejpain.2008.02.003
   Cunha TM, 2008, J LEUKOCYTE BIOL, V83, P824, DOI 10.1189/jlb.0907654
   Cunha TM, 2005, P NATL ACAD SCI USA, V102, P1755, DOI 10.1073/pnas.0409225102
   da Rocha LF, 2012, J RHEUMATOL, V39, P1320, DOI 10.3899/jrheum.111027
   Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697
   FERREIRA SH, 1988, NATURE, V334, P698, DOI 10.1038/334698a0
   Geboes L, 2009, ARTHRITIS RHEUM-US, V60, P390, DOI 10.1002/art.24220
   Grespan R, 2008, ARTHRITIS RHEUM, V58, P2030, DOI 10.1002/art.23597
   Ikeuchi H, 2005, ARTHRITIS RHEUM-US, V52, P1037, DOI 10.1002/art.20965
   Ji H, 2002, J EXP MED, V196, P77, DOI 10.1084/jem.20020439
   Jorgensen C, 1991, Eur Cytokine Netw, V2, P207
   Justa S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093279
   Kim KW, 2012, ARTHRITIS RHEUM-US, V64, P1015, DOI 10.1002/art.33446
   Kolly L, 2009, J IMMUNOL, V183, P4003, DOI 10.4049/jimmunol.0802173
   Kotenko SV, 2001, J BIOL CHEM, V276, P2725, DOI 10.1074/jbc.M007837200
   Leipe J, 2011, ANN RHEUM DIS, V70, P1453, DOI 10.1136/ard.2011.152074
   LEY K, 1993, BLOOD, V81, P177
   Ma HL, 2008, J CLIN INVEST, V118, P597, DOI 10.1172/JCI33263
   Marijnissen RJ, 2011, ARTHRITIS RHEUM-US, V63, P2939, DOI 10.1002/art.30469
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Miossec P, 2004, CURR OPIN RHEUMATOL, V16, P218, DOI 10.1097/00002281-200405000-00009
   Ouyang WJ, 2011, ANNU REV IMMUNOL, V29, P71, DOI 10.1146/annurev-immunol-031210-101312
   Petrow PK, 1996, IMMUNOL INVEST, V25, P341, DOI 10.3109/08820139609059316
   Pineda MA, 2014, ARTHRITIS RHEUMATOL, V66, P1492, DOI 10.1002/art.38392
   Pinto LG, 2010, PAIN, V148, P247, DOI 10.1016/j.pain.2009.11.006
   Pohlers D, 2004, CLIN EXP IMMUNOL, V135, P409, DOI 10.1111/j.1365-2249.2003.02381.x
   Richter F, 2012, ARTHRITIS RHEUM-US, V64, P4125, DOI 10.1002/art.37695
   Sarkar S, 2013, ARTHRITIS RHEUM-US, V65, P960, DOI 10.1002/art.37849
   Sonnenberg GF, 2010, J EXP MED, V207, P1293, DOI 10.1084/jem.20092054
   van Hamburg JP, 2013, ANN RHEUM DIS, V72, P1700, DOI 10.1136/annrheumdis-2012-202373
   van Hamburg JP, 2009, ARTHRITIS RHEUM-US, V60, P750, DOI 10.1002/art.24329
   Verri WA, 2008, P NATL ACAD SCI USA, V105, P2723, DOI 10.1073/pnas.0712116105
   Witte E, 2010, CYTOKINE GROWTH F R, V21, P365, DOI 10.1016/j.cytogfr.2010.08.002
   Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007
   Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503
   Wolk K, 2010, SEMIN IMMUNOPATHOL, V32, P17, DOI 10.1007/s00281-009-0188-x
   Wong PKK, 2006, ARTHRITIS RHEUM-US, V54, P158, DOI 10.1002/art.21537
   Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200
   Zenewicz LA, 2011, INT IMMUNOL, V23, P159, DOI 10.1093/intimm/dxr001
   Zhang L, 2011, J CLIN IMMUNOL, V31, P606, DOI 10.1007/s10875-011-9540-8
   Zhao L, 2013, INT J RHEUM DIS, V16, P518, DOI 10.1111/1756-185X.12099
   Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505
NR 58
TC 20
Z9 21
U1 0
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478-6354
EI 1478-6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD SEP 2
PY 2015
VL 17
AR 235
DI 10.1186/s13075-015-0759-2
PG 13
WC Rheumatology
SC Rheumatology
GA CQ2KM
UT WOS:000360428900001
PM 26330334
OA DOAJ Gold, Green Published
DA 2020-11-11
ER

PT J
AU Wu, C
   Thalhamer, T
   Franca, RF
   Xiao, S
   Wang, C
   Hotta, C
   Zhu, C
   Hirashima, M
   Anderson, AC
   Kuchroo, VK
AF Wu, Chuan
   Thalhamer, Theresa
   Franca, Rafael F.
   Xiao, Sheng
   Wang, Chao
   Hotta, Chie
   Zhu, Chen
   Hirashima, Mitsuomi
   Anderson, Ana C.
   Kuchroo, Vijay K.
TI Galectin-9-CD44 Interaction Enhances Stability and Function of Adaptive
   Regulatory T Cells
SO IMMUNITY
LA English
DT Article
ID GROWTH-FACTOR-BETA; TGF-BETA; FOXP3 EXPRESSION; REG-CELLS; IN-VIVO;
   SIGNAL-TRANSDUCTION; DENDRITIC CELLS; RETINOIC-ACID; IFN-GAMMA;
   INFLAMMATION
AB The beta-galactoside-binding protein galectin-9 is critical in regulating the immune response, but the mechanism by which it functions remains unclear. We have demonstrated that galectin-9 is highly expressed by induced regulatory T cells (iTreg) and was crucial for the generation and function of iTreg cells, but not natural regulatory T (nTreg) cells. Galectin-9 expression within iTreg cells was driven by the transcription factor Smad3, forming a feed-forward loop, which further promoted Foxp3 expression. Galectin-9 increased iTreg cell stability and function by directly binding to its receptor CD44, which formed a complex with transforming growth factor-beta (TGF-beta) receptor I (TGF-beta RI), and activated Smad3. Galectin-9 signaling was further found to regulate iTreg cell induction by dominantly acting through the CNS1 region of the Foxp3 locus. Our data suggest that exogenous galectin-9, in addition to being an effector molecule for Treg cells, acts synergistically with TGF-beta to enforce iTreg cell differentiation and maintenance.
C1 [Wu, Chuan; Thalhamer, Theresa; Franca, Rafael F.; Xiao, Sheng; Wang, Chao; Hotta, Chie; Zhu, Chen; Anderson, Ana C.; Kuchroo, Vijay K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Evergrande Ctr Immunol Dis, Boston, MA 02115 USA.
   [Hirashima, Mitsuomi] Kagawa Univ, Fac Med, Dept Immunol & Immunopathol, Kagawa 7610793, Japan.
RP Kuchroo, VK (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Evergrande Ctr Immunol Dis, Boston, MA 02115 USA.
EM vkuchroo@rics.bwh.harvard.edu
RI ; Wu, Chuan/H-6379-2013
OI Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007; Wang,
   Chao/0000-0003-3084-6093; Wu, Chuan/0000-0003-2288-353X
FU National Multiple Sclerosis SocietyNational Multiple Sclerosis Society
   [FG2046]; Austrian Science Fund (FWF)Austrian Science Fund (FWF) [J
   3091-B12]; US National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [K01DK090105, P01AI073748, P01AI056299, P01AI039671, R01NS045937]; Sao
   Paulo Research Foundation FAPESPFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [2012/14924-7]; American Cancer SocietyAmerican
   Cancer Society [RSG-11-057-01-LIB]; Slomo and Cindy Silvian Foundation;
   Tempero Pharmaceuticals
FX We thank D. Kozoriz for cell sorting. A. Rudensky provided the
   CNS1-deficient mice. C.W. was supported by a Postdoctoral Fellowship
   from the National Multiple Sclerosis Society (FG2046). T.T. was
   supported by the Austrian Science Fund (FWF, J 3091-B12). S.X. was
   supported by the US National Institutes of Health (K01DK090105). R.F.F.
   was supported by Sao Paulo Research Foundation FAPESP (2012/14924-7).
   A.C.A was supported by the American Cancer Society (RSG-11-057-01-LIB)
   and the Slomo and Cindy Silvian Foundation. V.K.K. was supported by the
   US National Institutes of Health (P01AI073748, P01AI056299, P01AI039671,
   and R01NS045937). V.K.K. is a founder of, and has financial interest in,
   Tempero Pharmaceuticals. The company has interests in research and
   therapy development in areas related to this research. V.K.K.'s
   interests were reviewed and are managed by the Brigham and Women's
   Hospital and Partners Healthcare in accordance with their conflict of
   interest policies.
CR Alam S, 2011, J BIOL CHEM, V286, P44211, DOI 10.1074/jbc.M111.242289
   Anderson AC, 2007, SCIENCE, V318, P1141, DOI 10.1126/science.1148536
   Arikawa T, 2010, EUR J IMMUNOL, V40, P548, DOI 10.1002/eji.200939886
   Arikawa T, 2009, CLIN IMMUNOL, V133, P382, DOI 10.1016/j.clim.2009.09.004
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032
   Bollyky PL, 2009, J IMMUNOL, V183, P2232, DOI 10.4049/jimmunol.0900191
   Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200
   Chaudhry A, 2011, IMMUNITY, V34, P566, DOI 10.1016/j.immuni.2011.03.018
   Chou FC, 2009, EUR J IMMUNOL, V39, P2403, DOI 10.1002/eji.200839177
   Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590
   Datto MB, 1999, MOL CELL BIOL, V19, P2495
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Ferber IA, 1996, J IMMUNOL, V156, P5
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Hirashima M, 2002, GLYCOCONJUGATE J, V19, P593, DOI 10.1023/B:GLYC.0000014090.63206.2f
   Jayaraman P, 2010, J EXP MED, V207, P2343, DOI 10.1084/jem.20100687
   Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623
   Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772
   Kared H, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003422
   Katoh S, 2007, AM J RESP CRIT CARE, V176, P27, DOI 10.1164/rccm.200608-1243OC
   Kim HP, 2005, J BIOL CHEM, V280, P34042, DOI 10.1074/jbc.M505833200
   Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0
   Li XC, 2010, NAT REV NEPHROL, V6, P577, DOI 10.1038/nrneph.2010.101
   Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157
   Liu FT, 2010, ANN NY ACAD SCI, V1183, P158, DOI 10.1111/j.1749-6632.2009.05131.x
   Liu T, 2009, BIOL DIRECT, V4, DOI 10.1186/1745-6150-4-40
   Lu LH, 2007, J BIOCHEM, V141, P157, DOI 10.1093/jb/mvm019
   MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6
   Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753
   Nagahara K, 2008, J IMMUNOL, V181, P7660, DOI 10.4049/jimmunol.181.11.7660
   Ohkura N, 2012, IMMUNITY, V37, P785, DOI 10.1016/j.immuni.2012.09.010
   Oomizu S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048574
   Ouyang WM, 2010, IMMUNITY, V32, P642, DOI 10.1016/j.immuni.2010.04.012
   PENDER MP, 1992, J AUTOIMMUN, V5, P401, DOI 10.1016/0896-8411(92)90001-7
   Rabinovich GA, 2009, NAT REV IMMUNOL, V9, P338, DOI 10.1038/nri2536
   Reddy PBJ, 2011, J IMMUNOL, V187, P5745, DOI 10.4049/jimmunol.1102105
   Ruan QG, 2009, IMMUNITY, V31, P932, DOI 10.1016/j.immuni.2009.10.006
   Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017
   Rubtsov YP, 2010, SCIENCE, V329, P1667, DOI 10.1126/science.1191996
   Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785
   Schlenner SM, 2012, J EXP MED, V209, P1529, DOI 10.1084/jem.20112646
   Sehrawat S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000882
   Seki M, 2008, CLIN IMMUNOL, V127, P78, DOI 10.1016/j.clim.2008.01.006
   Seki M, 2007, ARTHRITIS RHEUM-US, V56, P3968, DOI 10.1002/art.23076
   Siddiqui KRR, 2008, MUCOSAL IMMUNOL, V1, pS34, DOI 10.1038/mi.2008.43
   Su EW, 2011, GLYCOBIOLOGY, V21, P1258, DOI 10.1093/glycob/cwq214
   Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602
   Takimoto T, 2010, J IMMUNOL, V185, P842, DOI 10.4049/jimmunol.0904100
   Tanikawa R, 2010, BIOCHEM BIOPH RES CO, V394, P317, DOI 10.1016/j.bbrc.2010.02.175
   Toker A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001783
   Toms C, 2008, IMMUNOLOGY, V125, P302, DOI 10.1111/j.1365-2567.2008.02857.x
   Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549
   Tsuboi Y, 2007, CLIN IMMUNOL, V124, P221, DOI 10.1016/j.clim.2007.04.015
   Vasta GR, 2009, NAT REV MICROBIOL, V7, P424, DOI 10.1038/nrmicro2146
   Wang F, 2009, IMMUNOBIOLOGY, V214, P342, DOI 10.1016/j.imbio.2008.10.007
   Wang ZJ, 2006, J CLIN INVEST, V116, P2434, DOI 10.1172/JCI25826
   Weiss JM, 2012, J EXP MED, V209, P1723, DOI 10.1084/jem.20120914
   Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437
   Xu LL, 2010, IMMUNITY, V33, P313, DOI 10.1016/j.immuni.2010.09.001
   Yadav M, 2012, J EXP MED, V209, P1713, DOI 10.1084/jem.20120822
   Zheng Y, 2007, NAT IMMUNOL, V8, P457, DOI 10.1038/ni1455
   Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750
   Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674
   Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774
   Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271
NR 68
TC 108
Z9 112
U1 0
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD AUG 21
PY 2014
VL 41
IS 2
BP 270
EP 282
DI 10.1016/j.immuni.2014.06.011
PG 13
WC Immunology
SC Immunology
GA AO6JA
UT WOS:000341455300014
PM 25065622
OA Bronze, Green Accepted
DA 2020-11-11
ER

PT J
AU Chavez, JH
   Franca, RFO
   Oliveira, CJF
   de Aquino, MTP
   Farias, KJS
   Machado, PRL
   de Oliveira, TFM
   Yokosawa, J
   Soares, EG
   da Silva, JS
   da Fonseca, BAL
   Figueiredo, LTM
AF Chavez, Juliana H.
   Franca, Rafael F. O.
   Oliveira, Carlo J. F.
   de Aquino, Maria T. P.
   Farias, Kleber J. S.
   Machado, Paula R. L.
   de Oliveira, Thelma F. M.
   Yokosawa, Jonny
   Soares, Edson G.
   da Silva, Joao S.
   da Fonseca, Benedito A. L.
   Figueiredo, Luiz T. M.
TI Influence of the CCR-5/MIP-1 alpha Axis in the Pathogenesis of Rocio
   Virus Encephalitis in a Mouse Model
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID NITRIC-OXIDE; MIP-1 ALPHA; CHEMOKINES; INFECTION; CCR5; RECEPTOR;
   BIOLOGY; SYSTEM
AB Rocio virus (ROCV) caused an outbreak of human encephalitis during the 1970s in Brazil and its immunopathogenesis remains poorly understood. CC-chemokine receptor 5 (CCR5) is a chemokine receptor that binds to macrophage inflammatory protein (MIP-1 alpha). Both molecules are associated with inflammatory cells migration during infections. In this study, we demonstrated the importance of the CCR5 and MIP-1 alpha, in the outcome of viral encephalitis of ROCV-infected mice. CCR5 and MIP-1 alpha knockout mice survived longer than wild-type (WT) ROCV-infected animals In addition, knockout mice had reduced inflammation in the brain. Assessment of brain viral load showed mice virus detection five days post-infection in wild-type and CCR5-/- mice, while MIP-1 alpha-/- mice had lower viral loads seven days post-infection. Knockout mice required a higher lethal dose than wild-type mice as well. The CCR5/MIP-1 alpha axis may contribute to migration of infected cells to the brain and consequently affect the pathogenesis during ROCV infection.
C1 [Chavez, Juliana H.; de Oliveira, Thelma F. M.; Yokosawa, Jonny] Univ Fed Uberlandia, Inst Ciencias Biomed, Virol Lab, BR-38405302 Uberlandia, MG, Brazil.
   Univ Sao Paulo, Fac Med, Dept Patol Ribeirao Preto, Ctr Pesquisa Virol,Dept Bioquim & Imunol, Sao Paulo, Brazil.
   [Oliveira, Carlo J. F.] Univ Fed Triangulo Mineiro, Inst Ciencias Biol & Nat, Uberaba, MG, Brazil.
   [Farias, Kleber J. S.] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, BR-59072970 Natal, RN, Brazil.
   [Machado, Paula R. L.] Univ Fed Rio Grande do Norte, Dept Anal Clin & Toxicol, BR-59072970 Natal, RN, Brazil.
RP Chavez, JH (corresponding author), Univ Fed Uberlandia, Inst Ciencias Biomed, Virol Lab, Av Amazonas 2210, BR-38405302 Uberlandia, MG, Brazil.
EM julianachavez@yahoo.com.br; rafaelfranca@usp.br; carlo@icbn.uftm.edu.br;
   teresaaq@terra.com.br; kfarias3@hotmail.com; paulamachado2@hotmail.com;
   thelmao@umuarama.ufu.br; jyokosawa@icbim.ufu.br; egsoares@fmrp.usp.br;
   jsdsilva@fmrp.usp.br; baldfons@fmrp.usp.br; ltmfigue@fmrp.usp.br
RI FARIAS, KLEBER/AAC-9815-2019; Silva, Joao S/A-4484-2008; Oliveira, Carlo
   Jose Freire/AAY-8751-2020; Fonseca, Benedito/F-3252-2012
OI Silva, Joao S/0000-0002-3410-3927; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007; Fonseca, Benedito/0000-0003-3159-5687
FU Fundacao de Amparo a Pesquisa do Estado de Minas Gerais/Brasil; Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo/BrasilFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP)
FX This study was partially supported by Fundacao de Amparo a Pesquisa do
   Estado de Minas Gerais/Brasil and Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo/Brasil.
CR Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   Alkhatib G, 2009, CURR OPIN HIV AIDS, V4, P96, DOI 10.1097/COH.0b013e328324bbec
   Brenier-Pinchart MP, 2001, TRENDS PARASITOL, V17, P292, DOI 10.1016/S1471-4922(01)01902-X
   Chavez JH, 2006, VIRUS REV RES, V11, P28
   Cook DN, 1996, J LEUKOCYTE BIOL, V59, P61
   DESOUZALOPES O, 1978, AM J EPIDEMIOL, V108, P394, DOI 10.1093/oxfordjournals.aje.a112637
   Barros VED, 2009, REV INST MED TROP SP, V51, P141, DOI 10.1590/S0036-46652009000300004
   de Barros VED, 2011, AM J TROP MED HYG, V85, P363, DOI 10.4269/ajtmh.2011.10-0246
   Ferreira Ivani B., 1994, Revista do Instituto de Medicina Tropical de Sao Paulo, V36, P265, DOI 10.1590/S0036-46651994000300011
   Figueiredo LTM, 2000, MICROBES INFECT, V2, P1643, DOI 10.1016/S1286-4579(00)01320-4
   Frydas S, 2003, INT J IMMUNOPATH PH, V16, P221, DOI 10.1177/039463200301600306
   GENTRY MK, 1982, AM J TROP MED HYG, V31, P548, DOI 10.4269/ajtmh.1982.31.548
   Glass WG, 2005, J EXP MED, V202, P1087, DOI 10.1084/jem.20042530
   Gubler DJ, 2007, FIELDS VIROLOGY, P1154
   Henriques DF, 2012, MEM I OSWALDO CRUZ, V107, P630, DOI 10.1590/S0074-02762012000500009
   Kasama Tsuyoshi, 2006, Recent Pat Antiinfect Drug Discov, V1, P275, DOI 10.2174/157489106778777655
   Kuhl SJ, 1998, WESTERN J MED, V168, P176
   Lim JK, 2008, J INFECT DIS, V197, P262, DOI 10.1086/524691
   Lim JK, 2006, TRENDS IMMUNOL, V27, P308, DOI 10.1016/j.it.2006.05.007
   Locati M, 2002, ALLERGY, V57, P972, DOI 10.1034/j.1398-9995.2002.02166.x
   LOPES ODS, 1978, AM J EPIDEMIOL, V107, P444
   Medeiros DBA, 2007, J GEN VIROL, V88, P2237, DOI 10.1099/vir.0.82883-0
   MONATH TP, 1978, AM J TROP MED HYG, V27, P1251, DOI 10.4269/ajtmh.1978.27.1251
   Nansen A, 2002, BLOOD, V99, P1237, DOI 10.1182/blood.V99.4.1237
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217
   Straatmann A, 1997, Rev Soc Bras Med Trop, V30, P511, DOI 10.1590/S0037-86821997000600012
   Wilkin TJ, 2012, ANNU REV MED, V63, P81, DOI 10.1146/annurev-med-052010-145454
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
NR 29
TC 6
Z9 6
U1 0
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2013
VL 89
IS 5
BP 1013
EP 1018
DI 10.4269/ajtmh.12-0591
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 251BZ
UT WOS:000326904100034
PM 24080631
OA Green Published, Bronze
DA 2020-11-11
ER

PT J
AU Franca, RFO
   da Silva, CC
   De Paula, SO
AF Franca, R. F. O.
   da Silva, C. C.
   De Paula, S. O.
TI Recent advances in molecular medicine techniques for the diagnosis,
   prevention, and control of infectious diseases
SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
LA English
DT Review
ID REVERSE TRANSCRIPTION PCR; RECOMBINANT ADENOVIRUS; PERPETUAL CHALLENGE;
   INFLUENZA-VIRUS; VACCINE; TRIAL; HIV; TUBERCULOSIS; VECTOR;
   IMMUNOGENICITY
AB In recent years we have observed great advances in our ability to combat infectious diseases. Through the development of novel genetic methodologies, including a better understanding of pathogen biology, pathogenic mechanisms, advances in vaccine development, designing new therapeutic drugs, and optimization of diagnostic tools, significant infectious diseases are now better controlled. Here, we briefly describe recent reports in the literature concentrating on infectious disease control. The focus of this review is to describe the molecular methods widely used in the diagnosis, prevention, and control of infectious diseases with regard to the innovation of molecular techniques. Since the list of pathogenic microorganisms is extensive, we emphasize some of the major human infectious diseases (AIDS, tuberculosis, malaria, rotavirus, herpes virus, viral hepatitis, and dengue fever). As a consequence of these developments, infectious diseases will be more accurately and effectively treated; safe and effective vaccines are being developed and rapid detection of infectious agents now permits countermeasures to avoid potential outbreaks and epidemics. But, despite considerable progress, infectious diseases remain a strong challenge to human survival.
C1 [Franca, R. F. O.] Univ Sao Paulo, Dept Pharmacol, Sch Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
   [da Silva, C. C.; De Paula, S. O.] Univ Fed Vicosa, Dept Gen Biol, BR-36570000 Vicosa, MG, Brazil.
   [De Paula, S. O.] Univ Fed Vicosa, Lab Mol Immunovirol, BR-36571000 Vicosa, MG, Brazil.
RP De Paula, SO (corresponding author), Univ Fed Vicosa, Lab Mol Immunovirol, Av PH Rolfs S-N, BR-36571000 Vicosa, MG, Brazil.
EM depaula@ufv.br
RI De Paula, Sergio/N-2609-2018
OI De Paula, Sergio/0000-0002-2275-5768; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPEMIG, BrazilMinas Gerais State Research Foundation (FAPEMIG);
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX This work was supported by CNPq and FAPEMIG, Brazil. RFOF was supported
   by a scholarship from the FAPESP and SOP was supported by a scholarship
   from the CNPq.
CR Aggleton P, 2012, AIDS, V26, P1215, DOI 10.1097/QAD.0b013e3283536bc5
   Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287
   Alexander J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031177
   Bartlett John M S, 2003, Methods Mol Biol, V226, P3
   Bartolini B, 2011, NEW MICROBIOL, V34, P391
   Bassett JD, 2011, EXPERT REV VACCINES, V10, P1307, DOI [10.1586/erv.11.88, 10.1586/ERV.11.88]
   Belshe RB, 2012, NEW ENGL J MED, V366, P34, DOI 10.1056/NEJMoa1103151
   Catanzaro AT, 2006, J INFECT DIS, V194, P1638, DOI 10.1086/509258
   Churchyard GJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021225
   Connell TG, 2011, J INFECT DIS, V204, pS1151, DOI 10.1093/infdis/jir413
   De Cock KM, 2011, EMERG INFECT DIS, V17, P1044, DOI [10.3201/eid1706.100184, 10.3201/eid/1706.100184]
   De Paula SO, 2008, ARCH VIROL, V153, P2215, DOI 10.1007/s00705-008-0250-3
   Dheda K, 2010, INFECT DIS CLIN N AM, V24, P705, DOI 10.1016/j.idc.2010.05.001
   Fauci AS, 2012, NEW ENGL J MED, V366, P454, DOI 10.1056/NEJMra1108296
   Franca RFO, 2011, AIDS RES HUM RETROV, V27, P903, DOI [10.1089/aid.2010.0266, 10.1089/AID.2010.0266]
   Garcia-Sierra N, 2011, J CLIN MICROBIOL, V49, P3683, DOI 10.1128/JCM.01239-11
   Girard MP, 2011, VACCINE, V29, P6191, DOI [10.1016/j.vaccine.2011.06.085, 10.1016/j.vaccine.2011.08.031]
   Gueudin M, 2012, J CLIN MICROBIOL, V50, P831, DOI 10.1128/JCM.05669-11
   Guy B, 2011, VACCINE, V29, P7229, DOI 10.1016/j.vaccine.2011.06.094
   Henn MR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002529
   Hoffmann AA, 2011, NATURE, V476, P454, DOI 10.1038/nature10356
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Kien DTH, 2011, J VIROL METHODS, V177, P168, DOI 10.1016/j.jviromet.2011.08.002
   KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180
   Kottaridi C, 2012, J VIROL METHODS, V180, P49, DOI 10.1016/j.jviromet.2011.12.009
   Kyle JL, 2008, ANNU REV MICROBIOL, V62, P71, DOI 10.1146/annurev.micro.62.081307.163005
   Lauck M, 2012, J VIROL, V86, P3952, DOI 10.1128/JVI.06627-11
   Li SW, 2005, VACCINE, V23, P2893, DOI 10.1016/j.vaccine.2004.11.064
   Lima DM, 2011, VACCINE, V29, P831, DOI 10.1016/j.vaccine.2010.10.078
   Lumsden JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020775
   Mach KE, 2009, J UROLOGY, V182, P2735, DOI 10.1016/j.juro.2009.08.028
   Martina BEE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018995
   McCormack S, 2010, LANCET, V376, P1329, DOI 10.1016/S0140-6736(10)61086-0
   McGowan I, 2011, AIDS, V25, P1057, DOI 10.1097/QAD.0b013e328346bd3e
   McMeniman CJ, 2009, SCIENCE, V323, P141, DOI 10.1126/science.1165326
   Moorthy VS, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-312
   Morens DM, 2008, LANCET INFECT DIS, V8, P710, DOI 10.1016/S1473-3099(08)70256-1
   Morens DM, 2009, NEW ENGL J MED, V361, P225, DOI 10.1056/NEJMp0904819
   Mujika M, 2009, BIOSENS BIOELECTRON, V24, P1253, DOI 10.1016/j.bios.2008.07.024
   Muldrew KL, 2009, CURR OPIN PEDIATR, V21, P102, DOI 10.1097/MOP.0b013e328320d87e
   Murphy SC, 2012, AM J TROP MED HYG, V86, P383, DOI 10.4269/ajtmh.2012.10-0658
   O'Hara GA, 2012, J INFECT DIS, V205, P772, DOI 10.1093/infdis/jir850
   Paris R, 2012, VACCINE, V30, P832, DOI 10.1016/j.vaccine.2011.11.002
   Plotkin SA, 2009, CLIN VACCINE IMMUNOL, V16, P1709, DOI 10.1128/CVI.00290-09
   Reyes-Sandoval A, 2012, MOL THER, V20, P1633, DOI 10.1038/mt.2012.25
   Roedig JV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027989
   Saxena P, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-20
   Schell JB, 2011, J VIROL, V85, P5764, DOI 10.1128/JVI.00342-11
   Townsend MB, 2006, J CLIN MICROBIOL, V44, P2863, DOI 10.1128/JCM.00134-06
   Wu WJ, 2009, CLIN LAB MED, V29, P673, DOI 10.1016/j.cll.2009.07.005
   Zhu FC, 2010, LANCET, V376, P895, DOI 10.1016/S0140-6736(10)61030-6
   Zou SM, 2007, J CLIN MICROBIOL, V45, P1889, DOI 10.1128/JCM.02392-06
NR 52
TC 11
Z9 11
U1 2
U2 64
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0934-9723
EI 1435-4373
J9 EUR J CLIN MICROBIOL
JI Eur. J. Clin. Microbiol. Infect. Dis.
PD JUN
PY 2013
VL 32
IS 6
BP 723
EP 728
DI 10.1007/s10096-013-1813-0
PG 6
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 149DO
UT WOS:000319298400002
PM 23339016
OA Green Published
DA 2020-11-11
ER

PT J
AU Peres, RS
   Talbot, J
   Carregaro, V
   Oliveira, RDR
   Almeida, SL
   Pinto, LG
   Franca, RFO
   Alves, JC
   Cunha, TM
   Liew, FY
   Cunha, FQ
AF Sanches Peres, R.
   Talbot, J.
   Carregaro, V.
   Oliveira, R. D. R.
   Almeida, S. L.
   Pinto, L. G.
   Franca, R. F. O.
   Alves-Filho, J. C.
   Cunha, T. M.
   Liew, F. Y.
   Cunha, F. Q.
TI Effect of Methotrexate in antigen-induced arthritis depends on
   regulatory T cells expression
SO IMMUNOLOGY
LA English
DT Meeting Abstract
CT European Congress of Immunology
CY SEP 05-08, 2012
CL Glasgow, SCOTLAND
C1 [Sanches Peres, R.; Talbot, J.; Carregaro, V.; Oliveira, R. D. R.; Almeida, S. L.; Pinto, L. G.; Franca, R. F. O.; Alves-Filho, J. C.; Cunha, T. M.; Cunha, F. Q.] Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, Brazil.
   [Liew, F. Y.] Univ Glasgow, Glasgow, Lanark, Scotland.
RI Cunha, Fernando Q/M-3090-2014; Cunha, Thiago M/B-7729-2012; Pinto,
   Larissa G/J-5697-2015; Oliveira, Rene/C-4467-2012
OI Cunha, Thiago M/0000-0003-1084-0065; Oliveira, Rene/0000-0003-0229-6864;
   Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD SEP
PY 2012
VL 137
SU 1
SI SI
BP 576
EP 576
PG 1
WC Immunology
SC Immunology
GA 011TW
UT WOS:000309189105034
DA 2020-11-11
ER

PT J
AU Saraiva, AL
   Talbot, J
   Franca, RF
   Peres, RS
   Veras, FP
   Raymond, J
   Cunha, TM
   Cunha, FQ
   Alves, JC
AF Saraiva, A. L.
   Talbot, J.
   Franca, R. F.
   Peres, R. S.
   Veras, F. P.
   Raymond, J.
   Cunha, T. M.
   Cunha, F. Q.
   Alves-Filho, J. C.
TI Succinate enhances experimental arthritis
SO IMMUNOLOGY
LA English
DT Meeting Abstract
CT European Congress of Immunology
CY SEP 05-08, 2012
CL Glasgow, SCOTLAND
C1 [Saraiva, A. L.; Talbot, J.; Franca, R. F.; Peres, R. S.; Veras, F. P.; Raymond, J.; Cunha, T. M.; Cunha, F. Q.; Alves-Filho, J. C.] Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, Brazil.
RI Cunha, Fernando Q/M-3090-2014; Cunha, Thiago M/B-7729-2012
OI Cunha, Thiago M/0000-0003-1084-0065; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD SEP
PY 2012
VL 137
SU 1
SI SI
BP 588
EP 588
PG 1
WC Immunology
SC Immunology
GA 011TW
UT WOS:000309189105067
DA 2020-11-11
ER

PT J
AU Vieira, SM
   Cunha, TM
   Franca, RFO
   Pinto, LG
   Talbot, J
   Turato, WM
   Lemos, HP
   Lima, JB
   Verri, WA
   Almeida, SCL
   Ferreira, SH
   Louzada, P
   Zamboni, DS
   Cunha, FQ
AF Vieira, Silvio M.
   Cunha, Thiago M.
   Franca, Rafael F. O.
   Pinto, Larissa G.
   Talbot, Jhimmy
   Turato, Walter M.
   Lemos, Henrique P.
   Lima, Jonilson B.
   Verri, Waldiceu A., Jr.
   Almeida, Sergio C. L.
   Ferreira, Sergio H.
   Louzada-Junior, Paulo
   Zamboni, Dario S.
   Cunha, Fernando Q.
TI Joint NOD2/RIPK2 Signaling Regulates IL-17 Axis and Contributes to the
   Development of Experimental Arthritis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ANTIGEN-INDUCED ARTHRITIS; OLIGOMERIZATION DOMAIN 2; CASPASE RECRUITMENT
   DOMAIN; INNATE IMMUNE-RESPONSES; MICE DEFICIENT; MURINE MODEL; NOD2;
   INTERLEUKIN-17; PROTEIN; SUSCEPTIBILITY
AB Intracellular pattern recognition receptors such as the nucleotide-binding oligomerization domain (NOD)-like receptors family members are key for innate immune recognition of microbial infection and may play important roles in the development of inflammatory diseases, including rheumatic diseases. In this study, we evaluated the role of NOD1 and NOD2 on development of experimental arthritis. Ag-induced arthritis was generated in wild-type, NOD1(-/-)!, NOD2(-/-), or receptor-interacting serine-threonine kinase 2(-/-) (RIPK2(-/-)) immunized mice challenged intra-articularly with methylated BSA. Nociception was determined by electronic Von Frey test. Neutrophil recruitment and histopathological analysis of proteoglycan lost was evaluated in inflamed joints. Joint levels of inflammatory cytokine/chemokine were measured by ELISA. Cytokine (IL-6 and IL-23) and NOD2 expressions were determined in mice synovial tissue by RT-PCR. The NOD2(-/-) and RIPK2(-/-), but not NOD1(-/-), mice are protected from Ag-induced arthritis, which was characterized by a reduction in neutrophil recruitment, nociception, and cartilage degradation. NOD2/RIPK2 signaling impairment was associated with a reduction in proinflammatory cytokines and chemokines (TNF, IL-1 beta, and CXCL1/KC). IL-17 and IL-17 triggering cytokines (IL-6 and IL-23) were also reduced in the joint, but there is no difference in the percentage of CD4(+) IL-17(+) cells in the lymph node between arthritic wild-type and NOD2(-/-) mice. Altogether, these findings point to a pivotal role of the NOD2/RIPK2 signaling in the onset of experimental arthritis by triggering an IL-17-dependent joint immune response. Therefore, we could propose that NOD2 signaling is a target for the development of new therapies for the control of rheumatoid arthritis. The Journal of Immunology, 2012, 188: 5116-5122.
C1 [Vieira, Silvio M.; Cunha, Thiago M.; Franca, Rafael F. O.; Pinto, Larissa G.; Talbot, Jhimmy; Turato, Walter M.; Lemos, Henrique P.; Verri, Waldiceu A., Jr.; Ferreira, Sergio H.; Cunha, Fernando Q.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pharmacol, BR-14049900 Sao Paulo, Brazil.
   [Vieira, Silvio M.] Natl Inst Res Amazon, Pharmacol Lab, BR-69077000 Manaus, Amazonas, Brazil.
   [Lima, Jonilson B.; Zamboni, Dario S.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Cell Biol, BR-14049900 Sao Paulo, Brazil.
   [Almeida, Sergio C. L.; Louzada-Junior, Paulo] Univ Sao Paulo, Sch Med Ribeirao Preto, Div Clin Immunol, BR-14049900 Sao Paulo, Brazil.
RP Cunha, FQ (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pharmacol, Ave Bandeirantes 3900, BR-14049900 Sao Paulo, Brazil.
EM thicunha@fmrp.usp.br; dszamboni@fmrp.usp.br; fdqcunha@fmrp.usp.br
RI WA, Verri/I-1330-2013; Cunha, Fernando Q/M-3090-2014; Vieira, Silvio
   Manfredo/T-8283-2019; Louzada-Junior, Paulo/E-4132-2012; Cunha, Thiago
   M/B-7729-2012; Pinto, Larissa G/J-5697-2015; Zamboni, Dario
   S/D-3024-2012; Lima, Jonilson Berlink/E-1531-2015; de Paula Lemos,
   Henrique/AAI-2698-2020
OI WA, Verri/0000-0003-2756-9283; Vieira, Silvio
   Manfredo/0000-0001-8036-4223; Louzada-Junior, Paulo/0000-0003-2585-3870;
   Cunha, Thiago M/0000-0003-1084-0065; Zamboni, Dario
   S/0000-0002-7856-7512; Lima, Jonilson Berlink/0000-0002-1403-4768; de
   Paula Lemos, Henrique/0000-0002-0539-3283; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007; Cunha, Fernando Queiroz/0000-0003-4755-1670;
   Pinto, Larissa G/0000-0002-3619-907X
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Brazil)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Fundacao de Amparo a
   Pesquisa do Estado do Amazonas (Brazil); Conselho Nacional de Pesquisa
   (Brazil)National Council for Scientific and Technological Development
   (CNPq); Coordenadoria de Aperfeicoamento de Pessoal de Nivel Superior
   (Brazil); Fundacao de Amparo a Pesquisa do Estado do Amazonas
FX This work was supported by grants front Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (Brazil), Fundacao de Amparo a Pesquisa do Estado do
   Amazonas (Brazil), Conselho Nacional de Pesquisa (Brazil), and
   Coordenadoria de Aperfeicoamento de Pessoal de Nivel Superior (Brazil).
   S.M.V. was a recipient of a fellowship from Fundacao de Amparo a
   Pesquisa do Estado do Amazonas.
CR BRACKERTZ D, 1977, J IMMUNOL, V118, P1639
   Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457
   Burkhardt D, 2001, OSTEOARTHR CARTILAGE, V9, P238, DOI 10.1053/joca.2000.0381
   Chabaud M, 1999, ARTHRITIS RHEUM-US, V42, P963, DOI 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E
   Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a
   Egan PJ, 2008, ARTHRITIS RHEUM-US, V58, P3720, DOI 10.1002/art.24075
   Ekman AK, 2010, IMMUNOLOGY, V130, P55, DOI 10.1111/j.1365-2567.2009.03212.x
   Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200
   Heinhuis B, 2010, ANN RHEUM DIS, V69, P1866, DOI 10.1136/ard.2009.127399
   Hruz P, 2008, CURR OPIN GASTROEN, V24, P108, DOI 10.1097/MOG.0b013e3282f50fdf
   Hsu LC, 2008, P NATL ACAD SCI USA, V105, P7803, DOI 10.1073/pnas.0802726105
   Hsu YMS, 2007, NAT IMMUNOL, V8, P198, DOI 10.1038/ni1426
   Huber LC, 2006, RHEUMATOLOGY, V45, P669, DOI 10.1093/rheumatology/kel065
   Hueber AJ, 2010, J IMMUNOL, V184, P3336, DOI 10.4049/jimmunol.0903566
   Inohara N, 2000, J BIOL CHEM, V275, P27823
   Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347
   Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296
   Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200
   Joosten LAB, 2008, P NATL ACAD SCI USA, V105, P9017, DOI 10.1073/pnas.0710445105
   Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a
   Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911
   KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475
   Lemos HP, 2009, P NATL ACAD SCI USA, V106, P5954, DOI 10.1073/pnas.0812782106
   LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5
   Lubberts E, 2004, ARTHRITIS RHEUM-US, V50, P650, DOI 10.1002/art.20001
   McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968
   Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200
   Ospelt C, 2009, ARTHRITIS RHEUM, V60, P355, DOI 10.1002/art.24226
   Park JH, 2007, J IMMUNOL, V178, P2380, DOI 10.4049/jimmunol.178.4.2380
   Petrow PK, 1996, IMMUNOL INVEST, V25, P341, DOI 10.3109/08820139609059316
   Pinto LG, 2010, PAIN, V148, P247, DOI 10.1016/j.pain.2009.11.006
   Pohlers D, 2004, CLIN EXP IMMUNOL, V135, P409, DOI 10.1111/j.1365-2249.2003.02381.x
   Rosenzweig HL, 2009, J LEUKOCYTE BIOL, V85, P711, DOI 10.1189/jlb.0808478
   Rosenzweig HL, 2010, ARTHRITIS RHEUM-US, V62, P1051, DOI 10.1002/art.27335
   Sidiropoulos PI, 2008, ANN RHEUM DIS, V67, P1382, DOI 10.1136/ard.2007.078014
   Smolen JS, 2007, LANCET, V370, P1861, DOI 10.1016/S0140-6736(07)60784-3
   TAKTAK YS, 1991, J IMMUNOL METHODS, V136, P11, DOI 10.1016/0022-1759(91)90243-9
   van Beelen AJ, 2007, IMMUNITY, V27, P660, DOI 10.1016/j.immuni.2007.08.013
   Vieira SM, 2009, BRIT J PHARMACOL, V158, P779, DOI 10.1111/j.1476-5381.2009.00367.x
NR 39
TC 31
Z9 31
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 15
PY 2012
VL 188
IS 10
BP 5116
EP 5122
DI 10.4049/jimmunol.1004190
PG 7
WC Immunology
SC Immunology
GA 937BP
UT WOS:000303634300044
PM 22491249
OA Bronze
DA 2020-11-11
ER

PT J
AU Franca, R
   Peres, R
   Talbot, J
   Cunha, T
   Cunha, F
AF Franca, Rafael
   Peres, Raphael
   Talbot, Jhimmy
   Cunha, Thiago
   Cunha, Fernando
TI The role of nucleotide-binding oligomerization domain 2 (Nod2) in
   initiation of rheumatoid arthritis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Franca, Rafael; Talbot, Jhimmy; Cunha, Thiago; Cunha, Fernando] Univ Sao Paulo, Dept Pharmacol, BR-14049 Ribeirao Preto, Brazil.
RI Cunha, Fernando Q/M-3090-2014; Cunha, Thiago M/B-7729-2012
OI Cunha, Thiago M/0000-0003-1084-0065
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700513
DA 2020-11-11
ER

PT J
AU Silva, J
   Talbot, J
   Lopes, A
   Franca, R
   Fonseca, B
   Cunha, T
   Cunha, F
AF Silva, Jaqueline
   Talbot, Jhimmy
   Lopes, Alexandre
   Franca, Rafael
   Fonseca, Benedito
   Cunha, Thiago
   Cunha, Fernando
TI Evaluation of immune response in dorsal root ganglion of mice infected
   with Herpes Simplex Virus type 1 (HSV-1)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Silva, Jaqueline; Fonseca, Benedito; Cunha, Thiago; Cunha, Fernando] Univ Sao Paulo, Dept Biochem & Immunol, Ribeirao Preto Sch Med, BR-14049 Ribeirao Preto, Brazil.
   [Talbot, Jhimmy; Lopes, Alexandre; Franca, Rafael] Univ Sao Paulo, Dept Pharmacol, Ribeirao Preto Sch Med, BR-14049 Ribeirao Preto, Brazil.
RI Cunha, Thiago M/B-7729-2012; Cunha, Fernando Q/M-3090-2014
OI Cunha, Thiago M/0000-0003-1084-0065; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700593
DA 2020-11-11
ER

PT J
AU de Barros, VED
   Saggioro, FP
   Neder, L
   Franca, RFD
   Mariguela, V
   Chavez, JH
   Penharvel, S
   Forjaz, J
   da Fonseca, BAL
   Figueiredo, LTM
AF Dias de Barros, Veridiana Ester
   Saggioro, Fabiano P.
   Neder, Luciano
   de Oliveira Franca, Rafael Freitas
   Mariguela, Viviane
   Chavez, Juliana Helena
   Penharvel, Sandra
   Forjaz, Jorge
   Lopes da Fonseca, Benedito Antonio
   Moraes Figueiredo, Luiz Tadeu
TI An Experimental Model of Meningoencephalomyelitis by Rocio Flavivirus in
   Balb/C Mice: Inflammatory Response, Cytokine Production, and
   Histopathology
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID YELLOW-FEVER VIRUS; ARBOVIRUS DISEASE; ENCEPHALITIS; INFECTION; CELLS;
   IDENTIFICATION; ASTROCYTES; EMERGENCE; BRAZIL
AB Rocio virus (ROCV) is a flavivirus, probably transmitted by Culex mosquitoes and maintained in nature as a zoonosis of wild birds. Rocio virus caused a human epidemic of severe encephalitis that lasted from 1973 to 1980 in the Ribeira valley, in the southeastern coast of Brazil. After this outbreak, serologic evidence of ROCV circulation has been reported and public health authorities are concerned about a return of ROCV outbreaks in Brazil. We show here a study on the pathogenesis and the physiopathology of ROCV disease in the central nervous system of a Balb/C young adult mice experimental model. The animals were intraperitoneally infected by ROCV and followed from 0 to 9 days after infection, when all of them died. Nervous tissue samples were collected from infected animals for immunohistochemistry and molecular biology analysis. We observed the virus in the central nervous system, the inflammatory changes induced by Th1 and Th2 cytokines, and the final irreversible damage of nervous tissues by neuronal degeneration and apoptosis. These findings can help to better understand the pathogenesis and physiopathology of the human meningoencephalomyelitis by ROCV and other flaviviruses.
C1 [Moraes Figueiredo, Luiz Tadeu] Univ Sao Paulo, Sch Med Ribeirao Preto, Virol Res Ctr, Dept Pathol,Dept Surg & Anat, BR-14049900 Ribeirao Preto, Brazil.
RP Figueiredo, LTM (corresponding author), Univ Sao Paulo, Sch Med Ribeirao Preto, Virol Res Ctr, Dept Pathol,Dept Surg & Anat, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, Brazil.
EM veridias@yahoo.com.br; ltmfigue@fmrp.usp.br
RI Mariguela, Viviane/F-6083-2013; Figueiredo, Luiz T/E-3702-2012; Fonseca,
   Benedito/F-3252-2012
OI Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007; Fonseca,
   Benedito/0000-0003-3159-5687
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPQ)National Council for
   Scientific and Technological Development (CNPq) [141893/2005-2]
FX We are grateful to Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) and Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPQ) (141893/2005-2) for supporting this study.
CR ABBAS AK, 2005, IMMUNOLOGIA CELULAR, P268
   Barca O, 2003, J NEUROIMMUNOL, V139, P155, DOI 10.1016/S0165-5728(03)00160-7
   Beasley DWC, 2002, VIROLOGY, V296, P17, DOI 10.1006/viro.2002.1372
   Bronzoni RVD, 2005, J CLIN MICROBIOL, V43, P696, DOI 10.1128/JCM.43.2.696-702.2005
   CHAMBERS TJ, 1990, VIROLOGY, V177, P159, DOI 10.1016/0042-6822(90)90470-C
   Chavez JH, 2006, VIRUS REV RES, V11, P28
   DAROSA JFS, 1998, OVERVIEW ARBOVIROLOG, P19
   Diniz JAP, 2006, AM J TROP MED HYG, V75, P691, DOI 10.4269/ajtmh.2006.75.691
   Figueiredo LTM, 2000, MICROBES INFECT, V2, P1643, DOI 10.1016/S1286-4579(00)01320-4
   Fujii Y, 2008, JPN J INFECT DIS, V61, P40
   Garlet GP, 2007, CLIN EXP IMMUNOL, V147, P128, DOI 10.1111/j.1365-2249.2006.03260.x
   Ghoshal A, 2007, GLIA, V55, P483, DOI 10.1002/glia.20474
   Gould EA, 2003, ADV VIRUS RES, V59, P277, DOI 10.1016/S0065-3527(03)59008-X
   Haseloff RF, 2005, CELL MOL NEUROBIOL, V25, P25, DOI 10.1007/s10571-004-1375-x
   IVERSSON LB, 1997, TRATADO INFEECT, P233
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   Liu T, 2001, J VIROL, V75, P2107, DOI 10.1128/JVI.75.5.2107-2118.2001
   LOPES OD, 1981, AM J EPIDEMIOL, V113, P122
   LOPES ODS, 1978, AM J EPIDEMIOL, V107, P444
   LOPES OS, 1978, AM J TROP MED HYG, V27, P418
   Matthews V, 2000, INT J EXP PATHOL, V81, P31, DOI 10.1046/j.1365-2613.2000.00135.x
   Medeiros DBA, 2007, J GEN VIROL, V88, P2237, DOI 10.1099/vir.0.82883-0
   MITCHELL CJ, 1981, AM J TROP MED HYG, V30, P465, DOI 10.4269/ajtmh.1981.30.465
   RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707
   Samuel MA, 2007, P NATL ACAD SCI USA, V104, P17140, DOI 10.1073/pnas.0705837104
   Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0
   Shrestha B, 2006, J VIROL, V80, P5338, DOI 10.1128/JVI.00274-06
   Swarup V, 2007, NEUROSCI LETT, V420, P144, DOI 10.1016/j.neulet.2007.04.071
   Tiriba AC, 1975, THESIS ESCOLA PAULIS
   Vasconcelos P., 1998, OVERVIEW ARBOVIROLOG, P72
   Vasconcelos PFC, 1992, CIENC CULT-SAO PAULO, V43, P117
   Xiao SY, 2001, EMERG INFECT DIS, V7, P714
   2003, NAT REV IMMUNOL, V3, P493
NR 33
TC 6
Z9 6
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD AUG
PY 2011
VL 85
IS 2
BP 363
EP 373
DI 10.4269/ajtmh.2011.10-0246
PG 11
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 803WN
UT WOS:000293613000029
PM 21813860
OA Green Published, Bronze
DA 2020-11-11
ER

PT J
AU Franca, RFO
   Castro-Jorge, LA
   Neto, RJP
   Jorge, DMM
   Lima, DM
   Colares, JKB
   Paula, SO
   da Fonseca, BAL
AF Franca, Rafael F. O.
   Castro-Jorge, Luiza A.
   Neto, Roberto J. P.
   Jorge, Daniel M. M.
   Lima, Danielle M.
   Colares, Jeova K. B.
   Paula, Sergio O.
   Lopes da Fonseca, Benedito A.
TI Genotypic Characteristics of HIV Type 1 Based on gp120 Hypervariable
   Region 3 of Isolates from Southern Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PHENOTYPE; SEQUENCE; STRAINS; USAGE
AB The aim of this study was to investigate HIV-1 molecular diversity and the epidemiological profile of HIV-1-infected patients from Ribeirao Preto, Brazil. A nested PCR followed by sequencing of a 302-base pair fragment of the env gene (C2-V3 region) was performed in samples from HIV-1-positive patients. A total of 45 sequences were aligned with final manual adjustments. The phylogenetic analyses showed a higher prevalence of HIV-1 subtype B in the studied population (97.8%) with only one sample yielding an F1 subtype. The viral genotyping prediction showed that CCR5 tropism was the most prevalent in the studied cohort. Geno2pheno analysis showed that R5 and CXCR4 prediction were 69% and 31%, respectively. There was no statistical significance, either in viral load or in CD4(+) T cell count when R5 and X4 prediction groups were compared. Moreover, the GPGR tetramer was the most common V3 loop core motif identified in the HIV-1 strains studied (34.1%) followed by GWGR, identified in 18.1% of the samples. The high level of B subtype in this Brazilian population reinforces the nature of the HIV epidemic in Brazil, and corroborates previous data obtained in the Brazilian HIV-infected population.
C1 [Lopes da Fonseca, Benedito A.] Univ Sao Paulo, Mol Virol Lab, Dept Clin Med, Fac Med Ribeirao Preto, BR-14049900 Sao Paulo, Brazil.
   [Franca, Rafael F. O.; Castro-Jorge, Luiza A.; Lopes da Fonseca, Benedito A.] Univ Sao Paulo, Program Grad Studies Appl & Basic Immunol, Sch Med Ribeirao Preto, BR-14049900 Sao Paulo, Brazil.
   [Neto, Roberto J. P.] Univ Fed Ceara, Sch Med, Fortaleza, Ceara, Brazil.
   [Jorge, Daniel M. M.] Univ Sao Paulo, Dept Genet, Sch Med Ribeirao Preto, BR-14049900 Sao Paulo, Brazil.
   [Paula, Sergio O.] Univ Fed Vicosa, Dept Biol, Vicosa, MG, Brazil.
RP da Fonseca, BAL (corresponding author), Univ Sao Paulo, Mol Virol Lab, Dept Clin Med, Fac Med Ribeirao Preto, Ave Bandeirantes 3900, BR-14049900 Sao Paulo, Brazil.
EM baldfons@fmrp.usp.br
RI Colares, Jeova Keny Baima/C-5257-2014; Jorge, Daniel M/B-4533-2010; De
   Paula, Sergio/N-2609-2018; de Castro Jorge, Luiza Antunes/D-3773-2009;
   da Justa Pires Neto, Roberto/AAB-3425-2020; Lima, Danielle/A-6108-2013;
   Fonseca, Benedito/F-3252-2012
OI Colares, Jeova Keny Baima/0000-0003-1367-6272; Jorge, Daniel
   M/0000-0002-8387-3215; De Paula, Sergio/0000-0002-2275-5768; da Justa
   Pires Neto, Roberto/0000-0003-0291-9523; Lima,
   Danielle/0000-0003-2734-6768; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007; Fonseca, Benedito/0000-0003-3159-5687
CR Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   Diaz RS, 2008, VIROLOGY, V381, P184, DOI 10.1016/j.virol.2008.08.014
   Essex M, 1999, ADV VIRUS RES, V53, P71, DOI 10.1016/S0065-3527(08)60343-7
   FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992
   Kuiken C, 2000, AM J EPIDEMIOL, V152, P814, DOI 10.1093/aje/152.9.814
   Leal E, 2008, VIROLOGY, V381, P222, DOI 10.1016/j.virol.2008.08.029
   Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012
   Mefford ME, 2008, AIDS RES HUM RETROV, V24, P1215, DOI 10.1089/aid.2008.0009
   MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569
   Santoro-Lopes G, 2000, AIDS RES HUM RETROV, V16, P953, DOI 10.1089/08892220050058362
   Saracino A, 2007, VIRUS RES, V130, P34, DOI 10.1016/j.virusres.2007.05.011
   Thomson MM, 2002, LANCET INFECT DIS, V2, P461, DOI 10.1016/S1473-3099(02)00343-2
   Veras NMC, 2007, AIDS RES HUM RETROV, V23, P1481, DOI 10.1089/aid.2007.0145
   WOLFS TFW, 1990, P NATL ACAD SCI USA, V87, P9938, DOI 10.1073/pnas.87.24.9938
NR 15
TC 6
Z9 6
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD AUG
PY 2011
VL 27
IS 8
BP 903
EP 909
DI 10.1089/aid.2010.0266
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 803IV
UT WOS:000293575900011
PM 21087177
DA 2020-11-11
ER

PT J
AU Bonfa, A
   Saito, RSN
   Franca, RFO
   Fonseca, BAL
   Petri, DFS
AF Bonfa, Alfredo
   Saito, Rafael S. N.
   Franca, Rafael F. O.
   Fonseca, Benedito A. L.
   Petri, Denise F. S.
TI Poly(ethylene glycol) decorated poly(methylmethacrylate) nanoparticles
   for protein adsorption
SO MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Poly(ethylene)glycol; Nanoparticles; BSA; Concanavalin A; Dengue virus;
   Adsorption
ID CONCANAVALIN-A; THIN-FILMS; ALBUMIN; BINDING; PARTICLES; BEHAVIOR; PH
AB Poly(ethylene glycol) decorated poly( methyl methacrylate) particles were synthesized by means of emulsion polymerization using poly(ethylene glycol) sorbitan monolaurate (Tween-20) as surfactant. PMMA/PEG particles presented mean diameter (195 +/- 15) nm, indicating narrow size distribution. The adsorption behavior of bovine serum albumin (BSA) and concanavalin A (ConA) onto PMMA/PEG particles was investigated by means of spectrophotometry. Adsorption isotherms obtained for BSA onto PMMA/PEG particles fitted well sigmoidal function, which is typical for multilayer adsorption. Con A adsorbed irreversibly onto PMMA/PEG particles. The efficiency of ConA covered particles to induce dengue virus quick agglutination was evaluated. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Bonfa, Alfredo; Saito, Rafael S. N.; Petri, Denise F. S.] Univ Sao Paulo, Inst Quim, BR-05513970 Sao Paulo, Brazil.
   [Franca, Rafael F. O.] Univ Sao Paulo, Fac Med Ribeirao Preto, Programa Pos Grad Imunol Basica & Aplicada, Ribeirao Preto, Brazil.
   [Fonseca, Benedito A. L.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Ribeirao Preto, Brazil.
RP Petri, DFS (corresponding author), Univ Sao Paulo, Inst Quim, POB 26077, BR-05513970 Sao Paulo, Brazil.
EM dfsp@iq.usp.br
RI PETRI, DENISE/H-5004-2012; Petri, Denise/L-5084-2019; Fonseca,
   Benedito/F-3252-2012
OI PETRI, DENISE/0000-0003-4814-8357; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007; Fonseca, Benedito/0000-0003-3159-5687
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)
FX Authors gratefully acknowledge CNPq and FAPESP for financial support.
CR Adamson A. W., 1997, PHYS CHEM SURFACES
   Almeida AT, 2002, LANGMUIR, V18, P6914, DOI 10.1021/la0202982
   Amim J, 2009, MAT SCI ENG C-BIO S, V29, P420, DOI 10.1016/j.msec.2008.08.018
   Bock G., 2006, NEW TREATMENT STRATE
   BREWER CF, 1983, BIOCHEMISTRY-US, V22, P3691, DOI 10.1021/bi00284a024
   CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153
   Castro LBR, 2006, LANGMUIR, V22, P3757, DOI 10.1021/la053080z
   Castro LBR, 2005, J NANOSCI NANOTECHNO, V5, P2063, DOI 10.1166/jnn.2005.501
   Castro LBR, 2004, IND ENG CHEM RES, V43, P7774, DOI 10.1021/ie0495271
   Chern CS, 1999, COLLOID POLYM SCI, V277, P528, DOI 10.1007/s003960050420
   de Moura MR, 2009, MAT SCI ENG C-MATER, V29, P2319, DOI 10.1016/j.msec.2009.05.022
   DOSERPO APV, 1991, J BIOM MAT RES, V46, P376
   Francis GL, 2010, CYTOTECHNOLOGY, V62, P1, DOI 10.1007/s10616-010-9263-3
   Fuller EL, 2007, MICROPOR MESOPOR MAT, V98, P102, DOI 10.1016/j.micromeso.2006.08.019
   Giacomelli CE, 2001, J COLLOID INTERF SCI, V233, P234, DOI 10.1006/jcis.2000.7219
   Gilbert R. G., 1995, EMULSION POLYM MECH
   Goubko CA, 2009, MAT SCI ENG C-MATER, V29, P1855, DOI 10.1016/j.msec.2009.02.016
   Jelinek R, 2004, CHEM REV, V104, P5987, DOI 10.1021/cr0300284
   Jo TA, 2009, MAT SCI ENG C-BIO S, V29, P631, DOI 10.1016/j.msec.2008.10.035
   Kim HR, 2007, ELECTROPHORESIS, V28, P2252, DOI 10.1002/elps.200600694
   LOVGREN U, 1995, J CHROMATOGR B, V672, P33, DOI 10.1016/0378-4347(95)00198-R
   Malmsten M, 1998, J COLLOID INTERF SCI, V202, P507, DOI 10.1006/jcis.1998.5513
   Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/NMAT2442, 10.1038/nmat2442]
   Pancera SM, 2006, J PHYS CHEM B, V110, P2674, DOI 10.1021/jp0532364
   Pancera SM, 2002, LANGMUIR, V18, P3517, DOI 10.1021/la0110693
   PAULA SOD, 2002, T R SOC TROP MED HYG, V96, P266
   Pereira EMA, 2008, COLLOID SURFACE B, V66, P45, DOI 10.1016/j.colsurfb.2008.05.013
   Pereira EMA, 2010, ACS APPL MATER INTER, V2, P2602, DOI 10.1021/am100442f
   Peters T. J., 1996, ALL ALBUMIN
   Serefoglou E, 2007, BIOMACROMOLECULES, V8, P1195, DOI 10.1021/bm061094t
   Sierakowski MR, 2002, CARBOHYD POLYM, V49, P167, DOI 10.1016/S0144-8617(01)00321-6
   Tada D, 2007, MAT SCI ENG C-BIO S, V27, P870, DOI 10.1016/j.msec.2006.10.008
   Taylor ME, 2006, INTRO GLYCOBIOLOGY
   Tlili A, 2005, MAT SCI ENG C-BIO S, V25, P490, DOI 10.1016/j.msec.2005.02.001
   Tretiakov KV, 2009, J PHYS CHEM A, V113, P3799, DOI 10.1021/jp809447m
   VanderVegt W, 1996, COLLOID POLYM SCI, V274, P27, DOI 10.1007/BF00658906
NR 37
TC 13
Z9 13
U1 0
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928-4931
EI 1873-0191
J9 MAT SCI ENG C-MATER
JI Mater. Sci. Eng. C-Mater. Biol. Appl.
PD APR 8
PY 2011
VL 31
IS 3
BP 562
EP 566
DI 10.1016/j.msec.2010.11.020
PG 5
WC Materials Science, Biomaterials
SC Materials Science
GA 730PE
UT WOS:000288045600009
DA 2020-11-11
ER

PT J
AU Lima, DM
   de Paula, SO
   Franca, RFD
   Palma, PVB
   Morais, FR
   Gomes-Ruiz, AC
   de Aquino, MTP
   da Fonseca, BAL
AF Lima, Danielle Malta
   de Paula, Sergio Oliveira
   de Oliveira Franca, Rafael Freitas
   Palma, Patricia V. B.
   Morais, Fabiana R.
   Gomes-Ruiz, Alessandra Cristina
   Prudente de Aquino, Maria Teresa
   Lopes da Fonseca, Benedito Antonio
TI A DNA vaccine candidate encoding the structural prM/E proteins elicits a
   strong immune response and protects mice against dengue-4 virus
   infection
SO VACCINE
LA English
DT Article
DE Dengue-4; Recombinant DNA; Vaccine; Plasmid
ID DOG KIDNEY-CELLS; NEUTRALIZING ANTIBODIES; JAPANESE-ENCEPHALITIS;
   DOMAIN-III; ENVELOPE PROTEIN; IMMUNOGENICITY; FEVER; IMMUNIZATION;
   INDUCTION; SEROTYPES
AB A DNA vaccine expressing dengue-4 virus premembrane (prM) and envelope (E) genes was produced by inserting these genes into a mammalian expression plasmid (pCI).
   Following a thorough screening, including confirmation of protein expression in vitro, a recombinant clone expressing these genes was selected and used to immunize BALB/c mice. After 3 immunizations all the animals produced detectable levels of neutralizing antibodies against dengue-4 virus. The cytokines levels and T cell proliferation, detected ex vivo from the spleen of the immunized mice, showed that our construction induced substantial immune stimulation after three doses. Even though the antibody levels, induced by our DNA vaccine, were lower than those obtained in mice immunized with dengue-4 virus the levels of protection were high with this vaccine.
   This observation is further supported by the fact that 80% of the vaccine immunized group was protected against lethal challenge. In conclusion, we developed a DNA vaccine employing the genes of the prM and E proteins from dengue-4 virus that protects mice against this virus. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Lopes da Fonseca, Benedito Antonio] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Sch Med Ribeirao Preto,Lab Virol Mol, BR-14049900 Sao Paulo, Brazil.
   [de Oliveira Franca, Rafael Freitas; Prudente de Aquino, Maria Teresa] Univ Sao Paulo, Sch Med Ribeirao Preto, Program Grad Studies Appl & Basic Immunol, BR-14049900 Sao Paulo, Brazil.
   [de Paula, Sergio Oliveira] Univ Fed Vicosa, Dept Gen Biol, Vicosa, MG, Brazil.
   [Palma, Patricia V. B.; Morais, Fabiana R.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Clin Med, Lab Flow Cytometry, BR-14049900 Sao Paulo, Brazil.
RP da Fonseca, BAL (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Sch Med Ribeirao Preto,Lab Virol Mol, Ave Bandeirantes,3900 Ribeirao Preto, BR-14049900 Sao Paulo, Brazil.
EM baldfons@fmrp.usp.br
RI De Paula, Sergio/N-2609-2018; de aquino, maria teresa/C-9012-2015; Lima,
   Danielle/A-6108-2013; de Aquino, M. Teresa P./AAD-9743-2020; Fonseca,
   Benedito/F-3252-2012
OI De Paula, Sergio/0000-0002-2275-5768; Lima,
   Danielle/0000-0003-2734-6768; Fonseca, Benedito/0000-0003-3159-5687;
   Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Sao
   Paulo, BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2003/07959-0]; FAPESPFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [01/08523-5]
FX This study was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP), Sao Paulo, Brazil (Grant #2003/07959-0). Danielle
   Malta Lima was supported by a FAPESP scholarship (Grant #01/08523-5).
CR Bhamarapravati N, 2000, VACCINE, V18, P44, DOI 10.1016/S0264-410X(00)00040-2
   Blaney JE, 2006, VIRAL IMMUNOL, V19, P10, DOI 10.1089/vim.2006.19.10
   Chambers TJ, 1997, VACCINE, V15, P1494, DOI 10.1016/S0264-410X(97)00195-3
   Chattergoon MA, 1998, J IMMUNOL, V160, P5707
   De Paula SO, 2008, ARCH VIROL, V153, P2215, DOI 10.1007/s00705-008-0250-3
   Durbin AP, 2006, HUM VACCINES, V2, P255, DOI 10.4161/hv.2.6.3494
   Eckels KH, 2003, AM J TROP MED HYG, V69, P12, DOI 10.4269/ajtmh.2003.69.12
   Edelman R, 2003, AM J TROP MED HYG, V69, P48, DOI 10.4269/ajtmh.2003.69.48
   Etemad B, 2008, AM J TROP MED HYG, V79, P353, DOI 10.4269/ajtmh.2008.79.353
   FONSECA BAL, 1994, VACCINE, V12, P279, DOI 10.1016/0264-410X(94)90206-2
   GUIRAKHOO F, 1992, VIROLOGY, V191, P921, DOI 10.1016/0042-6822(92)90267-S
   Guirakhoo F, 2001, J VIROL, V75, P7290, DOI 10.1128/JVI.75.16.7290-7304.2001
   Guirakhoo F, 2006, HUM VACCINES, V2, P60, DOI 10.4161/hv.2.2.2555
   Gurunathan S, 2000, CURR OPIN IMMUNOL, V12, P442, DOI 10.1016/S0952-7915(00)00118-7
   Guy B, 2009, AM J TROP MED HYG, V80, P302, DOI 10.4269/ajtmh.2009.80.302
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   Halstead SB, 2003, AM J TROP MED HYG, V69, P5
   HEINZ FX, 1994, VIROLOGY, V198, P109, DOI 10.1006/viro.1994.1013
   Imoto J, 2007, VACCINE, V25, P1076, DOI 10.1016/j.vaccine.2006.09.059
   Innis BL, 2003, AM J TROP MED HYG, V69, P1
   Jacobs M, 2000, T ROY SOC TROP MED H, V94, P7, DOI 10.1016/S0035-9203(00)90416-4
   Jimenez RO, 2000, VACCINE, V19, P648, DOI 10.1016/S0264-410X(00)00247-4
   Khanam S, 2006, VACCINE, V24, P6513, DOI 10.1016/j.vaccine.2006.06.031
   Kitchener S, 2006, VACCINE, V24, P1238, DOI 10.1016/j.vaccine.2005.09.029
   Konishi E, 2000, VACCINE, V18, P1133, DOI 10.1016/S0264-410X(99)00376-X
   Mangada MM, 2005, J IMMUNOL, V175, P2676, DOI 10.4049/jimmunol.175.4.2676
   Mathenge EGM, 2004, J GEN VIROL, V85, P2503, DOI 10.1099/vir.0.80120-0
   Mellado-Sanchez G, 2010, ARCH VIROL, V155, P847, DOI 10.1007/s00705-010-0652-x
   Mota J, 2005, VACCINE, V23, P3469, DOI 10.1016/j.vaccine.2004.12.028
   Pang TK, 2003, CURR OPIN BIOTECH, V14, P332, DOI 10.1016/S0958-1669(03)00061-2
   Putnak Robert, 2003, Adv Virus Res, V61, P445, DOI 10.1016/S0065-3527(03)61012-2
   Raviprakash K, 2000, VACCINE, V18, P2426, DOI 10.1016/S0264-410X(99)00570-8
   Raviprakash K, 2006, VIROLOGY, V353, P166, DOI 10.1016/j.virol.2006.05.005
   Rigau-Perez JG, 1998, LANCET, V352, P971, DOI 10.1016/S0140-6736(97)12483-7
   Rothman AL, 1996, J VIROL, V70, P6540, DOI 10.1128/JVI.70.10.6540-6546.1996
   RUSSELL PK, 1967, J IMMUNOL, V99, P291
   Simmons M, 2010, VIROLOGY, V396, P280, DOI 10.1016/j.virol.2009.10.023
   Tan GK, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000672
   Tighe H, 1998, IMMUNOL TODAY, V19, P89, DOI 10.1016/S0167-5699(97)01201-2
   Tolle Michael A, 2009, Curr Probl Pediatr Adolesc Health Care, V39, P97, DOI 10.1016/j.cppeds.2009.01.001
   Wu SF, 2003, VACCINE, V21, P3919, DOI 10.1016/S0264-410X(03)00310-4
NR 41
TC 20
Z9 23
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 17
PY 2011
VL 29
IS 4
BP 831
EP 838
DI 10.1016/j.vaccine.2010.10.078
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 715AT
UT WOS:000286853500031
PM 21115054
DA 2020-11-11
ER

PT J
AU Franca, RFD
   Zucoloto, S
   da Fonseca, BAL
AF de Oliveira Franca, Rafael Freitas
   Zucoloto, Sergio
   Lopes da Fonseca, Benedito Antonio
TI A BALB/c mouse model shows that liver involvement in dengue disease is
   immune-mediated
SO EXPERIMENTAL AND MOLECULAR PATHOLOGY
LA English
DT Article
DE Liver; Inflammation; Dengue; Cytokine; Animal model
ID NECROSIS-FACTOR-ALPHA; HEMORRHAGIC-FEVER; VIRUS-INFECTION; MICE;
   IDENTIFICATION; PATHOGENESIS; ANTIBODY; SHOCK
AB In the present study, BALB/c mice were used to develop a model for the hepatic injury associated to dengue infection. Histological analysis after subcutaneous inoculation with a low viral dose of dengue-2 virus showed Kupffer cell hyperplasia and an increased inflammatory cellular infiltrate next to the bile ducts on days 5, 7 and 14 post-inoculation, mainly characterized by the presence of mononuclear cells. The liver mRNA transcription level of IL-1 beta was highest on the 5th day post-infection (p.i.) and decreased by the 21st day, TNF-alpha showed a peak of mRNA transcription after 14 days p.i. coinciding with the regression of cellular infiltrates and elevated expression of TGF-beta mRNA. Serum AST and ALT levels were slightly elevated at 7 and 14 days post-infection. Dengue-2 RNA levels were undetectable in the liver on any of the days following inoculation. Our observations suggest that, as it is true for humans, the animals undergo a transient and slight liver inflammation, probably due to local cytokine production and cellular infiltration in the liver. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Lopes da Fonseca, Benedito Antonio] Univ Sao Paulo, Mol Virol Lab, Dept Clin Med, Fac Med Ribeirao Preto,Sch Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
   [de Oliveira Franca, Rafael Freitas; Lopes da Fonseca, Benedito Antonio] Univ Sao Paulo, Program Grad Studies Appl & Basic Immunol, Sch Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Zucoloto, Sergio] Univ Sao Paulo, Dept Pathol, Sch Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil.
RP da Fonseca, BAL (corresponding author), Univ Sao Paulo, Mol Virol Lab, Dept Clin Med, Fac Med Ribeirao Preto,Sch Med Ribeirao Preto, Ave Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM baldfons@fmrp.usp.br
RI Fonseca, Benedito/F-3252-2012
OI Fonseca, Benedito/0000-0003-3159-5687; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007
CR An J, 1999, VIROLOGY, V263, P70, DOI 10.1006/viro.1999.9887
   Atrasheuskaya A, 2003, FEMS IMMUNOL MED MIC, V35, P33, DOI 10.1111/j.1574-695X.2003.tb00646.x
   Barth OM, 2006, MEM I OSWALDO CRUZ, V101, P905, DOI 10.1590/S0074-02762006000800014
   Bente Dennis A, 2006, Drug Discov Today Dis Models, V3, P97, DOI 10.1016/j.ddmod.2006.03.014
   Bethell DB, 1998, J INFECT DIS, V177, P778, DOI 10.1086/517807
   BHAMARAPRAVATI N, 1989, REV INFECT DIS, V11, pS826
   BURKE T, 1968, T ROY SOC TROP MED H, V62, P682, DOI 10.1016/0035-9203(68)90120-X
   Chakravarti A, 2006, INDIAN J MED RES, V123, P25
   Chen HC, 2004, J MED VIROL, V73, P419, DOI 10.1002/jmv.20108
   Chen HC, 2007, J VIROL, V81, P5518, DOI 10.1128/JVI.02575-06
   Couvelard A, 1999, HUM PATHOL, V30, P1106, DOI 10.1016/S0046-8177(99)90230-7
   FRESH JW, 1969, J LAB CLIN MED, V73, P451
   Green S, 1999, J MED VIROL, V59, P329, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;329::AID-JMV12&gt;3.0.CO;2-G
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   Gubler DJ, 2002, ARCH MED RES, V33, P330, DOI 10.1016/S0188-4409(02)00378-8
   HALSTEAD SB, 1989, REV INFECT DIS, V11, pS830
   Hober D, 1996, MICROBIOL IMMUNOL, V40, P569, DOI 10.1111/j.1348-0421.1996.tb01110.x
   HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324
   Houng HSH, 2001, J VIROL METHODS, V95, P19, DOI 10.1016/S0166-0934(01)00280-4
   Huang KJ, 2000, J GEN VIROL, V81, P2177, DOI 10.1099/0022-1317-81-9-2177
   Johnson AJ, 1999, J VIROL, V73, P783, DOI 10.1128/JVI.73.1.783-786.1999
   KUO CH, 1992, AM J TROP MED HYG, V47, P265, DOI 10.4269/ajtmh.1992.47.265
   Paes MV, 2005, VIROLOGY, V338, P236, DOI 10.1016/j.virol.2005.04.042
   REITMAN S, 1957, AM J CLIN PATHOL, V28, P56, DOI 10.1093/ajcp/28.1.56
   Rosen L, 1999, AM J TROP MED HYG, V61, P720, DOI 10.4269/ajtmh.1999.61.720
   ROSEN L, 1989, RES VIROLOGY, V140, P351, DOI 10.1016/S0923-2516(89)80115-3
   RUSSELL PK, 1967, J IMMUNOL, V99, P291
   Seneviratne SL, 2006, T ROY SOC TROP MED H, V100, P608, DOI 10.1016/j.trstmh.2005.10.007
   Shresta S, 2004, VIROLOGY, V319, P262, DOI 10.1016/j.virol.2003.09.048
   YADAV M, 1991, FEMS MICROBIOL IMMUN, V89, P45, DOI 10.1016/0378-1097(91)90062-F
NR 30
TC 25
Z9 27
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4800
J9 EXP MOL PATHOL
JI Exp. Mol. Pathol.
PD DEC
PY 2010
VL 89
IS 3
BP 321
EP 326
DI 10.1016/j.yexmp.2010.07.007
PG 6
WC Pathology
SC Pathology
GA 686FX
UT WOS:000284683300017
PM 20673760
DA 2020-11-11
ER

PT J
AU Pereira, EMA
   Dario, AF
   Franca, RFO
   Fonseca, BAL
   Petri, DFS
AF Pereira, Edla M. A.
   Dario, Aline F.
   Franca, Rafael F. O.
   Fonseca, Benedito A. L.
   Petri, Denise F. S.
TI Binding of Dengue Virus Partitcles and Dengue Proteins onto Solid
   Surfaces
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE lectin; dengue virus; ellipsometry; AFM; surface energy; polystyrene
ID CONCANAVALIN-A; CONFORMATIONAL-CHANGES; ENVELOPE PROTEIN; FREE-ENERGY;
   JACKFRUIT; PARTICLES; LECTIN; ADSORPTION; CARBOXYMETHYLCELLULOSE;
   IMMOBILIZATION
AB The interaction between dengue virus particles (DENV), sedimentation hemagglutinin particles (SHA), dengue virus envelope protein (Eprot), and solid surfaces was investigated by means of ellipsometry and atomic force microscopy (AFM). The surfaces chosen are bare Si/SiO2 wafers and Si/SiO2 wafers covered with concanavalin A (ConA), jacalin (Jac), polystyrene (PS), or poly(styrene sulfonate) (PSS) films. Adsorption experiments at pH 7.2 and pH 3 onto all surfaces revealed that (i) adsorption of DENV particles took place only onto ConA under pH 7.2, because of specific recognition between glycans on DENV surface and ConA binding site; (ii) DENV particles did not attach to any of the surfaces at pH 3, suggesting the presence of positive charges on DENV surface at this pH, which repel the positively charged lectin surfaces; (iii) SHA particles are positively charged at pH 7.2 and pH 3 because they adhered to negatively charged surfaces at pH 7.2 and repelled positively charged layers at pH 3; and (iv) SHA particles carry polar groups on the surface because they attached to silanol surfaces at pH 3 and avoided hydrophobic PS films at pH 3 and pH 7.2. The adsorption behavior of Eprot at pH 7.2 revealed affinity for ConA > Jac > PSS > PS approximate to bare Si/SiO2 layers. These findings indicate that selectivity of the Eprot adsorption is higher when it is part of virus structure than when it is free in solution. The correlation between surface energy values determined by means of contact angle measurements and DENV, SHA, or Eprot adsorption behavior was used to understand the intermolecular forces at the interfaces. A direct correlation was not found because the contributions from surface energy were probably surpassed by specific contributions.
C1 [Pereira, Edla M. A.; Dario, Aline F.; Petri, Denise F. S.] Univ Sao Paulo, Inst Quim, BR-05513970 Sao Paulo, Brazil.
   [Franca, Rafael F. O.] Univ Sao Paulo, Fac Med Ribeirao Preto, Programa Pos Grad Imunol Basica & Aplicada, Ribeirao Preto, Brazil.
   [Fonseca, Benedito A. L.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Ribeirao Preto, Brazil.
RP Petri, DFS (corresponding author), Univ Sao Paulo, Inst Quim, POB 26077, BR-05513970 Sao Paulo, Brazil.
EM dfsp@iq.usp.br
RI PETRI, DENISE/H-5004-2012; Fonseca, Benedito/F-3252-2012
OI PETRI, DENISE/0000-0003-4814-8357; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007; Fonseca, Benedito/0000-0003-3159-5687
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq/MCT)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX The authors acknowledge Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPq/MCT) and Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) for financial support.
CR Adamson WA, 1990, PHYS CHEM SURFACES
   AHMED H, 1989, J BIOL CHEM, V264, P9365
   Allison SL, 2001, J VIROL, V75, P4268, DOI 10.1128/JVI.75.9.4268-4275.2001
   Azzam R. M., 1987, ELLIPSOMETRY POLARIZ
   BOCK G, 2006, NOVARTIS FDN S SERIE
   BREWER CF, 1983, BIOCHEMISTRY-US, V22, P3691, DOI 10.1021/bi00284a024
   Briandet R, 2001, COLLOID SURFACE B, V21, P299, DOI 10.1016/S0927-7765(00)00213-7
   BUNNMORENO MM, 1981, J IMMUNOL, V127, P427
   Butti HJ, 1995, LANGMUIR, V11, P4735, DOI 10.1021/la00012a026
   Cacace MG, 1997, Q REV BIOPHYS, V30, P241, DOI 10.1017/S0033583597003363
   Casarano R, 2009, POLYMER, V50, P6218, DOI 10.1016/j.polymer.2009.10.048
   Castro LBR, 2006, LANGMUIR, V22, P3757, DOI 10.1021/la053080z
   Castro LBR, 2005, J NANOSCI NANOTECHNO, V5, P2063, DOI 10.1166/jnn.2005.501
   Chaudhury MK, 1996, MAT SCI ENG R, V16, P97, DOI 10.1016/0927-796X(95)00185-9
   De Paula SO, 2002, T ROY SOC TROP MED H, V96, P266, DOI 10.1016/S0035-9203(02)90094-5
   Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223
   Dobrynin AV, 2005, PROG POLYM SCI, V30, P1049, DOI 10.1016/j.progpolymsci.2005.07.006
   Efremova NV, 2000, BIOCHEMISTRY-US, V39, P3441, DOI 10.1021/bi992095r
   Fujimoto J, 2001, LANGMUIR, V17, P56, DOI 10.1021/la000731c
   Harnett EM, 2007, COLLOID SURFACE B, V55, P90, DOI 10.1016/j.colsurfb.2006.11.021
   HEALY TW, 1978, ADV COLLOID INTERFAC, V9, P303, DOI 10.1016/0001-8686(78)85002-7
   Jacquemart I, 2004, J COLLOID INTERF SCI, V278, P63, DOI 10.1016/j.jcis.2004.05.040
   Jelinek R, 2004, CHEM REV, V104, P5987, DOI 10.1021/cr0300284
   KABIR S, 1995, INT J BIOCHEM CELL B, V27, P147, DOI 10.1016/1357-2725(94)00071-I
   Kosaka PM, 2009, ACS SYM SER, V1019, P223
   Kullolli M, 2008, J SEP SCI, V31, P2733, DOI 10.1002/jssc.200800233
   Marmur A, 2006, SOFT MATTER, V2, P12, DOI 10.1039/b514811c
   Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100
   Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/NMAT2442, 10.1038/nmat2442]
   OWENS DK, 1969, J APPL POLYM SCI, V13, P1741, DOI 10.1002/app.1969.070130815
   Palik E D, 1985, HDB OPTICAL CONSTANT
   Pereira EMA, 2008, COLLOID SURFACE B, V66, P45, DOI 10.1016/j.colsurfb.2008.05.013
   PETRI DFS, 1999, COLLOID POLYM SCI, V277, P673
   REEKE GN, 1975, J BIOL CHEM, V250, P1525
   RUFFET E, 1992, BIOCHEM J, V286, P131, DOI 10.1042/bj2860131
   Smith EA, 2003, J AM CHEM SOC, V125, P6140, DOI 10.1021/ja034165u
   TAYLOR E, 2006, INTRO GLYCOBIOLOGY
   Turkova J, 1999, J CHROMATOGR B, V722, P11, DOI 10.1016/S0378-4347(98)00434-4
   VANDERVALK P, 1983, J BIOMED MATER RES, V17, P807, DOI 10.1002/jbm.820170508
   ZAND R, 1971, P NATL ACAD SCI USA, V68, P2173, DOI 10.1073/pnas.68.9.2173
   Zhang Y, 2004, STRUCTURE, V12, P1607, DOI 10.1016/j.str.2004.06.019
   Zhang Y, 2003, EMBO J, V22, P2604, DOI 10.1093/emboj/cdg270
NR 43
TC 9
Z9 9
U1 1
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD SEP
PY 2010
VL 2
IS 9
BP 2602
EP 2610
DI 10.1021/am100442f
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 652OR
UT WOS:000282017700020
PM 20715788
DA 2020-11-11
ER

PT J
AU De Paula, SO
   Lima, D
   Franca, RFD
   Gomes-Ruiz, AC
   da Fonseca, BAL
AF De Paula, Sergio Oliveira
   Lima, Danielle Malta
   de Oliveira Franca, Rafael Freitas
   Gomes-Ruiz, Alessandra Cristina
   Lopes da Fonseca, Benedito Antonio
TI A DNA vaccine candidate expressing dengue-3 virus prM and E proteins
   elicits neutralizing antibodies and protects mice against lethal
   challenge
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID ENCEPHALITIS-VIRUS; MONOCLONAL-ANTIBODIES; JAPANESE ENCEPHALITIS;
   HEMORRHAGIC-FEVER; ENVELOPE PROTEIN; E-GLYCOPROTEIN; DOMAIN-III; TYPE-2;
   EFFICACY; IDENTIFICATION
AB In an effort to develop a suitable DNA vaccine candidate for dengue, using dengue-3 virus (DENV-3) as a prototype, the genes coding for premembrane (prM) and envelope proteins (E) were inserted into an expression plasmid. After selecting recombinant clones containing prM/E genes, protein expression in the cell monolayer was detected by indirect immunofluorescence and immunoprecipitation assays. After selecting three vaccine candidates (pVAC1DEN3, pVAC2DEN3 and pVAC3DEN3), they were analyzed in vivo to determine their ability to induce a DENV-3-specific immune response. After three immunizations, the spleens of the immunized animals were isolated, and the cells were cultivated to measure cytokine levels by ELISA and used for lymphoproliferation assays. All of the animals inoculated with the recombinant clones induced neutralizing antibodies against DENV-3 and produced a T cell proliferation response after specific stimuli. Immunized and control mice were challenged with a lethal dose of DENV-3 and observed in order to assess their survival capability. The groups that presented the best survival rate after the challenge were the animals vaccinated with the pVAC3DEN3 clones, with an 80% survival rate. Thus, these data show that we have manufactured a vaccine candidate for DENV-3 that is able to induce a specific immune response and protects mice against a lethal challenge.
C1 [De Paula, Sergio Oliveira] Univ Fed Vi, Dept Biol Geral, LaboratA, Rio Imunovirologia Mol, BR-36570000 CEP 36570000, Brazil.
   [Lima, Danielle Malta; Gomes-Ruiz, Alessandra Cristina] Preto, Univ SA, Sch Med Ribeirao, Dept Internal Med, Ribeirao Preto, SP, Brazil.
   [De Paula, Sergio Oliveira] Univ Fed Vicosa, Dept Biol Geral, Lab Imunovirol Mol, BR-36570000 Vicosa, MG, Brazil.
   [Lima, Danielle Malta; de Oliveira Franca, Rafael Freitas; Gomes-Ruiz, Alessandra Cristina; Lopes da Fonseca, Benedito Antonio] Univ Sao Paulo, Sch Med Ribeirao, Dept Internal Med, Ribeirao Preto, Brazil.
RP De Paula, SO (corresponding author), Univ Fed Vicosa, Dept Biol Geral, Lab Imunovirol Mol, Av PH Rolfs,S-N, BR-36570000 Vicosa, MG, Brazil.
EM depaula@ufv.br
RI De Paula, Sergio/N-2609-2018; Fonseca, Benedito/F-3252-2012
OI De Paula, Sergio/0000-0002-2275-5768; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007; Fonseca, Benedito/0000-0003-3159-5687
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Sao
   Paulo, BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [00/12957-8]; FAPESPFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [00/09287-0]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP), Sao Paulo, Brazil (Grant 00/12957-8). SOP was
   supported by a FAPESP scholarship (Grants 00/09287-0). Thanks to Jeffrey
   Ryan Oar of Oregon State University for the revision and corrections
   made to the text.
CR Ada G, 2001, NEW ENGL J MED, V345, P1042, DOI 10.1056/NEJMra011223
   Bhamarapravati N, 2000, VACCINE, V18, P44, DOI 10.1016/S0264-410X(00)00040-2
   Blair PJ, 2006, VACCINE, V24, P1427, DOI 10.1016/j.vaccine.2005.09.032
   Burke D. S., 2001, FIELDS VIROLOGY, P1043
   CAZIONEZ RO, 2001, VACCINE, V19, P648
   Chambers TJ, 1997, VACCINE, V15, P1494, DOI 10.1016/S0264-410X(97)00195-3
   Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001
   Delves PJ, 2000, NEW ENGL J MED, V343, P37, DOI 10.1056/NEJM200007063430107
   DHARAKUL T, 1994, J INFECT DIS, V170, P27, DOI 10.1093/infdis/170.1.27
   EDELMAN R, 2004, AM J TROP MED HYG, V70, P336
   Fauquet C. M., 2005, 8 INT COMM TAX VIR
   FONSECA BAL, 1994, VACCINE, V12, P279, DOI 10.1016/0264-410X(94)90206-2
   Gibbons RV, 2002, BRIT MED J, V324, P1563, DOI 10.1136/bmj.324.7353.1563
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   Guirakhoo F, 2004, J VIROL, V78, P4761, DOI 10.1128/JVI.78.9.4761-4775.2004
   HAHN CS, 1988, P NATL ACAD SCI USA, V85, P5997, DOI 10.1073/pnas.85.16.5997
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   HEINZ FX, 1994, VIROLOGY, V198, P109, DOI 10.1006/viro.1994.1013
   Jaiswal S, 2004, PROTEIN EXPRES PURIF, V33, P80, DOI 10.1016/j.pep.2003.09.009
   KAUFMAN BM, 1987, AM J TROP MED HYG, V36, P427, DOI 10.4269/ajtmh.1987.36.427
   Konishi E, 2002, VACCINE, V20, P1058, DOI 10.1016/S0264-410X(01)00446-7
   Konishi E, 1998, J VIROL, V72, P4925, DOI 10.1128/JVI.72.6.4925-4930.1998
   KURANE I, 1989, J EXP MED, V170, P763, DOI 10.1084/jem.170.3.763
   LIN B, 1994, VIROLOGY, V202, P885, DOI 10.1006/viro.1994.1410
   Raviprakash K, 2000, VACCINE, V18, P2426, DOI 10.1016/S0264-410X(99)00570-8
   Rigau-Perez JG, 1998, LANCET, V352, P971, DOI 10.1016/S0140-6736(97)12483-7
   Rothman AL, 2001, VACCINE, V19, P4694, DOI 10.1016/S0264-410X(01)00236-5
   RUSSELL PK, 1967, J IMMUNOL, V99, P291
   Seligman SJ, 2004, LANCET, V363, P2073, DOI 10.1016/S0140-6736(04)16459-3
   TESH RB, 1979, AM J TROP MED HYG, V28, P1053, DOI 10.4269/ajtmh.1979.28.1053
   TRIRAWATANAPONG T, 1992, GENE, V116, P139, DOI 10.1016/0378-1119(92)90509-N
   Twiddy SS, 2003, J GEN VIROL, V84, P429, DOI 10.1099/vir.0.18660-0
   Wu SF, 2003, VACCINE, V21, P3919, DOI 10.1016/S0264-410X(03)00310-4
NR 33
TC 21
Z9 21
U1 0
U2 4
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0304-8608
J9 ARCH VIROL
JI Arch. Virol.
PD DEC
PY 2008
VL 153
IS 12
BP 2215
EP 2223
DI 10.1007/s00705-008-0250-3
PG 9
WC Virology
SC Virology
GA 391KJ
UT WOS:000262231900005
PM 19002647
DA 2020-11-11
ER

PT J
AU Pereira, EMA
   Sierakowski, MR
   Jo, TA
   Moreira, RA
   Monteiro-Moreira, ACO
   Franca, RFO
   Fonseca, BAL
   Petri, DFS
AF Pereira, Edla M. A.
   Sierakowski, Maria Rita
   Jo, Tatiane A.
   Moreira, Renato A.
   Monteiro-Moreira, Ana Cristina O.
   Franca, Rafael F. O.
   Fonseca, Benedito A. L.
   Petri, Denise F. S.
TI Lectins and/or xyloglucans/alginate layers as supports for
   immobilization of dengue virus particles
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE xyloglucan; lectin; dengue virus; ellipsometry; AFM
ID AMINO-TERMINATED SURFACES; BOVINE SERUM-ALBUMIN; X-RAY-SCATTERING;
   CONCANAVALIN-A; CONFORMATIONAL-CHANGES; ADSORPTION BEHAVIOR; DECORATED
   PARTICLES; ENVELOPE PROTEIN; HEPARAN-SULFATE; ALGINIC ACID
AB Formation of stable thin films of mixed xyloglucan (XG) and alginate (ALG) onto Si/SiO2 wafers was achieved under pH 11.6, 50 mM CaCl2, and at 70 degrees C. XG-ALG films presented mean thickness of (16 +/- 2) nun and globules rich surface, as evidenced by means of ellipsometry and atomic force microscopy (AFM), respectively. The adsorption of two glucose/mannose-binding seed (Canavalia ensiformis and Dioclea altissima) lectins, coded here as ConA and DAlt, onto XG-ALG surfaces took place under pH 5. Under this condition both lectins present positive net charge. ConA and DAIt adsorbed irreversibly onto XG-ALG forming homogenous monolayers similar to(4 +/- 1)nm thick. Lectins adsorption was mainly driven by electrostatic interaction between lectins positively charged residues and carboxylated (negatively charged) ALG groups. Adhesion of four serotypes of dengue virus, DENV (1-4), particles to XG-ALG surfaces were observed by ellipsometry and AFM. The attachment of dengue particles onto XG-ALG films might be mediated by (i) H bonding between E protein (located at virus particle surface) polar residues and hydroxyl groups present on XG-ALG surfaces and (ii) electrostatic interaction between E protein positively charged residues and ALG carboxylic groups. DENV-4 serotype presented the weakest adsorption onto XG-ALG surfaces, indicating that E protein on DENV-4 surface presents net charge (amino acid sequence) different from E proteins of other serotypes. All four DENV particles serotypes adsorbed similarly onto lectin films adsorbed. Nevertheless, the addition of 0.005 mol/L of mannose prevented dengue particles from adsorbing onto lectin films. XG-ALG and lectin layers serve as potential materials for the development of diagnostic methods for dengue. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Pereira, Edla M. A.; Petri, Denise F. S.] Univ Sao Paulo, Inst Quim, BR-05513970 Sao Paulo, Brazil.
   [Sierakowski, Maria Rita; Jo, Tatiane A.] Univ Fed Parana, Dept Quim, BIOPOL, BR-80060000 Curitiba, Parana, Brazil.
   [Moreira, Renato A.; Monteiro-Moreira, Ana Cristina O.] Univ Fortaleza, Ctr Ciencias Saude, Fortaleza, Ceara, Brazil.
   [Franca, Rafael F. O.; Fonseca, Benedito A. L.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, BR-14049 Ribeirao Preto, Brazil.
RP Petri, DFS (corresponding author), Univ Sao Paulo, Inst Quim, POB 26077, BR-05513970 Sao Paulo, Brazil.
EM dfsp@iq.usp.br
RI Sierakowski, Maria R/H-9213-2013; Monteiro-Moreira, Ana Cristina
   O/F-3685-2014; PETRI, DENISE/H-5004-2012; Petri, Denise/L-5084-2019;
   Fonseca, Benedito/F-3252-2012
OI Sierakowski, Maria R/0000-0002-8061-1199; Monteiro-Moreira, Ana Cristina
   O/0000-0002-3606-6808; PETRI, DENISE/0000-0003-4814-8357; Moreira,
   Renato de Azevedo/0000-0002-9626-6086; Fonseca,
   Benedito/0000-0003-3159-5687; Freitas de Oliveira Franca,
   Rafael/0000-0002-1846-6007
FU Conselho Nacional de Desenvolvimento Cientifico a Tecnologico
   (CNPq/MCT)National Council for Scientific and Technological Development
   (CNPq); Fundacao Araucaria and Funda ao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP)
FX The authors acknowledge Conselho Nacional de Desenvolvimento Cientifico
   a Tecnologico (CNPq/MCT), Fundacao Araucaria and Funda ao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) for financial support.
CR Allison SL, 2001, J VIROL, V75, P4268, DOI 10.1128/JVI.75.9.4268-4275.2001
   Alper J, 2001, SCIENCE, V291, P2339, DOI 10.1126/science.291.5512.2339
   Avaltroni F, 2007, BIOMACROMOLECULES, V8, P106, DOI 10.1021/bm060655d
   Azzam R. M. A., 1978, ELLIPSOMETRY POLARIZ
   Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729
   BHUSHAN B, 2004, APPL SCANNING PROBE
   Bock G., 2006, NEW TREATMENT STRATE
   Box GEP, 1978, STAT EXPT INTRO DESI
   Brandrup J., 1966, POLYM HDB
   Castro LBR, 2006, LANGMUIR, V22, P3757, DOI 10.1021/la053080z
   Castro LBR, 2005, J NANOSCI NANOTECHNO, V5, P2063, DOI 10.1166/jnn.2005.501
   Castro LBR, 2007, J PHYS CHEM B, V111, P8520, DOI 10.1021/jp0686543
   De Paula SO, 2002, T ROY SOC TROP MED H, V96, P266, DOI 10.1016/S0035-9203(02)90094-5
   DRAGET KI, 1994, CARBOHYD POLYM, V25, P31, DOI 10.1016/0144-8617(94)90159-7
   GRANT GT, 1973, FEBS LETT, V32, P195, DOI 10.1016/0014-5793(73)80770-7
   HEINZE T, 2005, ADV POLYM SCI POLYSA, V1
   Jelinek R, 2004, CHEM REV, V104, P5987, DOI 10.1021/cr0300284
   Lindenbach BD, 2003, ADV VIRUS RES, V59, P23, DOI 10.1016/S0065-3527(03)59002-9
   Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g
   Maciel JD, 2007, CARBOHYD POLYM, V69, P522, DOI 10.1016/j.carbpol.2007.01.013
   Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165
   Moreira RA, 1997, PHYTOCHEMISTRY, V46, P139, DOI 10.1016/S0031-9422(97)00262-8
   MORRIS ER, 1978, CARBOHYD RES, V66, P145, DOI 10.1016/S0008-6215(00)83247-4
   Palik E D, 1985, HDB OPTICAL CONSTANT
   Pancera SM, 2005, MACROMOL BIOSCI, V5, P331, DOI 10.1002/mabi.200400206
   QUEIROZ JC, 2007, NOVA, V30, P909
   REEKE GN, 1975, CONCANAVALIN
   Rostand KS, 1997, INFECT IMMUN, V65, P1
   Seo SJ, 2005, BIOMATERIALS, V26, P3607, DOI 10.1016/j.biomaterials.2004.09.025
   Sierakowski MR, 2007, J BRAZIL CHEM SOC, V18, P1017, DOI 10.1590/S0103-50532007000500021
   Sierakowski MR, 2002, CARBOHYD POLYM, V49, P167, DOI 10.1016/S0144-8617(01)00321-6
   Silva RA, 2007, INT J BIOL MACROMOL, V41, P404, DOI 10.1016/j.ijbiomac.2007.05.014
   SMIDSROD O, 1966, ACTA CHEM SCAND, V20, P1026, DOI 10.3891/acta.chem.scand.20-1026
   Spillmann D, 2001, BIOCHIMIE, V83, P811, DOI 10.1016/S0300-9084(01)01290-1
   Stokke BT, 2000, MACROMOLECULES, V33, P1853, DOI 10.1021/ma991559q
   Talarico LB, 2007, VIROLOGY, V363, P473, DOI 10.1016/j.virol.2007.01.043
   Ueta RR, 2008, COLLOID SURFACE B, V61, P244, DOI 10.1016/j.colsurfb.2007.08.010
   ZAND R, 1971, P NATL ACAD SCI USA, V68, P2173, DOI 10.1073/pnas.68.9.2173
   Zhang Y, 2004, STRUCTURE, V12, P1607, DOI 10.1016/j.str.2004.06.019
NR 39
TC 15
Z9 15
U1 0
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD OCT 1
PY 2008
VL 66
IS 1
BP 45
EP 52
DI 10.1016/j.colsurfb.2008.05.013
PG 8
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 345GI
UT WOS:000258983900007
PM 18579349
DA 2020-11-11
ER

EF